MALEIMIDE GROUP-MODIFIED ANGIOGENESIS INHIBITOR HM-1 AND USE THEREOF

Information

  • Patent Application
  • 20200270309
  • Publication Number
    20200270309
  • Date Filed
    September 07, 2018
    5 years ago
  • Date Published
    August 27, 2020
    3 years ago
Abstract
The present invention discloses a maleimide group-modified angiogenesis inhibitor HM-1 and the use thereof, which fall within the technical field of polypeptide drugs. According to the present invention, the selection of a suitable maleimide group to modify the N-terminal of the angiogenesis inhibitor polypeptide HM-1 obtains an unchanged X1-X90 polypeptide sequence target, also prolongs the in viwo half-life of the polypeptide molecules, has a low clearance rate, and reduces the immunogenicity and antigenicity. The maleimide group-modified angiogenesis inhibitor can be used for preventing and treating tumors, various inflammations and ocular neovascular diseases, and the anti-tumor activity remains unchanged. But the plasma concentration at the lesion site is increased, so that the administration frequency is reduced, that is, the administration frequency of the maleimide group-modified HM-1 is changed from twice a day to once every seven days.
Description
TECHNICAL FIELD

The present invention belongs to the technical field of polypeptide drugs, and more specifically, relates to a maleimide group-modified angiogenesis inhibitor HM-1 and use thereof.


BACKGROUND

Integrins are a family of receptors that recognize a variety of extracellular matrix components. The integrins are widely distributed on the cell surface, they can mediate the adhesion between cells and extracellular matrix and between cells, and can participate in angiogenesis through the interaction between intracellular cytoskeletal proteins and extracellular matrix molecules. Such receptors consist of α and β chains. At present, 15 α chains and 9 β chains have been found. The combination of different α chains and β chains determines the specificity of a ligand. Integrins α1β1, α2β1, α3β1, α6β1, α6β4, α5β1, αvβ3 and αvβ5 participate in angiogenesis and cell migration, among which αvβ3 can affect several key processes in carcinogenesis. αvβ3 can be expressed in a variety of cell types. It may recognize an Arg-Gly-Asp (RGD) sequence in ligand molecules, and involve in physiological and pathological processes, such as tumor angiogenesis, invasion, metastasis, inflammation, wound healing, and coagulation. Therefore, the RGD sequence can be used as a carrier for targeted transportation to neovascular endothelial cells, thus achieving more efficient treatment of neovascular diseases. Chinese patent application No. 201410324568.9, entitled MULTIFUNCTIONAL FUSION POLYPEPTIDES, AND PREPARATION METHOD AND USE THEREOF, provides several angiogenesis inhibitor polypeptides, one of which is HM-1, with the sequence of Arg-Gly-Ala-Asp-Arg-Ala-Gly-Gly-Gly-Gly-Arg-Gly-Asp (SEQ ID NO: 1). This sequence includes an integrin ligand sequence Gly-Gly-Gly-Gly-Arg-Gly-Asp (SEQ ID NO: 2) and an agiogenesis inhibiting sequence Arg-Gly-Ala-Asp-Arg-Ala (SEQ ID NO: 3). The polypeptide has been repeatedly evaluated in vivo and in vitro to prove its activity in treating solid tumors, rheumatoid arthritis and ocular neovascular diseases. However, the above polypeptide has a short half-life and needs frequent administration, which brings some pain to patients. Chinese patent application No. 201610211000.5, entitled POLYETHYLENE GLYCOL-MODIFIED ANGIOGENESIS INHIBITOR HM-1 AND USE THEREOF, discloses polyethylene glycol (PEG)-modified HM-1, which can prolong the half-life of a polypeptide. Compared with this patent, the present invention provides a more prolonged half-life of polypeptide. Due to their specificity, changes in any one amino acid or environment will directly affect the structures, activities and functions of polypeptide drugs. Moreover, different action sites of the polypeptide drugs also affect the selection of modification methods. The methods for modification of chemical drugs in the prior art do not have any technical enlightenment for the polypeptide drugs. Even the existing methods for modification of polypeptide drugs will not bring inevitable enlightenment because of the difference between polypeptide sequences. That is the reason that the process of developing new drugs is long and arduous.


In the literatures, modification of molecular structure is a common method to solve the problems of short half-life and frequent administration. After binding to the amino group of the side chain of maleimide group, the polypeptide can be bound to the sulfhydryl group at the 34th position of albumin through the maleimide group, thereby enhancing the stability in vivo and reducing the sensitivity to peptidase or protease degradation. At the same time, the molecular weight is increased after binding to albumin, thus not only prolonging the half-life of HM-1, but also increasing the plasma concentration at the lesion site. However, after the polypeptide is modified by the maleimide group and bound to albumin in vivo, the biological activity of protein and polypeptide is also affected. For example, the binding of the polypeptide to a target is affected. The degree of influence is related to the properties of the maleimide group, such as the length and flexibility of its side chain. The biological activity of the modified product needs to be determined through a series of in vivo and in vitro pharmacodynamic tests.


SUMMARY
1. PROBLEMS TO BE SOLVED

In view of the shortcomings of an existing angiogenesis inhibitor polypeptide HM-1 (the sequence is shown in SEQ ID NO: 1), such as short half-life, high plasma clearance rate, frequent administration, the present invention provides a maleimide group-modified angiogenesis inhibitor HM-1 and use thereof. The modified polypeptide can rapidly react with the sulfhydryl group at the 34th position of albumin at a molar ratio of 1:1, thereby reducing sensitivity to peptidase or protease degradation, increasing the molecular weight, prolonging the half-life of the polypeptide HM-1 and retaining the biological activity of the polypeptide HM-1. The synthesis method of the polypeptide is simple and low cost. It can be implemented by polypeptide solid phase synthesis. Furthermore, the polypeptide is better applied to the prevention and treatment of tumors, various inflammations and ocular neovascular diseases.


2. TECHNICAL SOLUTION

In order to solve the foregoing problems, the technical solutions adopted by the present invention are as follows:


A modified angiogenesis inhibitor polypeptide, wherein a maleimide group is used to modify the angiogenesis inhibitor polypeptide, and the carboxyl group of the maleimide group forms an amide bond with the amino group of N-terminal Arg of the polypeptide. For example, there are the following polypeptides P1-P4:




embedded image


Further, a modified angiogenesis inhibitor polypeptide sequence includes two functional groups A and B, wherein the functional group A is Arg-Gly-Ala-Asp-Arg-Ala or a derived polypeptide obtained by substituting, deleting or adding one or two amino acid residues in Arg-Gly-Ala-Asp-Arg-Ala, and the derived polypeptide has the same angiogenesis inhibition, anti-tumor and anti-inflammatory activities as Arg-Gly-Ala-Asp-Arg-Ala; the functional group B is Arg-Gly-Asp, wherein the functional groups A and B are ligated with each other through a linker, that is, the modified polypeptide sequence structure is A-linker-B.


Further, the linker is Gly-Gly-Gly-Gly (SEQ ID NO: 4), Glu-Ala-Ala-Ala-Lys (SEQ ID NO: 5) or Gly-Ser-Ser-Ser-Ser (SEQ ID NO: 6).


Further, the modified polypeptide sequence is:




embedded image


Further, a polypeptide chain is ligated with the maleimide group by different linkers, wherein n, m, x and y are the numbers of repeating structural unit methylene, methylene, oxyethylene and methylene respectively in the foregoing structural formulas; the n, m, x and y are all integers, and specific numerical ranges are: n=1-12, m=1-12, x=1-5, y=0-6. The specific polypeptide sequence structures are:




embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


The functional group A in the present invention includes a sequence Arg-Gly-Ala-Asp-Arg-Ala and a derived polypeptide obtained by substituting one amino acid with another amino acid, or deleting one amino acid, or adding one or two amino acids between two amino acids. As long as the derived polypeptide has the same angiogenesis inhibition, anti-tumor and anti-inflammatory activities as Arg-Gly-Ala-Asp-Arg-Ala, it can be modified with the maleimide group in the present invention to prolong the half-life and have anti-tumor activities.


For example:


1) polypeptide P5 has a 3-maleimidopropionic acid-modified structure in which amino acid Ala at the third position is substituted by Glu:




embedded image


2) polypeptide P6 has a 6-maleimidocaproic acid-modified structure in which amino acid Ala at the third position is substituted by Glu:




embedded image


3) polypeptide P7 has a 3-maleimidopropionic acid-modified structure in which amino acid Ala at the third position is deleted:




embedded image


4) polypeptide P8 has a 6-maleimidocaproic acid-modified structure in which amino acid Ala at the third position is deleted:




embedded image


5) polypeptide P9 has a 3-maleimidopropionic acid-modified structure in which a Val amino acid structure is added between an amino acid at the third position and an amino acid at the fourth position:




embedded image


and 6) polypeptide P10 has a 6-maleimidocaproic acid-modified structure in which a Val amino acid structure is added between an amino acid at the third position and an amino acid at the fourth position:




embedded image


The linker between the functional groups A and B mainly plays a ligating role, as long as it is a short peptide that can ligate the functional groups A and B and does not affect the activities of both. The preferred linkers are Gly-Gly-Gly-Gly-Lys (SEQ ID NO: 7), Glu-Ala-Ala-Ala-Lys, and Gly-Ser-Ser-Ser-Ser. For example:


P11 uses Glu-Ala-Ala-Ala-Lys as the linker and is modified by 3-maleimidopropionic acid:




embedded image


polypeptide P12 uses Glu-Ala-Ala-Ala-Lys as the linker and is modified by 6-maleimidocaproic acid:




embedded image


polypeptide P13 uses Gly-Ser-Ser-Ser-Ser as the linker and is modified by 3-maleimidopropionic acid:




embedded image


and polypeptide P14 uses Gly-Ser-Ser-Ser-Ser as the linker and is modified by 6-maleimidocaproic acid:




embedded image


Use of the above modified angiogenesis inhibitor polypeptide in the preparation of a medicament for treating tumors, inflammations and ocular neovascular diseases is provided.


Further, the tumors are primary or secondary cancers, melanoma, hemangioma and sarcoma originating from human head and neck, brain, thyroid, esophagus, pancreas, lung, liver, stomach, breast, kidney, gallbladder, colon or rectum, ovary, blood vessel, cervix, prostate, bladder or testis.


Further, the inflammations include rheumatoid arthritis, gouty arthritis, reactive arthritis, osteoarthritis, psoriasis, infectious arthritis, traumatic arthritis and ankylosing spondylitis.


Further, the ocular neovascular diseases include age-related macular degeneration (AMD), iris neovascular eye diseases, choroidal neovascular eye diseases, retinal neovascular eye diseases or corneal neovascular eye diseases.


A medicament for treating tumors, inflammations and/or ocular neovascular diseases comprises the above modified angiogenesis inhibitor polypeptide and pharmaceutically acceptable excipients.


Further, the medicament is administered by injection, including subcutaneous injection, intramuscular injection, intravenous injection, vitreous injection and intravenous drip.


A method for preparing the foregoing maleimide group-modified angiogenesis inhibitor HM-1 comprises the following steps: (1) synthesizing the sequence of the maleimide group-modified angiogenesis inhibitor HM-1; (2) performing separation and purification to obtain the maleimide group-modified angiogenesis inhibitor HM-1 in solution; (3) performing rotary evaporation on the modified product solution obtained by separation and purification, and performing vacuum freeze drying to obtain modified product powder, and storing the modified product powder at −70° C.


The sequence Arg-Gly-Ala-Asp-Arg-Ala has the effect of inhibiting tumor angiogenesis. An RGD sequence is an important ligand of integrin, and therefore, polypeptide Gly-Gly-Gly-Gly-Arg-Gly-Asp containing the RGD sequence can also specifically recognize the integrin. The angiogenesis inhibitor polypeptide HM-1 of the present invention is a polypeptide, which is obtained by ligating a Gly-Gly-Gly-Gly-Arg-Gly-Asp sequence to the C-terminal of an Arg-Gly-Ala-Asp-Arg-Ala sequence having an angiogenesis inhibiting effect. The polypeptide HM-1 has affinity and binding ability with integrins, but it has a short half-life and needs frequent administration. In order to prolong the half-life of the HM-1 sequence, the applicant has conducted a series of studies. Without affecting the target and biological activity of the HM-1 sequence, the N-terminal of the polypeptide HM-1 is modified by maleimide group. The final optimized sequences are the foregoing polypeptides (X1 to X90), which each contain a maleimide group and a polypeptide of 13 amino acids. The targets of the RGD sequence in the molecule are integrins αvβ3 and α5β1. However, the main binding target is still the integrin αvβ3, which is bound to a neovascularization inhibiting sequence in this sequence, thus effectively inhibiting tumor neoangiogenesis and further achieving the effect of inhibiting tumor growth and metastasis.


The target of the polypeptide HM-1 is unchanged after the modification by the maleimide group; meanwhile, the in vivo half-life of the polypeptide molecule is prolonged, the clearance rate is low (see CL(L/h/kg) in Table 1), the immunogenicity and antigenicity are reduced, and the anti-tumor activity remains unchanged (see experimental results in Table 5). However, the plasma concentration at the lesion site is increased, so that the administration frequency is reduced. That is to say, the administration frequency of the maleimide group-modified HM-1 is changed from twice a day to once every seven days. The polypeptide HM-1 modified by the maleimide group mainly functions by reacting with sulfhydryl group at the 34th position of albumin. The reasons why the albumin accumulates in the tumor site are: 1) the vascular endothelial gap of a tumor tissue is large, the reason why macromolecules can penetrate through the vascular wall of the tumor tissue is different from that why the macromolecules can penetrate through blood vessels of a healthy tissue, and the tumor site lacks lymphatic return, thus resulting in the enhanced permeability and retention (EPR) effect of the tumor tissue; 2) the albumin can be bound to specific receptor gp60 on the surface of the vascular endothelial cell membrane to activate caveolin-1 to form vesicles passing through endothelial cells, and then the vesicles are bound to secreted protein acidic and rich in cysteine (SPARC) in the tumor tissue gap. SPARC can specifically attract and adhere to albumin, so the albumin can be adsorbed and aggregated on the surface of tumor cells to induce tumor cell apoptosis.


According to a large number of experiments, the maleimide group-modified angiogenesis inhibitor in the present invention can obviously inhibit the proliferation and migration of human umbilical vein endothelial cells (HUVECs), and has obvious inhibition effect on the proliferation of tumor cells such as human cervical cancer HeLa cells, human colon cancer HCT 116 cells, human glioma U87 cells, and human breast cancer MDA-MB-231.


According to a large number of experiments, the maleimide group-modified angiogenesis inhibitor in the present invention can effectively treat angiogenesis inflammations. The experiments prove that the maleimide group-modified angiogenesis inhibitor of the present invention can target neovascular endothelium in the process of pannus formation in RA to inhibit neoangiogenesis, thereby achieving the effect of preventing or treating rheumatoid arthritis. Furthermore, rat adjuvant induced rheumatoid arthritis and DBA/1 mouse collagen induced rheumatoid arthritis models prove that the present invention has obvious effect of treating rheumatoid arthritis and has less side effects, less dosage and low costs.


According to a large number of experiments, the maleimide group-modified angiogenesis inhibitor in the present invention can inhibit the proliferation of human retinal capillary endothelial cells (HRCECs), and has a dose-dependent relationship within a certain range. The effect of the angiogenesis inhibitor polypeptide on mouse corneal neovascularization and rabbit iris neovascularization indicates that the maleimide group-modified angiogenesis inhibitor in the present invention can inhibit the growth of cornea and iris neovascularization, has the potential to be developed into drugs for treating corneal neovascular eye diseases and iris neovascular eye diseases, and has the potential effect of treating ocular neovascular diseases.


The choroid is located at the posterior of the eyeball. The experiments prove that the angiogenesis inhibitor can improve choroidal blood flow, which indicates that after doasing, the angiogenesis inhibitor can reach the choroid as soon as possible through systemic circulation or sclera-uvea-optic nerve pathway, and has inhibitory effect on choroidal neoangiogenesis of AMD. It is expected to be used for prevention or treatment of early AMD and other choroidal neovascular diseases. At the same time, the angiogenesis inhibitor has certain therapeutic effect on choroidal neovascular eye diseases including AMD by inhibiting the choroidal neoangiogenesis in rats.


The maleimide group-modified angiogenesis inhibitor in the present invention is scientific, reasonable, feasible and effective and can be used to prepare therapeutic drugs for treating human tumors, various inflammations and ocular neovascular diseases. The therapeutic spectrum of the angiogenesis inhibitor is greatly expanded, which provides new ideas and prospects for future drug development.


The half-life of the pre-modified polypeptide HM-1 is 0.34 h. The half-lives of maleimide group-modified polypeptides are shown in Tables 1-3.









TABLE 1







Comparison between the half-lives of polypeptides P1-P4 and


HM-1 (t1/2β is half-life)











Drug
T1/2β(h)
CL(L/h/kg)
AUC0-∞(mg/L/h)
MRT0-∞(h)





HM-1
 0.35 ± 0.14
1.49 ± 0.31
32.76 ± 8.41 
 0.068 ± 0.012


P1
36.96 ± 0.25
53.33 ± 14.18
0.0336 ± 0.0083
29.76 ± 8.03


P2
35.48 ± 0.30
51.20 ± 10.08
0.0350 ± 0.0076
28.57 ± 8.42


P3
38.89 ± 0.30
56.12 ± 11.65
0.0319 ± 0.0076
31.35 ± 7.31


P4
31.72 ± 0.26
45.77 ± 11.64
0.0391 ± 0.0066
25.58 ± 8.02
















TABLE 2







Comparison between the half-lives of polypeptides P5-P14 and


HM-1 (t1/2β is half-life)











Drug
T1/2β(h)
CL(L/h/kg)
AUC0-∞(mg/L/h)
MRT0-∞(h)





HM-1
 0.35 ± 0.14
1.49 ± 0.31
32.76 ± 8.41
0.068 ± 0.012


P5
36.28 ± 0.25
0.0342 ± 0.0090
29.24 ± 7.88
52.35 ± 12.15


P6
34.36 ± 0.25
0.0361 ± 0.0084
27.70 ± 7.13
49.58 ± 9.97 


P7
39.63 ± 0.28
0.0313 ± 0.0091
31.95 ± 7.82
57.19 ± 13.90


P8
38.67 ± 0.27
0.0321 ± 0.0093
31.15 ± 8.09
 55.8 ± 13.36


P9
34.64 ± 0.30
0.0358 ± 0.0068
27.93 ± 6.88
49.99 ± 10.65


P10
30.58 ± 0.31
0.0406 ± 0.0071
24.63 ± 7.03
44.13 ± 11.03


P11
39.16 ± 0.31
0.0317 ± 0.0091
31.55 ± 8.23
56.51 ± 11.62


P12
42.24 ± 0.29
0.0294 ± 0.0080
34.01 ± 6.88
60.95 ± 10.06


P13
3944 ± 0.27
0.0315 ± 0.0065
31.75 ± 8.09
56.91 ± 14.16


P14
39.85 ± 0.31
0.0311 ± 0.0071
32.15 ± 7.56
57.50 ± 9.63 
















TABLE 3







Comparison between the half-lives of polypeptides X1-X90 and


HM-1 (t1/2β is half-life)











Drug
T1/2β(h)
CL(L/h/kg)
AUC0-∞(mg/L/h)
MRT0-∞(h)





HM-1
 0.35 ± 0.14
1.49 ± 0.31
32.76 ± 8.41
0.068 ± 0.012


X1
35.99 ± 0.29
0.0345 ± 0.0059
28.99 ± 6.94
51.93 ± 10.18


X2
34.51 ± 0.28
0.0360 ± 0.0078
27.78 ± 7.51
49.78 ± 9.73 


X3
41.92 ± 0.32
0.0296 ± 0.0064
33.78 ± 7.66
60.46 ± 13.17


X4
37.44 ± 0.27
0.0332 ± 0.0091
30.12 ± 7.33
53.97 ± 10.52


X5
34.59 ± 0.29
0.0359 ± 0.0067
27.86 ± 7.03
49.91 ± 13.23


X6
37.86 ± 0.28
0.0328 ± 0.0076
30.49 ± 7.17
54.63 ± 12.19


X7
42.83 ± 0.29
0.0291 ± 0.0083
34.48 ± 6.96
61.82 ± 14.31


X8
34.68 ± 0.31
0.0358 ± 0.0087
27.93 ± 7.57
50.04 ± 12.62


X9
38.78 ± 0.31
0.0322 ± 0.0074
31.25 ± 7.35
55.96 ± 13.35


X10
38.64 ± 0.25
0.0321 ± 0.0086
31.15 ± 7.21
55.76 ± 12.95


X11
31.08 ± 0.29
0.0399 ± 0.0082
25.06 ± 8.26
44.85 ± 11.56


X12
36.20 ± 0.25
0.0343 ± 0.0084
29.15 ± 8.18
52.24 ± 9.78 


X13
41.58 ± 0.34
0.0298 ± 0.0089
33.56 ± 7.34
60.00 ± 12.54


X14
36.04 ± 0.32
0.0344 ± 0.0071
29.07 ± 7.66
52.01 ± 13.47


X15
42.65 ± 0.25
0.0291 ± 0.0063
34.36 ± 8.52
61.54 ± 10.04


X16
39.00 ± 0.24
0.0318 ± 0.0061
31.45 ± 8.39
56.28 ± 13.62


X17
37.26 ± 0.29
0.0333 ± 0.0071
30.03 ± 7.06
53.77 ± 12.34


X18
33.75 ± 0.27
0.0368 ± 0.0078
27.17 ± 7.31
48.70 ± 14.06


X19
39.95 ± 0.28
0.0311 ± 0.0087
32.15 ± 6.97
57.65 ± 10.75


X20
39.56 ± 0.28
0.0314 ± 0.0093
31.85 ± 8.32
57.09 ± 12.91


X21
42.24 ± 0.28
0.0294 ± 0.0075
34.01 ± 8.19
60.89 ± 9.41 


X22
35.03 ± 0.27
0.0354 ± 0.0071
28.25 ± 7.98
50.55 ± 13.64


X23
31.72 ± 0.25
0.0391 ± 0.0062
25.58 ± 8.51
45.77 ± 10.57


X24
36.77 ± 0.29
0.0337 ± 0.0061
29.67 ± 7.58
53.06 ± 13.51


X25
30.56 ± 0.32
0.0406 ± 0.0089
24.63 ± 7.53
 44.1 ± 10.67


X26
42.95 ± 0.36
0.0289 ± 0.0089
34.62 ± 8.34
61.98 ± 9.63 


X27
32.52 ± 0.25
0.0381 ± 0.0082
26.25 ± 7.25
46.93 ± 9.74 


X28
31.19 ± 0.26
0.0398 ± 0.0068
25.13 ± 7.92
45.01 ± 13.02


X29
39.91 ± 0.25
0.0311 ± 0.0072
32.15 ± 8.03
57.59 ± 10.58


X30
35.17 ± 0.37
0.0353 ± 0.0067
28.33 ± 6.88
50.75 ± 10.28


X31
35.58 ± 0.31
0.0349 ± 0.0067
28.65 ± 6.96
51.34 ± 11.26


X32
38.33 ± 0.31
0.0324 ± 0.0091
30.86 ± 7.75
55.31 ± 11.84


X33
42.15 ± 0.26
0.0294 ± 0.0087
34.01 ± 7.62
60.82 ± 11.96


X34
34.35 ± 0.26
0.0361 ± 0.0067
27.71 ± 8.15
49.57 ± 10.18


X35
39.60 ± 0.31
0.0313 ± 0.0078
31.95 ± 8.09
57.14 ± 14.19


X36
34.90 ± 0.27
0.0355 ± 0.0084
28.17 ± 8.09
50.36 ± 10.11


X37
33.76 ± 0.28
0.0367 ± 0.0057
27.25 ± 7.21
48.72 ± 13.61


X38
38.94 ± 0.25
0.0319 ± 0.0079
31.35 ± 7.55
56.19 ± 11.24


X39
40.73 ± 0.28
0.0305 ± 0.0065
32.79 ± 7.11
58.77 ± 13.08


X40
42.23 ± 0.27
0.0294 ± 0.0079
34.01 ± 7.83
60.94 ± 10.65


X41
32.89 ± 0.36
0.0377 ± 0.0071
26.53 ± 7.81
47.46 ± 13.88


X42
33.58 ± 0.24
0.0369 ± 0.0062
27.12 ± 8.01
48.46 ± 10.56


X43
33.14 ± 0.31
0.0374 ± 0.0091
26.74 ± 7.42
47.82 ± 9.93 


X44
33.26 ± 0.28
0.0373 ± 0.0067
26.81 ± 8.44
47.99 ± 11.55


X45
30.15 ± 0.26
0.0411 ± 0.0069
24.33 ± 8.33
43.51 ± 12.01


X46
39.23 ± 0.29
0.0316 ± 0.0064
31.65 ± 7.47
56.57 ± 11.01


X47
41.19 ± 0.27
0.0301 ± 0.0092
33.22 ± 7.13
59.44 ± 11.98


X48
36.64 ± 0.27
0.0339 ± 0.0091
29.25 ± 7.65
52.87 ± 12.14


X49
35.31 ± 0.32
0.0351 ± 0.0093
28.49 ± 7.29
50.95 ± 11.05


X50
33.33 ± 0.25
0.0372 ± 0.0092
26.88 ± 7.09
48.13 ± 14.21


X51
40.28 ± 0.24
0.0308 ± 0.0089
32.47 ± 7.31
58.12 ± 9.42 


X52
34.69 ± 0.34
0.0358 ± 0.0089
27.93 ± 8.18
50.06 ± 9.67 


X53
38.47 ± 0.24
0.0322 ± 0.0078
31.06 ± 7.94
55.51 ± 12.43


X54
33.83 ± 0.25
0.0367 ± 0.0091
27.25 ± 7.64
48.82 ± 11.23


X55
30.12 ± 0.36
0.0412 ± 0.0072
24.27 ± 8.15
43.46 ± 12.38


X56
40.86 ± 0.29
0.0304 ± 0.0057
32.89 ± 8.07
58.96 ± 10.05


X57
41.93 ± 0.24
0.0296 ± 0.0079
33.78 ± 8.18
60.51 ± 10.53


X58
32.57 ± 0.28
0.0381 ± 0.0074
26.25 ± 7.81
47.91 ± 13.49


X59
37.55 ± 0.27
0.0332 ± 0.0083
30.32 ± 7.11
54.18 ± 9.93 


X60
37.51 ± 0.25
0.0331 ± 0.0092
30.21 ± 7.29
54.13 ± 11.68


X61
31.69 ± 0.28
0.0391 ± 0.0075
25.58 ± 7.55
45.73 ± 13.62


X62
33.09 ± 0.28
0.0375 ± 0.0092
26.67 ± 8.16
47.75 ± 12.28


X63
39.97 ± 0.31
0.0310 ± 0.0082
32.26 ± 7.65
57.68 ± 13.32


X64
39.97 ± 0.28
0.0310 ± 0.0059
32.26 ± 7.25
57.68 ± 12.99


X65
39.53 ± 0.31
0.0314 ± 0.0083
31.85 ± 7.28
57.12 ± 12.24


X66
34.38 ± 0.25
0.0361 ± 0.0072
27.72 ± 7.51
49.61 ± 9.77 


X67
39.09 ± 0.28
0.0317 ± 0.0092
31.55 ± 8.03
56.41 ± 11.6 


X68
39.52 ± 0.34
0.0314 ± 0.0088
31.85 ± 7.92
57.03 ± 10.29


X69
33.38 ± 0.32
0.0372 ± 0.0073
26.88 ± 8.29
48.17 ± 14.31


X70
34.76 ± 0.26
0.0357 ± 0.0084
28.01 ± 8.16
50.16 ± 10.49


X71
35.13 ± 0.34
0.0353 ± 0.0057
28.33 ± 8.14
50.69 ± 13.41


X72
41.92 ± 0.29
0.0296 ± 0.0082
33.78 ± 7.14
60.46 ± 12.27


X73
33.16 ± 0.26
0.0374 ± 0.0074
26.74 ± 8.24
47.85 ± 13.58


X74
41.82 ± 0.29
0.0297 ± 0.0061
33.67 ± 7.09
60.35 ± 13.71


X75
33.15 ± 0.25
0.0374 ± 0.0058
26.74 ± 6.96
47.84 ± 13.94


X76
42.01 ± 0.33
0.0295 ± 0.0087
33.92 ± 7.64
60.62 ± 10.51


X77
42.91 ± 0.25
0.0289 ± 0.0061
34.63 ± 8.18
61.92 ± 9.54 


X78
37.02 ± 0.31
0.0335 ± 0.0056
29.85 ± 8.51
53.42 ± 9.94 


X79
37.87 ± 0.32
0.0328 ± 0.0061
30.49 ± 8.35
54.65 ± 10.24


X80
42.72 ± 0.25
0.0290 ± 0.0073
34.48 ± 7.33
61.65 ± 11.67


X81
38.06 ± 0.28
0.0326 ± 0.0091
30.67 ± 8.17
54.92 ± 11.49


X82
31.91 ± 0.35
0.0389 ± 0.0056
25.71 ± 7.22
46.05 ± 13.61


X83
36.23 ± 0.28
0.0342 ± 0.0073
29.24 ± 7.64
52.28 ± 11.73


X84
36.09 ± 0.28
0.0344 ± 0.0069
29.07 ± 8.23
52.08 ± 10.27


X85
40.97 ± 0.26
0.0303 ± 0.0082
33.12 ± 8.52
59.12 ± 10.41


X86
32.03 ± 0.31
0.0387 ± 0.0079
25.84 ± 8.05
46.22 ± 10.23


X87
41.42 ± 0.31
0.0299 ± 0.0085
33.44 ± 8.45
59.77 ± 10.55


X88
39.45 ± 0.33
0.0314 ± 0.0073
31.85 ± 7.13
56.93 ± 10.12


X89
40.95 ± 0.27
0.0303 ± 0.0091
33.11 ± 7.15
59.09 ± 11.83


X90
34.18 ± 0.31
0.0363 ± 0.0076
27.55 ± 8.16
49.32 ± 11.53









3. BENEFICIAL EFFECTS

Compared with the prior art, the present invention has the following beneficial effects:


(1) The half-life of the maleimide group-modified polypeptide HM-1 in the present invention is much longer than that of the HM-1 sequence, it is prolonged from 0.34 h to 30 h or more, the effect is very significant. Moreover, the modified polypeptide HM-1 increases the molecular weight and the plasma concentration at the lesion site after being bound to albumin, so that the administration frequency can be reduced from twice a day to once every seven days.


(2) According to the present invention, a solid phase synthesis method is adopted to enable the maleimide group to react with HM-1. Compared with PEG-modified HM-1, the present invention has the advantages of simple reaction, low cost, high yield and few impurities. The modified polypeptide in the present invention mainly functions by reacting the maleimide group with the sulfhydryl group at the 34th position of albumin at a molar ratio of 1:1. However, after the polypeptide reacts with the albumin through the maleimide group, due to the molecular weight of the polypeptide is small, while the molecular weight of the albumin is large, the albumin may cover active sites of the polypeptide, causing its activity to decrease or completely lose. This is unpredictable. The ideal molecules can be obtained only by selecting different molecules with maleimide groups. These ideal molecules do not affect the activity and can prolong the half-life.


(3) The present invention provieds a new molecule of the polypeptide HM-1 modified by the maleimide group. A large number of in vivo and in vitro activity studies have been performed on three types of maleimide group-modified angiogenesis inhibitors in the present invention, and their therapeutic effects on various diseases have been studied. It is found that under the condition of reduced administration frequency, various modified products maintain good activities of HM-1, surpassing the polypeptide HM-1 and the PEG-modified HM-1, and increasing their social value and economic value.


(4) For protein polypeptide molecules, a novel molecule is formed once each amino acid changes, which is the characteristic of biological macromolecules. Therefore, for biological macromolecules, including polypeptide molecules, no technology is universal, and it needs to explore and test to find out whether the technology is suitable for this novel molecule. The polypeptide in the present invention is a new molecule designed and discovered by the applicant, which is modified by the maleimide group for the first time. This requires a large number of experiments to obtain the expected effect and cannot be realized by speculation. The product modified by the maleimide group in the present invention also belongs to a novel molecule having different effects on activity from the pre-modified molecule.







DETAILED DESCRIPTION

The present invention is further described below with reference to specific examples.


Example 1

Preparation and Testing of Angiogenesis Inhibitor Polypeptides X1-X90


The polypeptides X1-X90 were synthesized by solid phase synthesis and separated and purified by preparative HPLC, and their purities were determined by analytical RP-HPLC.


The methods for synthesizing the polypeptides X1-X90 are similar and are all solid phase synthesis methods. The methods each include using Fmoc-wang-resin as a starting material, ligating protective amino acids to dipeptide to tridecapeptide, followed by maleimide group, performing adequate washing after the completion of the synthetic operation, and then cleaving the peptide and performing post treatment to obtain a crude angiogenesis inhibitor; dissolving the crude product, purifying with a preparative high performance liquid chromatography twice, performing concentration and freeze drying to obtain a pure product, and finally purifying for the third time to obtain a refined polypeptide. The methods can not only ensure the synthesis efficiency, but also improve the product purity.


1. The steps of peptide ligation are as follows:


weighing an appropriate amount of Fmoc-wang-resin, pouring the Fmoc-wang-resin into a glass sand core reaction column, adding an appropriate amount of CH2C12 to fully expand the resin, and sequentially ligating the following protected amino acids and maleimide groups which are dissolved in N, N-dimethylformamide (DMF) to the resin: Fmoc-Gly-OH, Fmoc-Arg(pbf)-OH, Fmoc-Gly-OH, Fmoc-Gly-OH, Fmoc-Gly-OH, Fmoc-Gly-OH, Fmoc-Ala-OH, Fmoc-Arg(pbf)-OH, Fmoc-Asp(otBu)-OH, Fmoc-Gly-OH, Fmoc-Arg(pbf)-OH and maleimide groups, and activating with 1-hydroxybenzotriazole (HOBT) and N,N′-diisopropylcarbodiimide (DIC) sequentially; using DMF solution containing 20% piperidine to remove the Fmoc protecting groups for 20 min; using trifluoroacetic acid, phenol, water, thioanisole and EDT at a ratio of 90:3:3:2:2 to cleave the peptide from the resin, and then precipitating with diethyl ether cooled by dry ice.


A. Deblocking: a proper amount of deblocking liquid of piperidine/DMF is added to react for a period of time, then the deblocking liquid is drained; during the process, the reactants are washed once with DMF, an addtional amount of deblocking liquid is add for reaction to remove Fmoc protecting groups.


B. Washing: the deblocking liquid is drained, and the resin is washed with DMF for several times, thereby fully washing off the by-products.


C. Condensation: the protective amino acids and activators for peptide ligation are dissolved in DMF and a condensing agent, and the mixture is shaked evenly; under the condition that the temperature is controlled at about 34° C., the reaction is fully carried out in a reactor.


D. Washing: the reaction liquid is drained, and the resin is fully washed with DMF, thereby washing off by-products.


2. The steps of peptide cleaving are as follows:


placing the drained resin into a round bottom flask, adding a lysate to fully lyse the synthesized X1-X90 intermediates, and separating the resin from the polypeptide by using a sand core funnel, wherein the lysate is composed of trifluoroacetic acid, phenol, water, thioanisole and EDT at the volume ratio of 90:3:3:2:2.


3. The steps of post treatment are as follows:


adding anhydrous diethyl ether first to the cleavage solution to precipitate the polypeptide, then centrifuging, pouring out the supernatant, then washing the polypeptide with the anhydrous diethyl ether, and draining to obtain the crude polypeptide.


4. The steps of purification are as follows:


A. Dissolution: the crude product is weighed accurately, an appropriate amount of purified water is added to prepare a solution with a concentration of 5-20 g/L, and the solution is ultrasonically stirred until a particle-free clear solution is obtained.


B. Filtration: the crude product solution is filtered with a 0.45 μm mixed filter membrane using a sand core filter.


C. Preparation: the primary purification, secondary purification and tertiary purification are performed by semi-preparative high performance liquid chromatography to obtain a refined qualified polypeptide, wherein the mobile phase comprises: acetonitrile in phase A and aqueous solution in phase B.


{circle around (1)} Primary purification: the 10% of acetonitrile and 90% of aqueous solution is used to rinse and equilibrate the preparative column for 10 min at a flow rate of 60 mL/min, and the crude product solution is loaded by an infusion pump. The elution gradient is shown in Table 4.









TABLE 4







The elution gradient of primary purification











Time
Flow rate


Wavelength


(min)
(mL/min)
A %
B %
(nm)














0
60
10
90
220


40
60
25
75
220









The solutions with the UV wavelength of 220 nm and an absorption value greater than 200 mV are collected, and the solutions with purity greater than 95% are pooled as a peak solution, which is subject to secondary separation and purification.


{circle around (2)} Secondary purification: the rotary evaporation is performed on the peak solution obtained by the primary purification to remove organic solvent; the 5% of acetonitrile and 95% of aqueous solution is used to rinse and equilibrate the preparative column for 10 min at a flow rate of 60 mL/min; and the product solution is loaded by an infusion pump. The elution gradient is shown in Table 5.









TABLE 5







The elution gradient of secondary purification











Time
Flow rate


Wavelength


(min)
(mL/min)
A %
B %
(nm)














0
60
7
95
220


40
60
15
85
220









The solutions with the UV wavelength of 220 nm and an absorption value greater than 200 mV are collected, and the solutions with purity greater than 98.5% were taken as qualified solutions.


D. Concentration, filtration and freeze-drying: the qualified solutions are concentrated under reduced pressure at 37° C. by a rotary evaporator to remove the residual solvent and part of moisture. Finally, the concentrated solutions are filtered with a 0.22 μm filter membrane, and the filtrate is put into a freeze-drying plate, and freeze-dried with a freeze dryer to obtain pure product.


5. Purity analysis of product


The purity of the freeze-dried product is analyzed by analytical high performance liquid chromatography under the following conditions:


analytical chromatographic column: COSMOSIL, 250 mm×4.6 mm(5 μm filler);


mobile phase: phase A is water and phase B is acetonitrile;


loading: 20 μL;


flow rate: 1 mL/min;


detection wavelength: 220 nm; and


elution gradient: see Table 6.









Table 6







RP-HPLC determination of the purity of polypeptides X1-X90











Numberof polypeptides
Peak area
Purity (%)







X1 
12106
97.94



X2 
12100
97.44



X3 
13004
97.77



X4 
12585
98.53



X5 
12791
98.62



X6 
12237
98.20



X7 
12335
97.57



X8 
12866
98.58



X9 
12483
98.60



X10
13087
98.36



X11
13564
98.19



X12
13382
98.28



X13
12577
97.56



X14
12289
97.94



X15
13803
98.07



X16
13947
97.85



X17
13286
98.71



X18
12703
98.23



X19
12975
98.69



X20
13564
98.17



X21
12507
98.67



X22
12896
97.77



X23
12580
97.65



X24
13913
98.46



X25
12652
97.44



X26
13897
98.59



X27
13163
98.52



X28
12899
97.92



X29
13266
97.65



X30
13175
97.98



X31
12161
98.32



X32
12667
98.12



X33
13077
98.17



X34
12472
98.51



X35
13212
97.65



X36
12524
97.96



X37
12323
98.00



X38
13814
97.50



X39
12994
98.68



X40
13681
98.34



X41
13071
98.34



X42
12114
97.48



X43
13983
97.59



X44
13478
97.70



X45
13798
98.11



X46
13561
98.74



X47
13536
98.43



X48
12835
97.96



X49
12246
97.46



X50
13169
97.77



X51
13833
98.27



X52
13008
98.12



X53
12150
98.70



X54
12528
98.75



X55
13726
98.28



X56
12280
98.14



X57
13729
97.50



X58
13223
97.85



X59
13617
98.68



X60
12782
97.62



X61
13850
98.32



X62
12497
98.65



X63
12648
97.71



X64
13387
98.19



X65
12216
98.75



X66
12686
97.89



X67
13047
98.61



X68
13175
97.69



X69
13188
98.37



X70
12976
98.15



X71
12312
98.49



X72
13300
97.97



X73
12117
97.60



X74
12797
98.32



X75
12204
97.57



X76
12977
97.54



X77
13314
97.98



X78
13087
97.94



X79
12609
98.37



X80
13924
98.25



X81
13725
97.78



X82
13364
97.76



X83
13564
98.44



X84
12689
98.30



X85
12316
98.74



X86
12902
98.21



X87
13138
97.43



X88
13282
97.91



X89
12533
97.69



X90
12595
97.57










Results: The synthesized polypeptides were analyzed by reversed phase liquid chromatography to obtain purity identification results. As shown in Table 6, the purities of the polypeptides X1-X90 are greater than 95%, which meets the design requirements.


Example 2

Proliferation Inhibition Experiment of Maleimide Group-Modified Angiogenesis Inhibitor Polypeptides on Various Tumor Cells


An MTT method was used to detect the inhibitory activity of X1-X90 on the growth of various tumor cells. Tumor cells were digested and collected with trypsin after being cultured in an incubator at 37° C. with 5% CO2 to a confluence of 90% or more. The cells were resuspended with a culture solution and counted under a microscope, the cell concentration was adjusted to 2×104 cells/mL, and the cell suspension was inoculated into a 96-well plate at 100 μL/well, and cultured overnight in an incubator at 37° C. with 5% CO2. X1-X90 were diluted to respective predetermined concentrations with the culture solution. Docetaxel was diluted to a final concentration with the culture solution. After the cells were completely adhered to the wall, each diluent was added into the 96-well plate (100 μL/well). Tumor cells with the addition of diluents of polypeptides X1-X90 were used as administration groups, tumor cells with the addition of docetaxel were used as a positive control group, and tumor cells with the addition of the culture solution without any drug were used as a negative control group. The cells were cultured in an incubator at 37° C. with 5% CO2 for 48 h. 5 mg/mL MTT was added into the 96-well plate, 20 μL per well, and the cultivation was continued for 4 h. The culture medium was removed, 150 μL of DMSO was added to each well for dissolution, and gent and uniform mixing was performed in a shaker for 10 min. The absorbance was measured at a detection wavelength of 570 nm and a reference wavelength of 630 nm using a microplate reader, and the proliferation inhibition rate (PIR) was calculated by the formula as follows:





PIR (%)=1−administration group/negative group


The experiment was repeated independently three times, and the results were expressed as mean ±SD. The experimental results are shown in Table 7.









TABLE 7





PIR (%) of polypeptides X1-X90 on various tumor cells

























Tumor cell












line source
HM-1
X1
X2
X3
X5
X6
X7
X8
X9
X10





Head and
36.12 ±
45.32 ±
49.44 ±
40.55 ±
69.15 ±
58.41 ±
40.15 ±
49.93 ±
37.65 ±
76.62 ±


neck cancers
11.21
10.94
18.24
17.92
16.66
11.59
15.57
18.85
18.92
17.47


Brain tumor
41.54 ±
61.34 ±
46.62 ±
47.71 ±
76.29 ±
62.37 ±
71.71 ±
73.5 ±
55.98 ±
71.95 ±



12.43
18.45
15.43
12.42
17.93
17.95
12.28
12.73
18.21
17.4


Thyroid
43.15 ±
55.15 ±
69.33 ±
64.22 ±
72.3 ±
73.62 ±
58.03 ±
73.95 ±
42.05 ±
63.94 ±


cancer
14.42
15.82
14.38
12.61
18.62
11.02
18.41
12.3
12.36
18 95


Esophageal
46.22 ±
62.32 ±
64.37 ±
36.11 ±
54.16 ±
70.62 ±
46.78 ±
75.56 ±
69.92 ±
59.44 ±


cancer
18.24
19.64
18.49
10.66
10.75
17.02
14.88
16.11
11.67
18.63


Pancreatic
45.03 ±
75.04 ±
69.94 ±
68.79 ±
78.51 ±
67.47 ±
74.36 ±
70.29 ±
72.1 ±
68.83 ±


cancer
13.18
16.68
19.94
15.74
14.26
19.99
15.33
18.12
14.74
10.76


Lung cancer
50.35 ±
50.55 ±
51.09 ±
73.31 ±
63.21 ±
75.24 ±
65.66 ±
71.42 ±
45.21 ±
49.77 ±



14.14
15.04
18.62
13.07
16.98
10.57
17.89
11.21
14.27
19.68


Liver cancer
44.45 ±
47.77 ±
48.67 ±
39.09 ±
56.49 ±
60.46 ±
52.51 ±
46.78 ±
70.57 ±
52.17 ±



13.46
15.96
13.64
19.99
16.35
13.32
18.03
11.22
18.17
13.39


Stomach
44.43 ±
46.42 ±
66.68 ±
36.88 ±
74.39 ±
66.17 ±
70.86 ±
70.39 ±
55.43 ±
67.71 ±


cancer
11.35
10.95
13.89
18.33
19.66
19.84
13.36
10.11
18.32
10.63


Breast cancer
41.54 ±
50.84 ±
38.08 ±
47.44 ±
56.98 ±
45.39 ±
43.24 ±
59.25 ±
41.76 ±
48.69 ±



14.28
14.38
12.92
13.73
12.93
15.53
10.21
13.82
16.73
17.43


Kidney
42.45 ±
62.65 ±
42.42 ±
69.87 ±
64.26 ±
35.68 ±
39.42 ±
45.77 ±
59.77 ±
55.27 ±


cancer
10.22
11.81
19.73
14.85
13.95
16.37
12.53
18.32
10.23
12.37


Colorectal
42.64 ±
69.65 ±
68.97 ±
56.23 ±
78.84 ±
43.61 ±
47.35 ±
43.97 ±
58.82 ±
36.56 ±


cancer
12.31
12.22
13.48
15.52
14.67
12.53
12.35
19.5
14.58
13.66


Ovarian
44.78 ±
56.91 ±
62.85 ±
45.82 ±
70.07 ±
35.33 ±
53.68 ±
66.00 ±
76.51 ±
67.9 ±


cancer
14.06
17.05
17.22
10.23
17.29
17.57
11.49
14.31
18.97
11.92


Cervical
46.03 ±
66.03 ±
68.94 ±
53.82 ±
65.31 ±
53.83 ±
50.12 ±
61.36 ±
36.05 ±
43.58 ±


cancer
14.71
16.73
14.21
15.25
13.87
18.12
15.57
10.83
13.62
12.38


Uterine
46.85 ±
44.85 ±
61.25 ±
37.31 ±
76.97 ±
47.04 ±
60.03 ±
74.99 ±
55.32 ±
69.42 ±


cancer
10.21
11.31
19.98
18.32
16.8
17.32
15.64
18.79
16.01
18.85


Prostate
50.14 ±
70.12 ±
52.24 ±
63.22 ±
75.07 ±
55.64 ±
40.17 ±
40.62 ±
69.35 ±
62.39 ±


cancer
14.13
17.1
18.33
15.99
13.88
19.58
15.73
11.39
15.14
12.52


Bladder
51.99 ±
52.59 ±
67.44 ±
58.84 ±
73.55 ±
76.54 ±
69.99 ±
39.36 ±
41.19 ±
41.05 ±


cancer
14.57
19.54
15.81
14.48
15.92
13.26
16.57
11.00
11.96
13.81


Melanoma
53.62 ±
53.73 ±
66.34 ±
43.28 ±
68.38 ±
54.92 ±
36.52 ±
66.92 ±
59.72 ±
73.63 ±



12.12
18.72
12.43
12.95
18.49
17.94
13.11
11.56
17.25
14 34


Hemangioma
46.23 ±
66.23 ±
56.24 ±
59.43 ±
65.27 ±
41.63 ±
71.12 ±
42.54 ±
44.06 ±
65.39 ±



12.09
10.06
19.91
16.89
10.67
18.32
13.01
12.49
19.17
18.56


Sarcoma
49.25 ±
69.22 ±
39.82 ±
47.97 ±
77.03 ±
47.72 ±
49.68 ±
48.86 ±
68.92 ±
49.55 ±



11.03
11.18
17.52
19.23
12.78
10.94
10.83
16.97
11.29
11.75





Tumor cell












line source
X11
X12
X13
X14
X16
X17
X18
X19
X20





Head and neck
70.38 ±
43.35 ±
52.83 ±
57.41 ±
45.08 ±
44.20 ±
72.52 ±
46.15 ±
35.32 ±



cancers
10.46
10.51
16.12
12.19
12.39
10.35
13.81
17.34
10.94



Brain tumor
43.5 ±
64.6 ±
45.99 ±
65.89 ±
63.52 ±
57.12 ±
76.72 ±
44.00 ±
61.34 ±




10.29
10.41
10.57
13.7
15.53
12.71
11.32
15.36
18.45



Thyroid
61.62 ±
48.73 ±
75.42 ±
69.82 ±
43.49 ±
65.07 ±
45.28 ±
61.38 ±
55.15 ±



cancer
16.5
13.45
14.25
11.28
17.57
12.16
15.02
14.8
15.82



Esophageal
75.25 ±
49.55 ±
39.83 ±
63.49 ±
42.86 ±
38.70 ±
64.11 ±
59.89 ±
62.32 ±



cancer
19.36
10.47
18.32
14.04
18.89
10.38
13.19
10.43
19.64



Pancreatic
68.62 ±
68.77 ±
73.27 ±
75.33 ±
65.36 ±
52.33 ±
60.53 ±
66.02 ±
45.04 ±



cancer
16.11
13.87
17.24
19.56
12.63
18.04
13.86
18.91
16.68



Lung cancer
74.71 ±
57.53 ±
69.83 ±
54.73 ±
61 82 ±
58.01 ±
56.29 ±
71.72 ±
50.55 ±




13.94
10.47
11.88
16.81
17.43
13.06
16.98
13.46
15.04



Liver cancer
39.36 ±
47.27 ±
47.27 ±
39.09 ±
37.73 ±
48.78 ±
68.38 ±
42.02 ±
47.77 ±




19.9
10.69
16.42
17.13
13.19
11.01
13.37
15.65
15.96



Stomach
67.3l ±
40.71 ±
60.66 ±
66.73 ±
55.87 ±
40.46 ±
72.54 ±
36.74 ±
46.4 ±



cancer
14.91
18.16
18.62
19.09
12.11
17.78
17.92
10.31
10.95



Breast cancer
72.88 ±
62.51 ±
56.91 ±
65.43 ±
55.22 ±
73.27 ±
54.26 ±
68.22 ±
50.84 ±




19.79
10.82
13.22
15.75
15.17
18.97
10.66
15.65
14.38



Kidney
51.24 ±
73.13 ±
45.54 ±
70.09 ±
61.25 ±
66.17 ±
55.34 ±
51.05 ±
62.65 ±



cancer
11.79
15.26
11.94
19.12
14.17
15.56
10.48
15.04
1181



Colorectal
41.66 ±
40.41 ±
65.38 ±
46.64 ±
60.82 ±
70.89 ±
57.09 ±
69.75 ±
69.65 ±



cancer
10.28
18.93
10.76
12.58
19.32
11.99
12.27
19.72
12.22



Ovarian
46.03 ±
70.05 ±
63.65 ±
37.09 ±
73.44 ±
52.42 ±
52.32 ±
68.98 ±
56.91 ±



cancer
17.88
19.95
11.23
18.1
15.92
14.4
18.59
15.57
17.05



Cervical
75.33 ±
39.8 ±
38.93 ±
38.36 ±
54.21 ±
76.64 ±
41.59 ±
74.61 ±
66.03 ±



cancer
11.37
11.93
15.38
15.55
19.74
16.75
10.98
12.49
16.73



Uterine
40.22 ±
41.28 ±
67.28 ±
50.56 ±
71.58 ±
67.20 ±
60.27 ±
75.49 ±
44.85 ±



cancer
18.4
17.34
19.72
14.78
18.16
15.42
16.22
17.93
11.31



Prostate
41.34 ±
46.03 ±
67.61 ±
39.41 ±
63.08 ±
75.20 ±
74.09 ±
38.65 ±
70.12 ±



cancer
15.08
18.52
13.78
17.12
13.98
17.35
13.02
13.79
17.21



Bladder
51.59 ±
42.17 ±
51.93 ±
46.15 ±
68.71 ±
42.48 ±
53.89 ±
49.44 ±
52.59 ±



cancer
12.27
18.37
11.55
16.28
15.12
16.74
14.29
18.24
19.54



Melanoma
73.35 ±
42.09 ±
60.97 ±
76.32 ±
66.03 ±
54.91 ±
63.33 ±
46.62 ±
53.73 ±




17.22
15.84
10.64
19.97
18.07
11.6
12.77
15.43
18.72



Hemangioma
51.73 ±
36.27 ±
55.41 ±
63 .62 ±
49.73 ±
57.68 ±
51.93 ±
69.33 ±
66.23 ±




15.04
14.02
19.69
11.34
10.09
19.18
18.53
14.38
10.06



Sarcoma
75.26 ±
56.74 ±
59.26 ±
72.57 ±
56.19 ±
73.67 ±
67.78 ±
64.37 ±
69.22 ±




10.29
12.92
11.12
14.25
18.81
11.87
14.37
18.49
11.18





Tumor cell












line source
X21
X22
X23
X24
X26
X27
X28
X29
X30





Head and
65.37 ±
41.81 ±
38.14 ±
47.69 ±
67.64 ±
35.7 ±
42.99 ±
62.68 ±
39.04 ±



neck cancers
12.94
19.53
11.14
11.08
14.25
11.09
13.38
18.91
17.98



Brain tumor
40.99 ±
43.94 ±
47.74 ±
40.49 ±
73.72 ±
63.22 ±
47.88 ±
56.05 ±
43.39 ±




17.15
10.64
18.81
11.86
16.04
12.73
15.33
15.02
12.99



Thyroid
41.77 ±
40.29 ±
71.79 ±
37.62 ±
49.45 ±
59.78 ±
63.91 ±
51.22 ±
73.79 ±



cancer
11.86
16.44
11.29
11.49
19.31
16.48
12.54
11.18
13.35



Esophageal
43.15 ±
69.17 ±
65.85 ±
55.87 ±
36.55 ±
37.45 ±
63.41 ±
54.58 ±
49.43 ±



cancer
12.94
15.02
12.51
19.15
11.12
17.97
17.78
12.69
12.02



Pancreatic
62.03 ±
70.94 ±
50.79 ±
71.49 ±
69.55 ±
74.52 ±
74.12 ±
65.63 ±
46.17 ±



cancer
17.34
11.72
17.97
16.47
13.45
11.34
19.3
10.54
14.33



Lung cancer
62.39 ±
39.95 ±
35.08 ±
40.66 ±
57.59 ±
60.92 ±
63.39 ±
38.75 ±
38.85 ±




18.81
14.11
10.52
1343
18.82
16.14
14.52
15.08
18.34



Liver cancer
56.3 ±
43.69 ±
61.83 ±
52.89 ±
61.04 ±
76.74 ±
67.73 ±
36.33 ±
73.83 ±




19.71
17.77
11.42
11.54
10.92
15.66
13.72
10.49
16.98



Stomach
36.47 ±
59.08 ±
38.39 ±
37.4 ±
63.35 ±
51.63 ±
54.97 ±
52.53 ±
58.32 ±



cancer
14.16
18.93
14.85
13.48
11.59
17.16
17.82
18.92
11.91



Breast cancer
38.96 ±
75.82 ±
39.96 ±
75.56 ±
37.61 ±
53.33 ±
71.89 ±
37.44 ±
46.39 ±




11.33
12.56
11.75
17.92
14.38
14.69
12.86
16.04
17.85



Kidney
74.18 ±
57.47 ±
42.09 ±
36.39 ±
64.84 ±
63.46 ±
73.61 ±
72.79 ±
63.35 ±



cancer
19.11
13.26
10.45
11.33
19.25
17.95
11.16
13.82
14.59



Colorectal
53.91 ±
63.73 ±
41.59 ±
69.36 ±
54.52 ±
49.88 ±
36.83 ±
37.95 ±
59.27 ±



cancer
15.15
14.02
16.05
14.11
15.74
10.16
18.74
12.31
19.00



Ovarian
52.65 ±
38.12 ±
59.19 ±
67.71 ±
36.94 ±
71.02 ±
47.82 ±
38.03 ±
53.44 ±



cancer
18.77
17.81
18.4
10.08
11.86
17.33
17.51
13.59
17.9



Cervical
69.23 ±
51.74 ±
54.67 ±
57.26 ±
57.01 ±
55.75 ±
63.32 ±
43.21 ±
76.45 ±



cancer
11.47
14.66
16.68
13.86
13.74
12.84
12.16
18.53
11.67



Uterine
63.43 ±
50.89 ±
42.53 ±
42.54 ±
64.21 ±
54.16 ±
43.3 ±
46.82 ±
56.25 ±



cancer
12.15
1096%
17.35
10.76
13.94
13.46
13.08
10.37
14.73



Prostate
37.86 ±
53.39 ±
36.21 ±
35.47 ±
64.17 ±
67.49 ±
40.94 ±
55.77 ±
59.54 ±



cancer
16.92
15.54
12.05
18.64
17.11
10.57
16.98
13.52
12.23



Bladder
37.75 ±
47.84 ±
50.54 ±
63.09 ±
50.89 ±
76.84 ±
44.24 ±
61.24 ±
39.65 ±



cancer
12.45
17.84
19.02
17.99
13.05
19.86
17.88
13.77
11.16



Melanoma
47.85 ±
61.05 ±
69.51 ±
54.36 ±
38.59 ±
35.73 ±
56.95 ±
64.53
55.41 ±




16.14
12.55
19.87
16.72
13.49
19.88
13.59
19.46
15.58



Hemangioma
62.98 ±
53.14 ±
70.64 ±
37.01 ±
37.45 ±
37.75 ±
38.68 ±
69.34 ±
48.32 ±




19.47
18.17
15.46
14.49
15.43
15.17
15.49
15.1
18.65



Sarcoma
46.06 ±
46.46 ±
39.37 ±
40.2 ±
49.91 ±
35.55 ±
70.91 ±
59.14 ±
67.77 ±




11.73
11.38
10.22
16.78
15.19
15.02
13.58
10.37
10.57





Tumor cell












line source
X31
X32
X33
X34
X36
X37
X38
X39
X40





Head and
59.09 ±
47.45 ±
37.58 ±
39.94 ±
56.51 ±
71.19 ±
39.93 ±
62.9 ±
61.85 ±



neck cancers
11.77
10.36
18.81
19.94
11.45
18.71
18.52
17.54
14.34



Brain tumor
37.42 ±
47.30 ±
60.86 ±
51.09 ±
38.39 ±
75.85 ±
39.71 ±
64.41 ±
37.43 ±




14.99
14.26
16.39
18.62
13.28
10.45
17.17
10.78
15.84



Thyroid
67.18 ±
40.25 ±
72.56 ±
48.67 ±
46.37 ±
66.79 ±
46.45 ±
64.57 ±
54.26 ±



cancer
13.35
18.76
10.91
13.64
15.24
14.56
16.12
18.46
11.41



Esophageal
35.00 ±
62.59 ±
69.52 ±
66.68 ±
50.5 ±
49.78 ±
56.35 ±
70.94 ±
66.23 ±



cancer
11.96
17.05
11.28
13.89
19.08
13.14
13.87
17.84
10.75



Pancreatic
36.26 ±
67.82 ±
46.18 ±
38.08 ±
41.26 ±
43.04 ±
44.09 ±
74.19 ±
42.92 ±



cancer
13.15
18.67
18.53
12.92
16.28
13.58
19.22
1588
17.04



Lung cancer
37.01 ±
64.40 ±
59.87 ±
42.42 ±
53.94 ±
64.69 ±
50.43 ±
59.01 ±
59.02 ±




19.88
14.44
1889
19.73
11.35
15.31
15.95
14.77
14.13



Liver cancer
65.28 ±
41.50 ±
47.79 ±
68.97 ±
53.72 ±
70.33 ±
74 45 ±
75.48 ±
40.28 ±




15.00
14.14
19.83
13.48
11.59
16.53
19.05
14.7
15.06



Stomach
43.64 ±
64.61 ±
74.39 ±
62.85 ±
42.63 ±
70.68 ±
38 56 ±
73.13 ±
57.6 ±



cancer
18.32
11.64
12.63
17.22
14.95
15.03
12.55
13.66
19.33



Breast cancer
59.94 ±
50.80 ±
40.54 ±
68.94 ±
72.93 ±
75.33 ±
42.19 ±
49.25 ±
52.71 ±




18.74
19.73
16.38
14.21
13.26
17.22
14.86
12.62
13.62



Kidney
58.09 ±
62.76 ±
71.31 ±
61.35 ±
69.37 ±
61.78 ±
43.37 ±
72.04 ±
49.08 ±



cancer
11.56
19.43
19.93
19.98
17.47
19.61
10.23
18.36
13.39



Colorectal
55.85 ±
65.59 ±
50.37 ±
52.24 ±
53.83 ±
51.57 ±
52.13 ±
75.22 ±
60.02 ±



cancer
15.14
16.95
1442
18.33
16.52
17.35
11.76
12.29
17.91



Ovarian
40.61 ±
58.83 ±
44.16 ±
67.44 ±
46.07 ±
36.29 ±
70.13 ±
65.05 ±
36.21 ±



cancer
17.82
14.79
19.51
15.81
15.34
15.57
16.95
12.23
13.51



Cervical
37.69 ±
60.95 ±
59.94 ±
66.34 ±
47.99 ±
42.92 ±
57.13 ±
62.28 ±
55.53 ±



cancer
13.66
10.91
17.51
12.43
17.22
12.23
13.93
11.24
13.76



Uterine
68.32 ±
70.59 ±
53.45 ±
56.24 ±
38.24 ±
75.62 ±
59.59 ±
70.32 ±
48.62 ±



cancer
12.00
10.48
12.20
19.91
12.39
10.59
11.12
18.57
18.19



Prostate
58.57 ±
54.52 ±
57.98 ±
39.80 ±
67.78 ±
56.05 ±
37.75 ±
67.22 ±
57.83 ±



cancer
11.14
15.17
11.51
17.52
15.22
17.78
15.12
17.94
15.36



Bladder
68.69 ±
47.88 ±
55.5 ±
39.15 ±
67.95 ±
37.03 ±
38.32 ±
50.68 ±
72.35 ±



cancer
13.76
14.12
16.52
16.66
11.94
11.84
18.93
11.3
17.77



Melanoma
37.58 ±
55.05 ±
42.06 ±
56.29 ±
44.02 ±
45.96 ±
43.72 ±
69.87 ±
71.94 ±




13.12
18.49
12.13
17.93
17.54
15.52
13.46
10.94
19.98



Hemangioma
43.57 ±
68.1 ±
58.53 ±
72.30 ±
68.06 ±
66.33 ±
41.49 ±
40.71 ±
57.56 ±




10.89
11.51
19.84
18.62
10.23
15.99
13.11
14.01
16.63



Sarcoma
75.54 ±
42.81 ±
44.99 ±
54.16 ±
39.39 ±
57.04 ±
62.42 ±
36.49 ±
56.97 ±




12.27
18.57
15.09
10.75
11.23
12.99
16.98
11.27
15.31





Tumor cell












line source
X41
X42
X43
X44
X46
X47
X48
X49
X50





Head and neck
43.57 ±
57.82 ±
45.72 ±
47.11 ±
65.93 ±
71.66 ±
72.66 ±
63.32 ±
35.25 ±



cancers
11.52
18.62
17.16
18.32
11.44
13.54
12.68
16.98
18.05



Brain tumor
67.93 ±
57.43 ±
38.23 ±
45.99 ±
40.92 ±
43.77 ±
74.95 ±
56.49 ±
66.21 ±




12.91
18.76
11.62
16.31
18.18
19.29
12.2
16.35
18.67



Thyroid cancer
74.41 ±
45.39 ±
70.14 ±
44.32 ±
43.73 ±
47.17 ±
51.53 ±
74.39 ±
61.88 ±




14.24
12.72
13.78
19.58
11.29
16.99
14.44
19.66
18.69



Esophageal
66.6 ±
39.81 ±
70.48 ±
63.23 ±
75.58 ±
62.93 ±
45.97 ±
56.98 ±
57.62 ±



cancer
18.75
19.98
11.52
12.00
17.98
11.00
19.69
12.93
14.81



Pancreatic
67.73 ±
68.34 ±
70.71 ±
57.18 ±
64.04 ±
62.95 ±
54.68 ±
54.36 ±
60.61 ±



cancer
18.13
17.07
18.98
15.60
11.93
15.06
13.49
13.95
14.92



Lung cancer
54.74 ±
72.97 ±
71.61 ±
73.36 ±
70.54 ±
46.59 ±
42.00 ±
58.84 ±
45.90 ±




17.54
13.34
12.51
19.38
19.32
15.12
14.24
14.67
13.01



Liver cancer
52.24 ±
44.69 ±
58.91 ±
37.45 ±
40.64 ±
59.38 ±
44.78 ±
70.07 ±
45.05 ±




14.33
17.55
16.57
14.63
11.24
18.24
17.1
17.29
15.28



Stomach cancer
61.92 ±
57.72 ±
54.13 ±
37.92 ±
40.50 ±
61.58 ±
72.03 ±
35.31 ±
62.97 ±




11.95
12.27
11.01
13.15
15.68
13.24
18.87
13.87
14.24



Breast cancer
64.46 ±
61.79 ±
57.59 ±
45.85 ±
39.62 ±
56.85 ±
48.41 ±
76.97 ±
73.69 ±




12.3
19.55
17.99
17.46
13.82
13.96
10.37
16.87
16.38



Kidney cancer
67.32 ±
62.18 ±
40.35 ±
36.95 ±
58.12 ±
65.49 ±
52.92 ±
75.07 ±
76.09 ±




11.68
10.77
14.15
13.61
10.96
15.66
14.91
13.88
10.99



Colorectal
42.94 ±
47.39 ±
64.08 ±
50.08 ±
46.96 ±
50.67 ±
40.83 ±
48.38 ±
64.83 ±



cancer
12.14
18.01
11.47
18.11
17.53
13.52
12.05
18.49
17.73



Ovarian cancer
39.68 ±
74.11 ±
61.54 ±
44.64 ±
37.37 ±
44.93 ±
61.05 ±
65.27 ±
75.15 ±




17.13
14.39
19.79
16.9
19.48
11.12
11.13
10.67
11.54



Cervical
47.37 ±
72.53 ±
47 07 ±
55.47 ±
64.16 ±
42.26 ±
55.52 ±
57.03 ±
51.98 ±



cancer
18.96
15.56
15.21
19.86
13.04
11.78
15.41
12.78
17.49



Uterine cancer
59.93 ±
70.55 ±
38.13 ±
68.83 ±
74.34 ±
35.35 ±
45.13 ±
40.55 ±
66.93 ±




14.82
12.92
18.8.3
13.88
12.93
10.02
15.15
17.92
16.18



Prostate cancer
54.51 ±
73.74 ±
47.49 ±
35.19 ±
51.00 ±
70.17 ±
70.81 ±
47.71 ±
39.81 ±




10.24
12.36
11.98
12.08
10.13
16.96
16.63
12.42
19.13



Bladder cancer
53.29 ±
60.39 ±
70.11 ±
43.34 ±
52.83 ±
62.79 ±
62.99 ±
64.22 ±
62.67 ±




11.03
12.52
16.32
14.41
17.75
10.07
14.78
12.63
18.21



Melanoma
56.44 ±
74.41 ±
67.28 ±
41.66 ±
73.83 ±
65.79 ±
38.81 ±
36.11 ±
56.05 ±




15.23
14.21
19.72
10.72
10.72
17.97
11.36
10.66
18.67



Hemangioma
40.91 ±
66.21 ±
66.87 ±
74.36 ±
75.45 ±
59.32 ±
67.47 ±
68.79 ±
39.90 ±




14.12
10.51
15.29
15.31
18.09
12.16
17.41
15.74
14.29



Sarcoma
74.05 ±
46.23 ±
44.1 ±
49.22 ±
55.78 ±
64.54 ±
71.83 ±
73.31 ±
55.03 ±




12.15
12.39
12.29
19.56
17.99
13.65
17.48
13.07
19.71





Tumor cell












line source
X51
X52
X53
X54
X56
X57
X58
X59
X60





Head and
71.73 ±
67.97 ±
50.5 ±
38.31 ±
35.55 ±
66.36 ±
40.34 ±
49.86 ±
70.78 ±



neck cancers
13.79
14.45
11.07
13.9
14.28
13.68
13.58
13.23
17.01



Brain tumor
38.48 ±
52.23 ±
62.85 ±
66.14 ±
37.61 ±
48.16 ±
36.05 ±
55.61 ±
50.82 ±




16.23
11.05
14.02
18.76
16.92
16.82
15.82
14.73
16.24



Thyroid
56.65 ±
53.23 ±
47.46 ±
35.55 ±
41.84 ±
51.93 ±
57.07 ±
48.16 ±
53.48 ±



cancer
15.18
19.88
13.43
17.12
12.29
15.96
12.62
15.78
10.27



Esophageal
39.56 ±
42.57 ±
53.96 ±
75.89 ±
49.57 ±
57.85 ±
55.44 ±
74.88 ±
45.45 ±



cancer
10.25
12.22
19.26
14.54
15.38
12.32
10.14
17.52
14.17



Pancreatic
43.25 ±
46.95 ±
45.87 ±
53.85 ±
57.21 ±
59.73 ±
73.61 ±
45.52 ±
50.92 ±



cancer
19.53
18.35
19.22
11.88
12.43
10.12
12.93
13.68
19.47



Lung cancer
54.77 ±
63.5 ±
39.93 ±
40.15 ±
51.03 ±
69.87 ±
49.64 ±
45.73 ±
62.47 ±




14.37
14.12
15.43
17.43
15.64
19.38
14.08
13.94
13.16



Liver cancer
64.82 ±
76.28 ±
44.85 ±
68.72 ±
47.39 ±
57.51 ±
37.68 ±
61.08 ±
57.27 ±




13.19
16.95
18.16
19.36
11.27
19.37
17.24
19.18
14.89



Stomach
49.52 ±
71.77 ±
61.27 ±
65.15 ±
43.77 ±
44.39 ±
69.28 ±
66.37 ±
58.56 ±



cancer
13.42
13.87
10.13
12.34
15.32
18.59
15.69
14.87
14.96



Breast cancer
45.34 ±
71.37 ±
55.81 ±
71.24 ±
45.15 ±
72.88 ±
55.26 ±
35.39 ±
64.38 ±




12.87
10.37
15.77
10.08
12.83
18.92
13.17
10.86
16.18



Kidney
68.57 ±
48.73 ±
50.42 ±
53.57 ±
52.29 ±
46.83 ±
39.21 ±
57.34 ±
47.11 ±



cancer
12.06
12.21
14.19
18.29
15.37
19.17
10.58
11.06
18.83



Colorectal
65.66 ±
73.22 ±
40.62 ±
69.25 ±
38.34 ±
51.68 ±
49.93 ±
56.47 ±
74.01 ±



cancer
12.27
10.18
12.76
12.45
13.74
12.59
16.52
12.62
16.85



Ovarian
36.23 ±
71.63 ±
41.92 ±
61.42 ±
52.51 ±
66 ±
71.78 ±
59.72 ±
37.71 ±



cancer
13.19
16.37
10.41
11.94
16.01
15.2
19.13
17.77
19.04



Cervical
64.98 ±
50.09 ±
63.12 ±
43.25 ±
62.12 ±
55.66 ±
69.74 ±
56.03 ±
68.51 ±



cancer
18.41
13.98
14.09
12.66
16.54
18.88
11.34
11.47
10.44



Uterine
36.86 ±
47.69 ±
49.15 ±
35.81 ±
61.69 ±
40.69 ±
52.07 ±
56.94 ±
54.36 ±



cancer
17.04
19.55
17.93
10.02
18.28
17.84
10.37
17.27
18.71



Prostate
64.4 ±
57.92 ±
67.39 ±
73.54 ±
76.33 ±
73.75 ±
71.72 ±
60.29 ±
59.57 ±



cancer
12.04
14.12
17.65
16.66
15.82
17.92
18.51
12.23
11.48



Bladder
63.28 ±
39.17 ±
38.66 ±
48.75 ±
37.33 ±
43.43 ±
65.05 ±
53.71 ±
57.48 ±



cancer
17.47
11.62
14.24
18.54
14.97
18.63
11.02
12.75
17.09



Melanoma
36.94 ±
37.8 ±
42.32 ±
53.92 ±
41.91 ±
45.92 ±
59.28 ±
45.12 ±
62.45 ±




11.26
18.44
15.63
17.91
17.71
13.04
17.18
13.72
17.77



Hemangioma
67.23 ±
50.46 ±
45.35 ±
67.47 ±
59.8 ±
45.15 ±
55.89 ±
61.25 ±
37.3 ±




11.25
10.54
14.66
13.18
13.33
13.98
12.13
19.99
10.21



Sarcoma
58.32 ±
48.85 ±
41.78 ±
67.01 ±
39.26 ±
48.03 ±
35.26 ±
36.57 ±
40.63 ±




13.38
19.52
16.51
12.85
19.06
10.76
14.88
11.96
19.46





Tumor cell












line source
X61
X62
X63
X64
X66
X67
X68
X69
X70





Head and
40.64 ±
60.36 ±
63.37 ±
39.09 ±
38.52 ±
42.23 ±
59.72 ±
51.77 ±
52.03 ±



neck cancers
19.78
16.07
12.42
19.99
12.49
15.76
17.24
16.13
12.38



Brain tumor
47.33 ±
69.94 ±
59.22 ±
36.88 ±
60.72 ±
73.26 ±
60.29 ±
55.81 ±
38.37 ±




13.12
19.70
15.12
18.33
15.43
14.09
13.47
18.92
13.24



Thyroid
39.88 ±
52.65 ±
62.03 ±
47.44 ±
38.37 ±
55.43 ±
59.88 ±
75.71 ±
37.92 ±



cancer
12.95
19.20
11.14
13.73
18.26
19.84
17.75
17.42
10.46



Esophageal
63.31 ±
52.77 ±
37.37 ±
69.87 ±
75.12 ±
35.62 ±
47.87 ±
38.73 ±
64.28 ±



cancer
17.56
10.21
15.10
14.85
19.14
19.46
13.16
17.62
18.75



Pancreatic
46.88 ±
35.43 ±
41.05 ±
56.23 ±
54.27 ±
58.71 ±
75.22 ±
61.73 ±
56.61 ±



cancer
10.17
19.91
11.77
15.52
19.84
15.04
19.54
10.56
10.79



Lung cancer
69.90 ±
42.92 ±
57.25 ±
45.82 ±
52.94 ±
68.04 ±
39.11 ±
60.18 ±
39.68 ±




16.79
15.59
15.89
10.23
19.25
19.12
18.74
17.44
19.33



Liver cancer
66.47 ±
70.65 ±
47.74 ±
53.82 ±
72.51 ±
52.65 ±
66.85 ±
67.87 ±
66.59 ±




16.50
18.33
17.07
15.25
18.64
17.17
17.46
18.98
12.84



Stomach
43.87 ±
74.79 ±
52.66 ±
37.31 ±
65.63 ±
38.72 ±
73.08 ±
63.46 ±
41.87 ±



cancer
12.66
11.78
19.90
18.20
11.49
14.66
11.27
17.98
16.14



Breast cancer
51.9 ±
60.66 ±
76.30 ±
63.22 ±
56.94 ±
71.39 ±
37.5 ±
69.52 ±
62.22 ±




18.43
13.30
14.50
15.99
11.83
10.03
18.46
15.05
13.67



Kidney
76.61 ±
73.08 ±
36.28 ±
58.84 ±
58.74 ±
74.09 ±
69.86 ±
54.11 ±
52.8 ±



cancer
11.74
12.10
15.22
14.48
10.17
11.22
10.14
13.04
12.14



Colorectal
61.34 ±
41.69 ±
40.50 ±
43.28 ±
76.92 ±
55.41 ±
76.38 ±
72.28 ±
74.94 ±



cancer
10.45
13.05
14.82
12.95
18.37
11.72
12.8
15.99
10.12



Ovarian
41.79 ±
65.50 ±
54.64 ±
59.43 ±
65.86±
74.42 ±
40.76 ±
64.39 ±
35.48 ±



cancer
11.50
12.11
12.72
16.89
13.29
12.21
15.85
11.63
15.43



Cervical
59.80 ±
52.13 ±
42.74 ±
47.97 ±
72.53 ±
64.38 ±
68.37 ±
52.37±
71.37 ±



cancer
10.07
10.40
18.42
19.23
14.78
12.38
14.74
15.37
19.36



Uterine
65.76 ±
36.40 ±
45.53 ±
51.12 ±
49.78 ±
71.374 ±
59.27 ±
48.37 ±
62.28 ±



cancer
11.21
13.07
10.70
14.37
17.98
19.74
12.48
16.37
13.27



Prostate
62.95 ±
53.04 ±
82.39 ±
51.33 ±
81.49±
80.25 ±
78.02 ±
79.09 ±
73.4 ±



cancer
11.09
18.63
12.84
17.15
11.84
11.87
11.55
16.05
10.31



Bladder
72.48 ±
65.40 ±
64.27 ±
71.51 ±
69.39 ±
50.89 ±
67.49 ±
55.74 ±
57.92 ±



cancer
10.86
13.99
19.88
14.26
18.29
18.8
17.29
12.17
18.52



Melanoma
39.81 ±
44.69 ±
76.84 ±
55.75 ±
60.92 ±
59.78 ±
56.74 ±
46.03 ±
70.05 ±




19.98
17.55
19.86
12.84
16.14
16.48
12.92
18.52
19.95



Hemangioma
68.34 ±
57.72 ±
35.73 ±
54.16 ±
76.74 ±
37.45 ±
35.7 ±
42.17 ±
39.8 ±




17.07
12.27
19.88
13.46
15.66
17.97
11.09
18.37
11.93



Sarcoma
72.97 ±
61.79 ±
37.75 ±
67.49 ±
51.63 ±
74.52 ±
63.22 ±
42.09 ±
41.28 ±




13.34
19.55
15.17
10.57
17.16
11.34
12.73
15.84
17.34





Tumor cell












line source
X71
X72
X73
X74
X76
X77
X78
X79
X80





Head and
49.18 ±
43.31 ±
44.27 ±
52.46 ±
56.29 ±
35.32 ±
71.09 ±
43.61 ±
68.51 ±



neck cancers
10.58
19.08
16.25
11.59
17.93
10.94
13.86
11.06
10.44



Brain tumor
47.61 ±
47.06 ±
74.32 ±
54.64 ±
72.3 ±
61.34 ±
55.15 ±
35.25 ±
54.36 ±




10.56
15.79
11.53
16.96
18.62
18.45
10.41
18.05
18.71



Thyroid
63.08 ±
41.47 ±
72.02 ±
56.97 ±
54.16 ±
55.15 ±
36.27 ±
66.21 ±
59.57 ±



cancer
19.04
15.52
10.95
15.87
10.75
15.82
17.48
18.67
11.48



Esophageal
49.81 ±
60.94 ±
73.19 ±
66.75 ±
71.51 ±
62.32 ±
40.3 ±
61.88 ±
57.48 ±



cancer
19.55
10.28
15.36
19.92
14.26
19.64
10.03
18.69
17.09



Pancreatic
51.23 ±
60.51 ±
67.14 ±
73.62 ±
63.2 ±
45.04 ±
37.68 ±
57.62 ±
62.45 ±



cancer
12.92
13.32
17.12
16.04
16.98
16.68
14.54
14.81
17.77



Lung cancer
48.32 ±
37.99 ±
72.63 ±
56.82 ±
56.49 ±
50.55 ±
61.72 ±
60.6 ±
37.3 ±




13.6
17.69
10.55
12.55
16.35
15.04
19.05
14.92
10.21



Liver cancer
51.96 ±
63.54 ±
66.15 ±
56.31 ±
74.39 ±
47.77 ±
76.66 ±
45.9 ±
40.63 ±




12.99
18.34
17.37
19.46
19.66
15.96
18.79
13.01
19.46



Stomach
66.04 ±
47.13 ±
55.77 ±
61.52 ±
56.98 ±
46.4 ±
51.62 ±
45.05 ±
63.28 ±



cancer
12.86
19.77
12.37
17.24
12.93
10.95
13.33
15.28
12.44



Breast cancer
46.31 ±
45.63 ±
59.16 ±
41.73 ±
54.6 ±
50.84 ±
61.67 ±
62.97 ±
38.5 ±




17.26
14.39
19.94
10.57
13.95
14.38
11.23
14.24
12.53



Kidney
54.18 ±
41.16±
48.74 ±
74.58 ±
58.84 ±
62.65 ±
64.65 ±
73.69 ±
54.93 ±



cancer
17.44
19.27
17.64
10.06
14.67
11.81
14.52
16.38
17.32



Colorectal
75.24 ±
58.68 ±
44.31 ±
63.58 ±
70.07 ±
69.65 ±
51.98 ±
76.09 ±
74.21 ±



cancer
14.77
18.55
17.17
13.74
17.29
12.22
12.13
10.99
10.49



Ovarian
41.72 ±
55.51 ±
73.97 ±
59.18 ±
35.31 ±
56.91 ±
75.88 ±
47.86 ±
46.04 ±



cancer
15.96
17.71
19.19
19.28
13.87
17.05
16.79
19.92
19.41



Cervical
67.28 ±
62.18 ±
48.18 ±
42.18 ±
76.97 ±
66.03 ±
49.43 ±
64.83 ±
62.81 ±



cancer
15.38
19.28
16.28
15.38
16.87
16.73
19.55
17.73
14.67



Uterine
69.28 ±
71.82 ±
69.27 ±
57.18 ±
75.07 ±
44.85 ±
63.93 ±
75.15 ±
60.89 ±



cancer
18.23
18.37
12.82
15.28
13.88
11.31
19.28
11.54
14.88



Prostate
72.7 ±
53.4 ±
69.45 ±
66.53 ±
43.55 ±
70.12 ±
55.13 ±
51.98 ±
70.68 ±



cancer
12.83
10.86
16.98
13.6
15.92
17.13
13.55
17.49
13.04



Bladder
52.72 ±
54.85 ±
76.11 ±
42.12 ±
48.38 ±
52.59 ±
36.37 ±
66.93 ±
39.66 ±



cancer
13.44
11.28
19.42
15.58
18.49
19.54
15.56
16.18
10.18



Melanoma
62.51 ±
57.53 ±
48.73 ±
66.04 ±
65.27 ±
53.73 ±
72.16 ±
39.81 ±
43.76 ±




10.82
10.47
13.45
12.86
10.67
18.72
17.97
19.13
11.78



Hemangioma
73.13 ±
47.27 ±
49.55 ±
46.31 ±
57.03 ±
66.23 ±
51.58 ±
62.67 ±
64.11 ±




15.26
10.69
10.47
17.26
12.78
10.06
14.73
18.21
14.09



Sarcoma
40.41 ±
40.71 ±
48.77 ±
54.18 ±
40.55 ±
69.22 ±
61.4 ±
56.05 ±
44.3 ±




18.93
18.16
13.87
17.44
17.92
11.18
15.31
18.67
19.11





Tumor cell












line source
X81
X82
X83
X84
X86
X87
X88
X89
X90
Docetaxel





Head and
48.17 ±
59.54 ±
50.81 ±
56.47 ±
43.21 ±
38.36 ±
57.41 ±
63.39 ±
69.83 ±
55.66 ±


neck cancers
19.43
12.23
15.59
12.62
18.53
15.55
12.19
14.52
11.88
18.88


Brain tumor
73.89 ±
39.65 ±
59.86 ±
59.72 ±
46.82 ±
50.56 ±
65.89 ±
67.73 ±
47.27 ±
70.69 ±



13.81
11.16
17.18
17.77
10.37
14.78
13.73
13.72
16.42
17.84


Thyroid
52.76 ±
55.41 ±
37.08 ±
56.03 ±
55.77 ±
39.41 ±
69.82 ±
54.97 ±
60.66 ±
73.75 ±


cancer
10.92
15.58
13.66
11.47
13.52
17.51
11.28
17.83
18.62
17.97


Esophageal
40.65 ±
48.32 ±
66.27 ±
56.94 ±
61.24 ±
46.15 ±
63.49 ±
71.89 ±
56.91 ±
53.43 ±


cancer
18.95
18.65
10.13
17.27
13.77
16.28
14.04
12.86
13.22
18.63


Pancreatic
75.95 ±
67.77 ±
61.34 ±
60.29 ±
64.53 ±
76.32 ±
55.33 ±
73.61 ±
45.54 ±
45.92 ±


cancer
14.61
10.57
15.92
12.23
19.46
19.97
19.56
11.16
11.94
13.04


Lung cancer
71.44 ±
64.08 ±
74.66 ±
53.71 ±
69.34 ±
63.62 ±
54.73 ±
36.83 ±
65.38 ±
65.15 ±



16.82
17.56
16.55
12.75
15.16
11.34
16.81
18.73
10.76
13.98


Liver cancer
70.78 ±
38.99 ±
56.56 ±
45.12 ±
59.1 ±
72.57 ±
39.09 ±
47.82 ±
63.65 ±
48.03 ±



17.01
17.57
12.71
13.77
10.37
14.25
17.13
17.51
11.26
10.76


Stomach
50.82 ±
75.66 ±
55.46 ±
61.25 ±
47.11 ±
62.68 ±
66.73 ±
63.32 ±
38.93 ±
43.31 ±


cancer
16.24
17.37
12.82
19.99
18.34
18.91
19.09
12.16
15.38
19.08


Breast cancer
53.48 ±
45.02 ±
42.85 ±
36.57 ±
45.99 ±
56.05 ±
65.43 ±
43.3 ±
67.28 ±
47.06 ±



10.27
17.87
11.47
11.96
16.31
15.02
15.76
13.08
19.72
15.79


Kidney
45.45 ±
52.08 ±
39.04 ±
52.46 ±
44.32 ±
51.22 ±
70.09 ±
40.94 ±
67.61±
71.47 ±


cancer
14.17
12.11
17.98
11.59
19.58
11.18
19.12
16.98
13.78
15.52


Colorectal
50.92 ±
49.37 ±
43.39 ±
54.64 ±
63.23 ±
54.58 ±
46.64 ±
44.2 ±
51.93 ±
60.94 ±


cancer
19.47
17.65
12.99
16.96
12.86
12.69
12.58
17.88
11.55
10.28


Ovarian
62.47 ±
59.7 ±
73.79 ±
56.97 ±
57.18 ±
65.63 ±
37.09 ±
56.95 ±
60.97 ±
60.51 ±


cancer
13.16
17.74
13.35
15.87
15.63
10.54
18.12
13.59
10.65
13.32


Cervical
57.27 ±
76.56 ±
49.43 ±
66.75 ±
73.36 ±
38.75 ±
73.19 ±
38.68 ±
55.41±
67.99 ±


cancer
14.89
12.97
12.02
19.92
19.38
15.08
15.36
15.49
19.69
17.69


Uterine
58.56 ±
66.23 ±
46.17 ±
73.62 ±
37.45 ±
36.33 ±
67.14 ±
70.91 ±
59.26 ±
63.54 ±


cancer
14.96
17.14
14.33
16.04
14.63
10.49
17.12
13.58
11.12
18.34


Prostate
64.38 ±
66.68 ±
38.85 x
56.8 ±
37.92 ±
52.53 ±
72.6 ±
45.72 ±
42.99 ±
67.13 ±


cancer
16.18
18.47
18.34
12.55
13.15
18.92
10.55
17.16
13.38
19.77


Bladder
47.11 ±
52.53 ±
73.83 ±
56.31 ±
45.85 ±
37.4 ±
66.15 ±
38.3 ±
47.88 ±
45.63 ±


cancer
18.83
13.36
16.98
19.46
17.46
16.04
17.37
11.62
15.33
14.39


Melanoma
58.42 ±
64.1 ±
58.32 ±
61.52 ±
36.95 ±
72.79 ±
55.77 ±
70.14 ±
63.91 ±
41.16 ±



11.82
12.77
11.91
17.24
13.61
13.82
12.37
13.78
12.54
19.27


Hemangioma
74.01 ±
56.97 ±
46.39 ±
41.73 ±
50.08 ±
37.95 ±
59.16 ±
70.48 ±
63.41 ±
58.68 ±



16.85
19.56
17.85
10.57
18.11
12.31
19.94
11.52
17.78
18.55


Sarcoma
37.71 ±
39.31 ±
63.35 ±
74.58 ±
44.64 ±
38.03 ±
48.74 ±
70.71 ±
74.12 ±
75.22 ±



19.04
13.21
14.59
10.06
16.94
13.59
17.64
18.98
19.33
19.23









Results: Compared with negative control, X1-X90 have significant inhibitory effects on the proliferation of various tumor cells, wherein X5 has the best effect, which provides a good prospect for the development of effective anti-tumor drugs for the present invention.


Example 3

PIR (%) of Maleimide Group-Modified Angiogenesis Inhibitor Polypeptides P1-P4 on Various Tumor Cells


An MTT method was used to detect the inhibitory activity of P1-P4 on the growth of various tumor cells. Tumor cells were digested and collected with trypsin after being cultured in an incubator at 37° C. with 5% CO2 to a confluence of 90% or more. The cells were resuspended with a culture solution and counted under a microscope, the cell concentration was adjusted to 2×104 cells/mL, and the cell suspension was inoculated into a 96-well plate at 100 μL/well, and cultured overnight in an incubator at 37° C. with 5% CO2. P1-P4 were diluted to respective predetermined concentrations with the culture solution. Docetaxel was diluted to a final concentration with the culture solution. After the cells were completely adhered to the wall, each diluent was added into the 96-well plate (100 μL/well). Tumor cells with the addition of diluents of polypeptides P1-P4 were used as administration groups, tumor cells with the addition of docetaxel were used as a positive control group, and tumor cells with the addition of the culture solution without any drug were used as a negative control group. The cells were cultured in an incubator at 37° C. with 5% CO2 for 48 h. 5 mg/mL MTT was added into the 96-well plate, 20 μL per well, and the culture was continued for 4 h. The culture medium was removed, 150 μL of DMSO was added to each well for dissolution, and gent and uniform mixing was performed in a shaker for 10 min. The absorbance was measured at a detection wavelength of 570 nm and a reference wavelength of 630 nm using a microplate reader, and the PIR was calculated with the formula as follows:





PIR (%)=1−administration group/negative group


The experiment was repeated independently three times, and the results were expressed as mean±SD. The experimental results are shown in Table 8.









TABLE 8







PIR (%) of polypeptides P1-P4 on various tumor cells












Tumor cell line







source
HM-1
P1
P2
P3
P4





Head and neck
36.12 ± 11.21
37.06 ± 13.32
 66.5 ± 17.54
64.96 ± 7.08 
44.15 ± 17.85


cancers







Brain tumor
41.54 ± 12.43
56.51 ± 6.86 
54.93 ± 15.06
43.62 ± 18.25
58.25 ± 12.61


Thyroid cancer
43.15 ± 14.42
43.67 ± 15.45
35.75 ± 11.63
47.86 ± 14.51
48.89 ± 7.69 


Esophageal cancer
46.22 ± 18.24
54.38 ± 7.77 
43.58 ± 12.41
59.78 ± 17.75
28.24 ± 11.35


Pancreatic cancer
45.03 ± 13.18
40.05 ± 5.25 
38.38 ± 18.64
54.79 ± 12.05
44.95 ± 13.72


Lung cancer
50.35 ± 14.14
52.65 ± 16.08
39.91 ± 15.09
32.58 ± 17.03
37.87 ± 18.18


Liver cancer
44.45 ± 13.46
42.88 ± 17.37
43.41 ± 6.31 
34.44 ± 4.11 
38.93 ± 9.36 


Stomach cancer
44.43 ± 11.35
53.13 ± 9.35 
 48.6 ± 16.54
54.71 ± 6.58 
56.72 ± 18.61


Breast cancer
41.54 ± 14.28
57.06 ± 17.75
37.51 ± 18.1 
41.01 ± 15.47
44.25 ± 8.52 


Kidney cancer
42.45 ± 10.22
47.06 ± 17.68
48.49 ± 8.42 
40.55 ± 6.43 
52.61 ± 11.68


Colorectal cancer
42.64 ± 12.31
62.11 ± 7.32 
45.97 ± 9.16 
63.43 ± 17.81
62.71 ± 16.89


Ovarian cancer
44.78 ± 14.06
54.26 ± 7.87 
49.75 ± 7.47 
44.51 ± 9.84 
63.24 ± 10.17


Cervical cancer
46.03 ± 14.71
40.19 ± 13.92
36.36 ± 8.62 
53.94 ± 7.45 
53.63 ± 5.91 


Uterine cancer
46.85 ± 10.21
42.01 ± 9.95 
40.72 ± 10.94
53.69 ± 14.84
41.41 ± 13.27


Prostate cancer
50.14 ± 14.13
50.81 ± 10.89
58.59 ± 12.29
47.73 ± 13.44
51.74 ± 14.43


Bladder cancer
51.99 ± 14.57
55.38 ± 6.97 
49.82 ± 14.66
59.56 ± 13.77
30.22 ± 16.44


Melanoma
53.62 ± 12.12
41.78 ± 18.03
45.42 ± 9.22 
49.52 ± 12.27
43.14 ± 17.36


Hemangioma
46.23 ± 12.09
51.22 ± 12.61
49.89 ± 14.65
48.68 ± 5.89 
49.07 ± 18.92


Sarcoma
49.25 ± 11.03
40.33 ± 13.89
48.34 ± 4.82 
47.91 ± 12.13
49.63 ± 13.17









Example 4

Migration Inhibition Effect of Polypeptides P1-P4 on HUVECs


10 mg/mL Matrigel was diluted with a culture medium special for HUVECs at a ratio of 1:2, coated on a transwell chamber membrane, and air-dried at room temperature. HUVECs cultured to a logarithmic growth period were digested with a trypsin digestion solution, collected, washed twice with PBS and then resuspended with a blank culture medium special for HUVECs. The cells were counted under a microscope and the cell concentration was adjusted to 1×105 cells/mL. The test solution of each group was prepared. The test solutions contained polypeptides P1-P4 with different concentrations, and were each diluted to 100 μL with a blank culture medium special for HUVECs. The cells were inoculated into the transwell chamber at 100 μL per well, and each group of test solution was added into the chamber. 0.6 mL of endothelial cell culture solution containing 5% fetal bovine serum and 1% ECGS was added to a 24-well plate to stimulate cell migration, and cultured for 24 h at 37° C. with 5% CO2. The culture solution in the well was discarded, the cells were fixed with 90% alcohol at normal temperature for 30 min, dyed with 0.1% crystal violet at normal temperature for 10 min and rinsed with clear water, the non-migrated cells on the upper layer were gently wiped off using cotton swabs. The observation was made under the microscope and four fields were selected to take photos for counting. The migration inhibition rate (MIR) was calculated according to the formula:







MI






(
%
)


=

1
-



N

t

e

s

t



N

c

o

n

t

r

o

l



×
100

%






wherein Ntest is the cell migration number of the test group and Ncontrol is the cell migration number of the blank control group.


The experiment was repeated independently three times. Mean±SD was calculated based on the results obtained from the experiment, and statistical T-test was conducted. *P<0.05 indicates significant difference, and **P<0.01 indicates extremely significant difference. The experimental results are shown in Table 9.









TABLE 9







Migration inhibition effect of polypeptides


P1-P4 on HUVECs














Cell migration





Dose
number
Inhibition



Group
(μM)
(Mean ± SD)
rate (%)
















X1
0.05
620.19 ± 46.98*
41.53%




0.1
560.81 ± 53.1* 
47.13%




0.2
555.64 ± 45.23*
47.62%



X2
0.05
645.98 ± 49.09*
39.10%




0.1
 516.64 ± 46.50**
51.29%




0.2
 486.11 ± 53.63**
54.17%



X3
0.05
633.68 ± 56.82*
40.26%




0.1
535.74 ± 59.20*
49.49%




0.2
570.83 ± 45.74*
46.19%



X4
0.05
 494.57 ± 51.18**
53.38%




0.1
 484.45 ± 54.52**
54.33%




0.2
626.68 ± 56.40*
40.92%



Avastin
0.2
 418.92 ± 61.42**
60.92%



Control

1060.74 ± 31.42 
0.00%










Example 5

PIR (%) of Derived Polypeptides P5-P10 on Various Tumor Cells


An MTT method was used to detect the inhibitory activity of P5-P10 on the growth of various tumor cells. Tumor cells were digested and collected with trypsin after being cultured in an incubator at 37° C. with 5% CO2 to a confluence of 90% or more. The cells were resuspended with a culture solution and counted under a microscope, the cell concentration was adjusted to 2×104 cells/mL, and the cell suspension was inoculated into a 96-well plate at 100 μL/well, and cultured overnight in an incubator at 37° C. with 5% CO2. P5-P10 were diluted to respective predetermined concentrations with the culture solution. Docetaxel was diluted to a final concentration with the culture solution. After the cells were completely adhered to the wall, each diluent was added into the 96-well plate (100 μL/well). Tumor cells with the addition of diluents of polypeptides P5-P10 were used as administration groups, tumor cells with the addition of docetaxel were used as a positive control group, and tumor cells with the addition of the culture solution without any drug were used as a negative control group. The cells were cultured in an incubator at 37° C. with 5% CO2 for 48 h. 5 mg/mL MTT was added into the 96-well plate, 20 μL per well, and the culture was continued for 4 h. The culture medium was removed, 150 μL of DMSO was added to each well for dissolution, and gent and uniform mixing was performed in a shaker for 10 min. The absorbance was measured at a detection wavelength of 570 nm and a reference wavelength of 630 nm using a microplate reader, and the PIR was calculated with the formula as follows:





PIR (%)=1−administration group/negative group


The experiment was repeated independently three times, and the results were expressed as mean±SD. The experimental results are shown in Table 10.









TABLE 10







PIR (%) of polypeptides P5-P10 on various tumor cells














Tumor cell line









source
HM-1
P5
P6
P7
P8
P9
P10





Head and neck
36.12 ± 11.21
45.96 ± 13.95
57.32 ± 16.75
27.29 ± 14.66
61.16 ± 17.39
49.01 ± 10.16
54.79 ± 7.99 


cancers









Brain tumor
41.54 ± 12.43
46.07 ± 18.12
42.44 ± 14.97
46.17 ± 12.06
40.85 ± 10.24
60.37 ± 7.63 
47.45 ± 15.83


Thyroid cancer
43.15 ± 14.42
44.99 ± 16.02
42.43 ± 17.62
64.14 ± 16.02
43.42 ± 10.02
50.54 ± 5.07 
50.13 ± 11.91


Esophageal cancer
46.22 ± 18.24
44.34 ± 10.55
63.13 ± 10.17
46.83 ± 12.66
52.34 ± 14.99
54.42 ± 7.55 
50.18 ± 11.45


Pancreatic cancer
45.03 ± 13.18
54.16 ± 11.51
56.09 ± 16.01
52.28 ± 15.01
55.17 ± 18.97
54.01 ± 9.61 
55.87 ± 17.76


Lung cancer
50.35 ± 14.14
46.99 ± 12.56
52.02 ± 14.84
45.16 ± 12.09
50.07 ± 15.94
58.29 ± 10.65
47.14 ± 17.26


Liver cancer
44.45 ± 13.46
50.79 ± 13.95
48.96 ± 15.15
55.21 ± 10.23
40.06 ± 16.28
52.61 ± 13.8 
55.93 ± 16.66


Stomach cancer
44.43 ± 11.35
47.78 ± 14.89
61.74 ± 10.29
64.23 ± 16.61
50.29 ± 13.73
53.19 ± 16.45
47.58 ± 10.45


Breast cancer
41.54 ± 14.28
54.73 ± 11.81
58.25 ± 14.52
44.79 ± 14.21
53.15 ± 11.06
46.84 ± 12.73
42.43 ± 10.62


Kidney cancer
42.45 ± 10.22
50.38 ± 12.35
45.24 ± 13.11
46.38 ± 14.44
60.73 ± 10.59
49.33 ± 16.14
58.26 ± 12.85


Colorectal cancer
42.64 ± 12.31
46.77 ± 15.91
51.82 ± 12.71
58.47 ± 12.52
51.42 ± 16.59
43.47 ± 13.21
52.63 ± 11.99


Ovarian cancer
44.78 ± 14.06
54.41 ± 15.45
48.86 ± 16.61
47.02 ± 12.88
57.79 ± 15.43
60.34 ± 16.21
43.46 ± 10.37


Cervical cancer
46.03 ± 14.71
50.07 ± 13.34
60.67 ± 11.23
55.13 ± 17.75
66.19 ± 16.16
60.43 ± 15.83
54.58 ± 16.81


Uterine cancer
46.85 ± 10.21
54.75 ± 12.45
57.74 ± 10.61
62.55 ± 18.95
43.22 ± 11.38
46.64 ± 9.21 
56.92 ± 17.33


Prostate cancer
50.14 ± 14.13
49.83 ± 11.08
62.66 ± 15.13
53.05 ± 17.12
53.22 ± 5.58 
56.53 ± 12.89
63.08 ± 16.07


Bladder cancer
51.99 ± 14.57
42.68 ± 16.85
62.75 ± 13.88
51.72 ± 11.34
 55.6 ± 15.76
58.27 ± 17.31
58.86 ± 13.61


Melanoma
53.62 ± 12.12
63.66 ± 16.06
48.19 ± 13.69
55.82 ± 11.53
57.51 ± 14.79
 43.4 ± 15.79
64.81 ± 13.65


Hemangioma
46.23 ± 12.09
55.17 ± 13.65
55.84 ± 10.17
43.38 ± 10.01
48.29 ± 12.71
 51.3 ± 14.18
43.88 ± 13.38


Sarcoma
49.25 ± 11.03
46.94 ± 13.83
51.45 ± 12.82
53.94 ± 13.91
 56.9 ± 12.53
43.47 ± 14.77
43.21 ± 12.84









Example 6

Migration Inhibition Effect of Polypeptides P5-P10 on HUVECs


10 mg/mL Matrigel was diluted with a culture medium special for HUVECs at a ratio of 1:2, coated on a transwell chamber membrane, and air-dried at room temperature. HUVECs cultured to a logarithmic growth period were digested with a trypsin digestion solution, collected, washed twice with PBS and then resuspended with a blank culture medium special for HUVECs. The cells were counted under a microscope and the cell concentration was adjusted to 1×105 cells/mL. The test solution of each group was prepared. The test solutions contained polypeptides P5-P10 with different concentrations, and were each diluted to 100 μL with a blank culture medium special for HUVECs. The cells were inoculated into the transwell chamber at 100 μL per well, and each group of test solution was added into the chamber. 0.6 mL of endothelial cell culture solution containing 5% fetal bovine serum and 1% ECGS was added to a 24-well plate to stimulate cell migration, and cultured for 24 h at 37° C. with 5% CO2. The culture solution in the well was discarded, the cells were fixed with 90% alcohol at normal temperature for 30 min, dyed with 0.1% crystal violet at normal temperature for 10 min and rinsed with clear water, the non-migrated cells on the upper layer were gently wiped off using cotton swabs. The observation was made under the microscope and four fields were selected to take photos for counting. The migration inhibition rate (MIR) was calculated according to the formula:







MI






(
%
)


=

1
-



N

t

e

s

t



N

c

o

n

t

r

o

l



×
100

%






wherein Ntest is the cell migration number of the test group and Ncontrol is the cell migration number of the blank control group.


The experiment was repeated independently three times. Mean±SD was calculated based on the results obtained from the experiment, and statistical T-test was conducted. *P<0.05 indicates significant difference, and **P<0.01 indicates extremely significant difference. The experimental results are shown in Table 11.









TABLE 11







Migration inhibition effect of polypeptides


P5-P10 on HUVECs












Cell migration




Dose
number
Inhibition


Group
(μM)
(Mean ± SD)
rate (%)













P5
0.05
568.79 ± 48.49* 
46.38%



0.1
476.01 ± 54.57**
55.12%



0.2
530.22 ± 56.20**
50.01%


P6
0.05
454.57 ± 50.52**
57.15%



0.1
510.26 ± 56.98* 
51.90%



0.2
590.16 ± 48.21* 
44.36%


P7
0.05
631.62 ± 58.2* 
40.45%



0.1
537.49 ± 52.54* 
49.33%



0.2
640.46 ± 50.11* 
39.62%


P8
0.05
483.56 ± 45.37**
54.41%



0.1
487.55 ± 51.75**
54.04%



0.2
481.83 ± 45.91**
54.58%


P9
0.05
516.51 ± 55.24* 
51.31%



0.1
622.28 ± 54.01* 
41.34%



0.2
604.50 ± 46.64* 
43.01%


P10
0.05
534.90 ± 56.85* 
49.57%



0.1
469.94 ± 56.40**
55.70%



0.2
537.73 ± 56.02* 
49.31%


Avastin
0.2
418.92 ± 61.42**
60.92%


Control

1060.74 ± 31.42  
0.00%









Example 7

PIR (%) of Derived Polypeptides P11-P14 on Various Tumor Cells


An MTT method was used to detect the inhibitory activity of polypeptides P11-P14 on the growth of various tumor cells. Tumor cells were digested and collected with trypsin after being cultured in an incubator at 37° C. with 5% CO2 to a confluence of 90% or more. The cells were resuspended with a culture solution and counted under a microscope, the cell concentration was adjusted to 2×104 cells/mL, and the cell suspension was inoculated into a 96-well plate at 100 μL/well, and cultured overnight in an incubator at 37° C. with 5% CO2. Polypeptides P11-P14 were diluted to respective predetermined concentrations with the culture solution. Docetaxel was diluted to a final concentration with the culture solution. After the cells were completely adhered to the wall, each diluent was added into the 96-well plate (100 μL/well). Tumor cells with the addition of diluents of polypeptides P11-P14 were used as administration groups, tumor cells with the addition of docetaxel were used as positive control groups, and the culture solution without any drug was used as the negative control group. The cells were cultured in an incubator at 37° C. with 5% CO2 for 48 h. 5 mg/mL MTT was added into the 96-well plate, 20 μL per well, and the culture was continued for 4 h. The culture medium was removed, 150 μL of DMSO was added to each well for dissolution, and gent and uniform mixing was performed in a shaker for 10 min. The absorbance was measured at a detection wavelength of 570 nm and a reference wavelength of 630 nm using a microplate reader, and the PIR was calculated with the formula as follows:





PIR (%)=1−administration group/negative group


The experiment was repeated independently three times, and the results were expressed as mean±SD. The experimental results are shown in Table 12.









TABLE 12







PIR (%) of polypeptides P11-P14 on various tumor cells












Tumor cell line source
HM-1
P11
P12
P13
P14





Head and neck
36.12 ± 11.21
59.36 ± 17.54
54.75 ± 17.34
51.75 ± 15.03
47.82 ± 9.11 


cancers







Brain tumor
41.54 ± 12.43
56.47 ± 7.02 
46.81 ± 4.73 
50.81 ± 14.26
58.27 ± 16.92


Thyroid cancer
43.15 ± 14.42
45.19 ± 17.58
54.55 ± 17.65
65.81 ± 15.21
65.73 ± 7.45 


Esophageal cancer
46.22 ± 18.24
57.74 ± 14.71
53.83 ± 18.54
51.39 ± 12.19
50.55 ± 18.34


Pancreatic cancer
45.03 ± 13.18
62.64 ± 7.73 
45.24 ± 15.93
56.11 ± 18.16
59.94 ± 17.29


Lung cancer
50.35 ± 14.14
26.07 ± 6.88 
40.73 ± 11.44
42.51 ± 14.27
 42.5 ± 14.82


Liver cancer
44.45 ± 13.46
51.17 ± 16.14
42.21 ± 16.23
65.23 ± 17.38
50.51 ± 15.19


Stomach cancer
44.43 ± 11.35
40.32 ± 6.92 
57.78 ± 6.27 
40.24 ± 5.45 
53.17 ± 15.69


Breast cancer
41.54 ± 14.28
50.34 ± 10.89
43.13 ± 11.96
51.61 ± 13.58
57.06 ± 13.32


Kidney cancer
42.45 ± 10.22
63.87 ± 9.86 
58.47 ± 16.23
50.91 ± 16.49
56.51 ± 6.86 


Colorectal cancer
42.64 ± 12.31
61.69 ± 6.84 
48.67 ± 10.76
61.95 ± 11.44
43.67 ± 15.45


Ovarian cancer
44.78 ± 14.06
59.14 ± 9.11 
58.57 ± 7.49 
41.41 ± 8.88 
54.38 ± 7.77 


Cervical cancer
46.03 ± 14.71
55.11 ± 14.82
64.68 ± 8.41 
59.93 ± 15.98
40.05 ± 5.25 


Uterine cancer
46.85 ± 10.21
56.32 ± 8.95 
50.94 ± 12.38
63.19 ± 8.87 
52.65 ± 16.08


Prostate cancer
50.14 ± 14.13
53.11 ± 10.21
55.15 ± 5.66 
62.25 ± 6.91 
42.88 ± 17.37


Bladder cancer
51.99 ± 14.57
57.05 ± 11.55
64.85 ± 6.21 
45.11 ± 4.24 
53.13 ± 9.35 


Melanoma
53.62 ± 12.12
57.64 ± 12.56
55.39 ± 7.79 
51.04 ± 18.16
57.06 ± 17.75


Hemangioma
46.23 ± 12.09
49.06 ± 16.98
44.54 ± 16.89
53.28 ± 12.71
47.06 ± 17.68


Sarcoma
49.25 ± 11.03
48.65 ± 6.94 
50.79 ± 15.65
50.13 ± 16.37
62.11 ± 7.32 









Example 8

Migration Inhibition Effect of Polypeptides P11-P14 on HUVECs


10 mg/mL Matrigel was diluted with a culture medium special for HUVECs at a ratio of 1:2, coated on a transwell chamber membrane, and air-dried at room temperature. HUVECs cultured to a logarithmic growth period were digested with a trypsin digestion solution, collected, washed twice with PBS and then resuspended with a blank culture medium special for HUVECs. The cells were counted under a microscope and the cell concentration was adjusted to 1×105 cells/mL. The test solution of each group was prepared. The test solutions contained polypeptides P11-P14 with different concentrations, and were each diluted to 100 μL with a blank culture medium special for HUVECs. The cells were inoculated into the transwell chamber at 100 μL per well, and each group of test solution was added into the chamber. 0.6 mL of endothelial cell culture solution containing 5% fetal bovine serum and 1% ECGS was added to a 24-well plate to stimulate cell migration, and cultured for 24 h at 37° C. with 5% CO2. The culture solution in the well was discarded, the cells were fixed with 90% alcohol at normal temperature for 30 min, dyed with 0.1% crystal violet at normal temperature for 10 min and rinsed with clear water, the non-migrated cells on the upper layer were gently wiped off using cotton swabs. The observation was made under the microscope and four fields were selected to take photos for counting. The migration inhibition rate (MIR) was calculated according to the formula:







MI






(
%
)


=

1
-



N

t

e

s

t



N

c

o

n

t

r

o

l



×
100

%






wherein Ntest is the cell migration number of the test group and Ncontrol is the cell migration number of the blank control group.


The experiment was repeated independently three times. Mean±SD was calculated based on the results obtained from the experiment, and statistical T-test was conducted. *P<0.05 indicates significant difference, and **P<0.01 indicates extremely significant difference. The experimental results are shown in Table 13.









TABLE 13







Migration inhibition effect of polypeptides


P11-P14 on HUVECs














Cell migration





Dose
number
Inhibition



Group
(μM)
(Mean ± SD)
rate (%)
















P11
0.05
544.91 ± 55.33*
48.63%




0.1
573.27 ± 51.88*
45.96%




0.2
610.30 ± 57.12*
42.46%



P12
0.05
563.30 ± 45.07*
46.90%




0.1
631.75 ± 56.63*
40.44%




0.2
640.32 ± 56.39*
39.63%



P13
0.05
563.36 ± 55.87*
46.89%




0.1
604.98 ± 53.51*
42.97%




0.2
629.42 ± 57.60*
40.66%



P14
0.05
 521.99 ± 46.56**
50.79%




0.1
 464.30 ± 51.86**
56.23%




0.2
631.30 ± 49.05*
40.48%



Avastin
0.2
 418.92 ± 61.42**
60.92%



control

1060.74 ± 31.42 
0.00%










Example 9

Migration Inhibition Effect of Polypeptides X1-X90 on HUVECs


10 mg/mL Matrigel was diluted with a culture medium special for HUVECs at a ratio of 1:2, coated on a transwell chamber membrane, and air-dried at room temperature. HUVECs cultured to a logarithmic growth period were digested with a trypsin digestion solution, collected, washed twice with PBS and then resuspended with a blank culture medium special for HUVECs. The cells were counted under a microscope and the cell concentration was adjusted to 1×105 cells/mL. The test solution of each group was prepared. The test solutions contained polypeptides X1-X90 with different concentrations, and were each diluted to 100 μL with a blank culture medium special for HUVECs. The cells were inoculated into the transwell chamber at 100 μL per well, and each group of test solution was added into the chamber. 0.6 mL of endothelial cell culture solution containing 5% fetal bovine serum and 1% ECGS was added to a 24-well plate to stimulate cell migration, and cultured for 24 h at 37° C. with 5% CO2. The culture solution in the well was discarded, the cells were fixed with 90% alcohol at normal temperature for 30 min, dyed with 0.1% crystal violet at normal temperature for 10 min and rinsed with clear water, the non-migrated cells on the upper layer were gently wiped off using cotton swabs. The observation was made under the microscope and four fields were selected to take photos for counting. The migration inhibition rate (MIR) was calculated according to the formula:







MI






(
%
)


=

1
-



N

t

e

s

t



N

c

o

n

t

r

o

l



×
100

%






wherein Ntest is the cell migration number of the test group and Ncontrol is the cell migration number of the blank control group.


The experiment was repeated independently three times. Mean±SD was calculated based on the results obtained from the experiment, and statistical T-test was conducted. *P<0.05 indicates significant difference, and **P<0.01 indicates extremely significant difference. The experimental results are shown in Table 14.









TABLE 14







Migration inhibition effect of polypeptides


X1 to X90 on HUVECs














Cell migration





Dose
number
Inhibition



Group
(μM)
(Mean ± SD)
rate (%)
















X1
0.05
596.50 ± 44.35*
43.77%




0.1
 528.57 ± 48.12**
50.17%




0.2
 514.51 ± 47.11**
52.00%



X2
0.05
640.75 ± 65.48*
40.22%




0.1
636.64 ± 63.41*
40.60%




0.2
 499.83 ± 69.77**
53.37%



X3
0.05
611.01 ± 58.38*
43.00%




0.1
564.24 ± 46.78*
47.36%




0.2
555.54 ± 53.63*
48.17%



X4
0.05
578.69 ± 63.60*
46.01%




0.1
560.12 ± 50.60*
47.74%




0.2
554.16 ± 43.38*
48.30%



X5
0.05
626.21 ± 40.84*
41.58%




0.1
616.15 ± 57.51*
42.52%




0.2
559.72 ± 47.65*
47.78%



X6
0.05
609.98 ± 66.18*
43.09%




0.1
 524.73 ± 53.87**
51.04%




0.2
 498.30 ± 60.64**
53.51%



X7
0.05
599.78 ± 48.52*
44.04%




0.1
 523.39 ± 41.62**
51.17%




0.2
 522.23 ± 60.37**
51.28%



X8
0.05
623.21 ± 49.06*
41.86%




0.1
589.09 ± 51.42*
45.04%




0.2
580.69 ± 48.61*
45.82%



X9
0.05
645.91 ± 58.77*
39.74%




0.1
604.04 ± 58.33*
43.65%




0.2
 459.92 ± 68.65**
57.09%



X10
0.05
570.02 ± 60.71*
46.82%




0.1
566.82 ± 47.23*
47.12%




0.2
536.75 ± 69.25*
49.92%



X11
0.05
590.60 ± 59.00*
44.90%




0.1
583.13 ± 46.68*
45.60%




0.2
555.75 ± 57.95*
48.15%



X12
0.05
574.61 ± 48.36*
46.39%




0.1
538.77 ± 53.35*
49.74%




0.2
 478.42 ± 47.91**
55.37%



X13
0.05
617.61 ± 43.62*
42.38%




0.1
 463.21 ± 46.79**
56.78%




0.2
 460.75 ± 47.48**
57.01%



X14
0.05
631.58 ± 62.75*
41.08%




0.1
 511.88 ± 65.93**
52.24%




0.2
 482.35 ± 59.07**
55.00%



X15
0.05
604.84 ± 67.76*
43.57%




0.1
558.61 ± 50.98*
47.88%




0.2
 470.58 ± 62.38**
56.10%



X16
0.05
643.45 ± 52.09*
39.97%




0.1
 505.06 ± 52.71**
52.88%




0.2
 469.22 ± 52.56**
56.22%



X17
0.05
547.07 ± 50.72*
48.96%




0.1
 483.55 ± 66.46**
54.89%




0.2
 455.35 ± 68.52**
57.52%



X18
0.05
635.26 ± 59.22*
40.73%




0.1
632.13 ± 55.39*
41.02%




0.2
594.30 ± 45.38*
44.55%



X19
0.05
632.53 ± 66.02*
40.99%




0.1
570.54 ± 51.64*
46.77%




0.2
 488.31 ± 53.35**
54.44%



X20
0.05
563.29 ± 41.22*
47.45%




0.1
538.18 ± 64.13*
49.79%




0.2
506.96 ± 57.65*
52.70%



X21
0.05
547.26 ± 48.17*
48.94%




0.1
 529.36 ± 68.43**
50.61%




0.2
 512.08 ± 47.73**
52.23%



X22
0.05
555.03 ± 66.81*
48.22%




0.1
 480.13 ± 67.49**
55.21%




0.2
 453.97 ± 57.23**
57.65%



X23
0.05
555.01 ± 40.99*
48.22%




0.1
 519.80 ± 57.39**
51.50%




0.2
 513.80 ± 43.43**
52.06%



X24
0.05
540.49 ± 60.98*
49.57%




0.1
536.51 ± 42.41*
49.95%




0.2
 525.06 ± 53.33**
51.01%



X25
0.05
556.73 ± 40.91*
48.06%




0.1
 511.9 ± 68.58**
52.24%




0.2
450.13 ± 52.7**
58.00%



X26
0.05
570.08 ± 49.26*
46.81%




0.1
546.86 ± 60.43*
48.98%




0.2
 494.57 ± 48.88**
53.86%



X27
0.05
574.65 ± 60.83*
46.39%




0.1
546.51 ± 46.67*
49.01%




0.2
 499.65 ± 59.06**
53.38%



X28
0.05
610.89 ± 42.79*
43.01%




0.1
 506.45 ± 65.00**
52.75%




0.2
 502.42 ± 40.72**
53.13%



X29
0.05
574.88 ± 55.42*
46.37%




0.1
 531.34 ± 47.59**
50.43%




0.2
 494.73 ± 56.78**
53.84%



X30
0.05
631.10 ± 64.04*
41.12%




0.1
 497.88 ± 65.38**
53.55%




0.2
 497.56 ± 68.24**
53.58%



X31
0.05
641.17 ± 61.85*
40.18%




0.1
571.62 ± 42.83*
46.67%




0.2
 480.05 ± 67.72**
55.21%



X32
0.05
622.57 ± 49.41*
41.92%




0.1
560.86 ± 50.91*
47.67%




0.2
 465.06 ± 48.23**
56.61%



X33
0.05
614.91 ± 68.92*
42.63%




0.1
563.23 ± 57.29*
47.45%




0.2
 490.88 ± 51.22**
54.20%



X34
0.05
557.95 ± 42.69*
47.95%




0.1
 513.64 ± 43.27**
52.08%




0.2
 496.39 ± 56.37**
53.69%



X35
0.05
615.18 ± 57.71*
42.61%




0.1
 529.83 ± 68.02**
50.57%




0.2
 461.34 ± 66.82**
56.96%



X36
0.05
 513.79 ± 55.46**
52.07%




0.1
 463.47 ± 50.27**
56.76%




0.2
 451.01 ± 43.85**
57.92%



X37
0.05
642.52 ± 55.55*
40.06%




0.1
 517.86 ± 41.17**
51.69%




0.2
 511.08 ± 66.22**
52.32%



X38
0.05
630.97 ± 66.64*
41.13%




0.1
619.85 ± 44.78*
42.17%




0.2
 531.57 ± 66.12**
50.41%



X39
0.05
628.13 ± 60.26*
41.40%




0.1
 509.81 ± 59.62**
52.44%




0.2
 460.22 ± 66.58**
57.06%



X40
0.05
 473.99 ± 63.82**
55.78%




0.1
 463.87 ± 51.75**
56.72%




0.2
 462.34 ± 49.75**
56.87%



X41
0.05
637.22 ± 61.82*
40.55%




0.1
588.93 ± 44.15*
45.06%




0.2
587.17 ± 63.28*
45.22%



X42
0.05
645.21 ± 40.07*
39.80%




0.1
630.25 ± 53.06*
41.20%




0.2
619.42 ± 53.04*
42.21%



X43
0.05
 503.90 ± 67.34**
52.99%




0.1
 464.90 ± 41.52**
56.63%




0.2
 457.03 ± 67.04**
57.36%



X44
0.05
644.35 ± 66.02*
39.88%




0.1
605.46 ± 67.29*
43.51%




0.2
 482.27 ± 45.88**
55.01%



X45
0.05
 506.46 ± 56.61**
52.75%




0.1
 493.96 ± 48.77**
53.92%




0.2
 491.44 ± 51.16**
54.15%



X46
0.05
639.42 ± 45.14*
40.34%




0.1
611.47 ± 46.48*
42.95%




0.2
606.59 ± 40.95*
43.41%



X47
0.05
628.14 ± 46.56*
41.40%




0.1
585.17 ± 45.06*
45.41%




0.2
 453.86 ± 55.76**
57.66%



X48
0.05
609.83 ± 42.93*
43.11%




0.1
 527.77 ± 47.87**
50.76%




0.2
 454.60 ± 43.39**
57.59%



X49
0.05
596.49 ± 59.46*
44.35%




0.1
591.86 ± 58.82*
44.78%




0.2
 564.8 ± 42.28*
47.31%



X50
0.05
588.02 ± 64.55*
45.14%




0.1
 491.92 ± 40.42**
54.11%




0.2
 484.66 ± 48.92**
54.78%



X51
0.05
570.95 ± 57.94*
46.73%




0.1
562.27 ± 69.67*
47.54%




0.2
 509.89 ± 46.32**
52.43%



X52
0.05
550.22 ± 66.35*
48.67%




0.1
 490.94 ± 45.96**
54.20%




0.2
 479.99 ± 49.33**
55.22%



X53
0.05
646.26 ± 52.89*
39.71%




0.1
614.63 ± 58.99*
42.66%




0.2
 508.07 ± 57.46**
52.60%



X54
0.05
539.50 ± 46.30*
49.67%




0.1
 511.39 ± 55.45**
52.29%




0.2
 458.68 ± 52.66**
57.21%



X55
0.05
567.43 ± 62.61*
47.06%




0.1
561.08 ± 58.02*
47.65%




0.2
546.15 ± 65.38*
49.05%



X56
0.05
 474.41 ± 60.05**
55.74%




0.1
 464.64 ± 66.21**
56.65%




0.2
453.36 ± 66.8**
57.70%



X57
0.05
585.89 ± 52.56*
45.34%




0.1
552.46 ± 63.62*
48.46%




0.2
537.05 ± 48.43*
49.90%



X58
0.05
544.75 ± 50.23*
49.18%




0.1
541.79 ± 47.41*
49.45%




0.2
 534.40 ± 62.82**
50.14%



X59
0.05
631.77 ± 42.86*
41.06%




0.1
548.18 ± 51.93*
48.86%




0.2
 450.01 ± 45.32**
58.02%



X60
0.05
570.05 ± 68.22*
46.82%




0.1
 516.14 ± 59.71**
51.85%




0.2
 487.66 ± 66.17**
54.50%



X61
0.05
 534.34 ± 60.15**
50.15%




0.1
 492.36 ± 56.92**
54.06%




0.2
 472.26 ± 44.23**
55.94%



X62
0.05
592.43 ± 41.82*
44.73%




0.1
 509.31 ± 64.35**
52.48%




0.2
 455.14 ± 54.72**
57.54%



X63
0.05
623.23 ± 65.91*
41.86%




0.1
568.93 ± 60.47*
46.92%




0.2
 530.05 ± 57.17**
50.55%



X64
0.05
598.19 ± 57.83*
44.19%




0.1
597.45 ± 57.61*
44.26%




0.2
491.49 ± 49.8**
54.15%



X65
0.05
603.59 ± 54.67*
43.69%




0.1
567.44 ± 60.62*
47.06%




0.2
 527.88 ± 56.82**
50.75%



X66
0.05
568.71 ± 46.23*
46.94%




0.1
 461.34 ± 55.31**
56.96%




0.2
 457.45 ± 40.12**
57.32%



X67
0.05
 484.76 ± 61.82**
54.77%




0.1
 484.16 ± 69.61**
54.83%




0.2
 461.41 ± 51.33**
56.95%



X68
0.05
644.14 ± 50.25*
39.90%




0.1
 493.79 ± 45.96**
53.93%




0.2
 457.27 ± 43.22**
57.34%



X69
0.05
626.86 ± 54.92*
41.52%




0.1
613.88 ± 66.11*
42.73%




0.2
609.37 ± 66.42*
43.15%



X70
0.05
572.09 ± 68.72*
46.63%




0.1
545.17 ± 59.19*
49.14%




0.2
 471.98 ± 58.66**
55.97%



X71
0.05
599.46 ± 41.62*
44.07%




0.1
573.23 ± 46.83*
46.52%




0.2
563.66 ± 57.47*
47.41%



X72
0.05
587.78 ± 65.32*
45.16%




0.1
562.36 ± 68.25*
47.53%




0.2
543.09 ± 68.53*
49.33%



X73
0.05
617.65 ± 52.54*
42.38%




0.1
610.91 ± 47.76*
43.00%




0.2
 526.93 ± 54.91**
50.84%



X74
0.05
643.13 ± 44.73*
40.00%




0.1
609.66 ± 40.19*
43.12%




0.2
 532.17 ± 58.72**
50.35%



X75
0.05
642.82 ± 44.87*
40.03%




0.1
599.44 ± 52.61*
44.07%




0.2
548.83 ± 69.17*
48.80%



X76
0.05
648.21 ± 59.68*
39.52%




0.1
615.72 ± 44.04*
42.56%




0.2
 531.49 ± 60.48**
50.41%



X77
0.05
590.26 ± 58.98*
44.93%




0.1
551.29 ± 67.77*
48.57%




0.2
 530.54 ± 61.73**
50.50%



X78
0.05
 532.89 ± 61.36**
50.28%




0.1
 470.25 ± 45.15**
56.13%




0.2
 451.24 ± 63.99**
57.89%



X79
0.05
593.18 ± 64.62*
44.66%




0.1
 508.03 ± 45.26**
52.60%




0.2
 486.72 ± 63.61**
54.59%



X80
0.05
626.73 ± 48.64*
41.53%




0.1
583.43 ± 64.15*
45.57%




0.2
 469.12 ± 69.73**
56.23%



X81
0.05
631.38 ± 41.32*
41.09%




0.1
 571.5 ± 63.73*
46.68%




0.2
 486.90 ± 67.98**
54.57%



X82
0.05
627.14 ± 61.36*
41.49%




0.1
 546.94 ± 64.81**
48.97%




0.2
 480.77 ± 51.82**
55.15%



X83
0.05
640.61 ± 51.53*
40.23%




0.1
575.66 ± 68.26*
46.29%




0.2
563.64 ± 64.56*
47.41%



X84
0.05
589.96 ± 45.51*
44.96%




0.1
571.18 ± 44.95*
46.71%




0.2
 466.05 ± 55.06**
56.52%



X85
0.05
638.88 ± 63.92*
40.40%




0.1
629.55 ± 51.71*
41.27%




0.2
590.65 ± 59.92*
44.89%



X86
0.05
549.03 ± 59.13*
48.78%




0.1
 503.77 ± 64.22**
53.00%




0.2
 497.53 ± 53.15**
53.58%



X87
0.05
540.03 ± 52.12*
49.09%




0.1
 511.06 ± 40.06**
51.82%




0.2
 484.92 ± 42.69**
54.28%



X88
0.05
579.07 ± 52.93*
45.41%




0.1
 464.58 ± 55.82**
56.20%




0.2
 454.59 ± 48.87**
57.14%



X89
0.05
531.58 ± 59.58*
49.89%




0.1
 500.27 ± 62.93**
52.84%




0.2
 488.42 ± 43.23**
53.95%



X90
0.05
608.29 ± 57.22*
42.65%




0.1
582.35 ± 67.26*
45.10%




0.2
573.28 ± 44.52*
45.95%



Avastin
0.2
 418.92 ± 61.42**
60.92%



control

1060.74 ± 31.42 
0.00%










Results: Under the action of polypeptide X1-X90, the number of migrated endothelial cells decreased significantly. Compared with the blank control group, the administration group can inhibit the migration of HUVECs induced by 5% fetal bovine serum and 1% ECGS. The inhibitory effect of the polypeptide X59 on cell migration at 0.2 μM dose was extremely significantly different from that of the blank control (**P<0.01), and the inhibition rate was 58.02%.


Example 10

Effect of Polypeptides X1-X90 on Proliferation of Splenic Lymphocytes in Mice


Spleens of mice were taken out under aseptic conditions, washed with blank 1640 culture medium 3 times, ground with a 5 mL syringe core, filtered with a 200-mesh sieve, made into a single cell suspension. The suspension was centrifuged (1000 rpm×5 min), and supernatant was removed. Red blood cells were lysed by Tris-NH4Cl, and placed in ice water bath for 4 min and centrifuged (1000 rpm×5 min). The supernatant was removed, and the cells were washed twice with sterile PBS. Finally, RPMI 1640 culture solution (5 mL) containing 10% calf serum was added to suspend the cells. The cells were counted and the cell concentration was adjusted to 5×106 cells/mL, and the cells were cultured in a 96-well culture plate.


Blank control group, concanavalin A (ConA) group and dexamethasone (Dex) group were set in the experiment, and polypeptide X1-X90 groups were set as test groups. After 100 μL of splenic lymphocytes suspension per well was added into each group, 100 μL of blank 1640 culture solution was added into the blank control group, ConA was added into the ConA group, Dex was added into the Dex group, and ConA was added into the test groups on the basis of adding different concentrations of polypeptides X1-X90. The cells were static cultured at 37° C. in a cell incubator for 48 h. After the cultivation was completed, 20 μL of MTT was added to each well, and the cultivation was continued for 4 h. Finally, all the solutions in each well were discarded. 100 μL DMSO was added to each well and shaken, and the OD value at 570 nm was detected with a microplate reader. Five parallel experiments were set in each well. Results are shown in Table 15.









TABLE 15







Effect of polypeptides X1-X90 on proliferation of


splenic lymphocytes in mice











Dose
A570 nm/
Inhibition


Group
(μM)
A630 nm
rate (%)














0.05
0.5690 ± 0.0501
15.75%


X1
0.1
0.5336 ± 0.0435
20.99%



0.2
0.5002 ± 0.1243
25.94%



0.05
0.5829 ± 0.1189
13.70%


X2
0.1
0.5290 ± 0.0543
21.68%



0.2
0.4767 ± 0.0569
29.42%



0.05
0.6137 ± 0.1127
 9.14%


X3
0.1
0.4903 ± 0.0507
27.41%



0.2
0.4790 ± 0.0396
29.08%



0.05
0.5747 ± 0.1223
14.91%


X4
0.1
0.5744 ± 0.0865
14.95%



0.2
0.4501 ± 0.0822
33.36%



0.05
0.5841 ± 0.1208
13.52%


X5
0.1
0.5074 ± 0.0893
24.87%



0.2
0.4354 ± 0.0491
35.53%



0.05
0.5281 ± 0.0787
21.81%


X6
0.1
0.5126 ± 0.0664
24.10%



0.2
0.4603 ± 0.0661
31.85%



0.05
0.5503 ± 0.1123
18.52%


X7
0.1
0.5420 ± 0.1094
19.75%



0.2
0.4359 ± 0.0755
35.46%



0.05
0.5701 ± 0.1244
15.59%


X8
0.1
0.5604 ± 0.0847
17.03%



0.2
0.5499 ± 0.0745
18.58%



0.05
0.5614 ± 0.0763
16.88%


X9
0.1
0.5347 ± 0.0627
20.83%



0.2
0.5162 ± 0.0760
23.57%



0.05
0.5705 ± 0.0488
15.53%


X10
0.1
0.4898 ± 0.0423
27.48%



0.2
0.4713 ± 0.0594
30.22%



0.05
0.6074 ± 0.0783
10.07%


X11
0.1
0.6002 ± 0.0945
11.13%



0.2
0.5755 ± 0.1175
14.79%



0.05
0.5668 ± 0.1043
16.08%


X12
0.1
0.4865 ± 0.0743
27.97%



0.2
0.4381 ± 0.0381
35.13%



0.05
0.6034 ± 0.1082
10.66%


X13
0.1
0.5122 ± 0.1124
24.16%



0.2
0.4334 ± 0.0973
35.83%



0.05
0.5894 ± 0.0562
12.73%


X14
0.1
0.5569 ± 0.0827
17.55%



0.2
0.5045 ± 0.0663
25.30%



0.05
0.5189 ± 0.0761
23.17%


X15
0.1
0.4459 ± 0.0996
33.98%



0.2
0.4413 ± 0.0806
34.66%



0.05
0.5703 ± 0.04654
15.56%


X16
0.1
0.5163 ± 0.0753
23.56%



0.2
0.4425 ± 0.1234
34.48%



0.05
0.6219 ± 0.0629
 7.92%


X17
0.1
0.5484 ± 0.1109
18.80%



0.2
0.5025 ± 0.0957
25.60%



0.05
0.6041 ± 0.0524
10.56%


X18
0.1
0.5571 ± 0.0554
17.52%



0.2
0.4402 ± 0.0534
34.82%



0.05
0.5093 ± 0.0372
24.59%


X19
0.1
0.5027 ± 0.0814
25.57%



0.2
0.4978 ± 0.0481
26.30%



0.05
0.5977 ± 0.1129
11.50%


X20
0.1
0.5419 ± 0.0423
19.77%



0.2
0.4947 ± 0.1213
26.75%



0.05
0.5904 ± 0.0399
12.59%


X21
0.1
0.5776 ± 0.1193
14.48%



0.2
0.4947 ± 0.1055
26.75%



0.05
0.5694 ± 0.0561
15.69%


X22
0.1
0.4603 ± 0.0873
31.85%



0.2
0.4521 ± 0.1194
33.06%



0.05
0.5946 ± 0.0378
11.96%


X23
0.1
0.4982 ± 0.1212
26.24%



0.2
0.4363 ± 0.0933
35.40%



0.05
0.5823 ± 0.0474
14.12%


X24
0.1
0.5615 ± 0.1155
16.86%



0.2
0.5142 ± 0.0636
23.87%



0.05
0.5838 ± 0.0861
13.56%


X25
0.1
0.5673 ± 0.0906
16.01%



0.2
0.4576 ± 0.1221
32.25%



0.05
0.5714 ± 0.1002
15.46%


X26
0.1
0.5365 ± 0.0543
20.57%



0.2
0.4991 ± 0.0743
26.10%



0.05
0.5388 ± 0.0643
20.23%


X27
0.1
0.5231 ± 0.0967
22.55%



0.2
0.4792 ± 0.0849
29.08%



0.05
0.5765 ± 0.0594
14.64%


X28
0.1
0.5541 ± 0.0486
17.96%



0.2
0.5087 ± 0.0793
24.68%



0.05
0.5595 ± 0.0932
17.16%


X29
0.1
0.5284 ± 0.0661
21.76%



0.2
0.5094 ± 0.1191
24.58%



0.05
0.5725 ± 0.0671
15.24%


X30
0.1
0.4914 ± 0.0652
27.24%



0.2
0.4759 ± 0.0702
29.54%



0.05
0.6142 ± 0.0512
 9.06%


X31
0.1
0.6134 ± 0.1148
9.18%



0.2
0.5450 ± 0.0838
19.31%



0.05
0.6117 ± 0.0672
9.43%


X32
0.1
0.5954 ± 0.0678
11.84%



0.2
0.5428 ± 0.0408
19.63%



0.05
0.5669 ± 0.1137
16.06%


X33
0.1
0.5297 ± 0.0479
21.57%



0.2
0.4492 ± 0.1069
33.49%



0.05
0.5469 ± 0.0655
19.03%


X34
0.1
0.4573 ± 0.1104
32.29%



0.2
0.4431 ± 0.1192
34.39%



0.05
0.6122 ± 0.1219
 9.36%


X35
0.1
0.5261 ± 0.0617
22.11%



0.2
0.4415 ± 0.0616
34.63%



0.05
0.6051 ± 0.0633
10.41%


X36
0.1
0.4566 ± 0.1223
32.40%



0.2
0.4401 ± 0.051
34.84%



0.05
0.5796 ± 0.0738
14.18%


X37
0.1
0.5792 ± 0.1065
14.24%



0.2
0.4659 ± 0.0948
31.02%



0.05
0.5618 ± 0.1042
16.82%


X38
0.1
0.4558 ± 0.0979
32.51%



0.2
0.4328 ± 0.0631
35.92%



0.05
0.6212 ± 0.0507
 8.02%


X39
0.1
0.4416 ± 0.0387
34.62%



0.2
0.4357 ± 0.0863
35.49%



0.05
0.5503 ± 0.1179
18.52%


X40
0.1
0.5416 ± 0.0875
19.81%



0.2
0.4765 ± 0.0889
29.45%



0.05
0.5735 ± 0.0874
15.09%


X41
0.1
0.5607 ± 0.1173
16.98%



0.2
0.4914 ± 0.0759
27.24%



0.05
0.5397 ± 0.0472
20.09%


X42
0.1
0.5107 ± 0.0539
24.39%



0.2
0.4931 ± 0.0829
26.99%



0.05
 0.579 ± 0.0424
14.27%


X43
0.1
0.5636 ± 0.0746
16.55%



0.2
0.5158 ± 0.0464
23.63%



0.05
0.4618 ± 0.0574
31.63%


X44
0.1
0.4546 ± 0.0849
32.69%



0.2
0.4397 ± 0.0381
34.90%



0.05
0.4925 ± 0.0885
27.08%


X45
0.1
0.4649 ± 0.0648
31.17%



0.2
0.4382 ± 0.0542
35.12%



0.05
0.5862 ± 0.0858
13.24%


X46
0.1
0.5312 ± 0.0611
21.35%



0.2
0.4555 ± 0.1123
32.56%



0.05
0.5974 ± 0.0873
11.55%


X47
0.1
0.5872 ± 0.0457
13.06%



0.2
0.5522 ± 0.0891
18.24%



0.05
0.4919 ± 0.1203
27.17%


X48
0.1
0.4673 ± 0.0677
30.81%



0.2
0.4320 ± 0.0449
36.04%



0.05
0.6195 ± 0.0383
 8.28%


X49
0.1
0.5796 ± 0.0546
14.18%



0.2
0.4814 ± 0.0475
28.72%



0.05
0.6230 ± 0.1001
 7.76%


X50
0.1
0.5842 ± 0.1217
13.50%



0.2
0.5679 ± 0.1122
15.92%



0.05
0.5059 ± 0.1217
25.10%


X51
0.1
0.4460 ± 0.0609
33.97%



0.2
0.4309 ± 0.0846
36.20%



0.05
0.5636 ± 0.0451
16.55%


X52
0.1
0.4912 ± 0.0789
27.27%



0.2
0.4696 ± 0.1046
30.47%



0.05
0.6080 ± 0.1023
 9.98%


X53
0.1
0.5264 ± 0.0724
22.06%



0.2
0.5256 ± 0.0637
22.18%



0.05
0.5155 ± 0.0467
23.67%


X54
0.1
0.4531 ± 0.0826
32.91%



0.2
0.4366 ± 0.0544
35.36%



0.05
0.6206 ± 0.1217
 8.11%


X55
0.1
0.5632 ± 0.0636
16.61%



0.2
0.4911 ± 0.0831
27.29%



0.05
0.5792 ± 0.0513
14.24%


X56
0.1
0.4813 ± 0.0694
28.74%



0.2
0.4731 ± 0.0773
29.95%



0.05
0.5872 ± 0.0843
13.06%


X57
0.1
0.5186 ± 0.0898
23.22%



0.2
0.4535 ± 0.0803
32.85%



0.05
 0.482 ± 0.1197
28.63%


X58
0.1
0.4726 ± 0.1193
30.03%



0.2
0.4484 ± 0.0383
33.61%



0.05
0.5684 ± 0.1051
15.84%


X59
0.1
0.4922 ± 0.1001
27.12%



0.2
0.4490 ± 0.0907
33.52%



0.05
0.5752 ± 0.0946
14.84%


X60
0.1
0.5287 ± 0.0535
21.72%



0.2
0.4516 ± 0.0451
33.14%



0.05
0.6027 ± 0.0421
10.76%


X61
0.1
0.5426 ± 0.0588
19.66%



0.2
0.5396 ± 0.0815
20.11%



0.05
0.5924 ± 0.0545
12.29%


X62
0.1
0.5410 ± 0.1178
19.90%



0.2
0.4946 ± 0.1136
26.77%



0.05
0.5120 ± 0.0424
24.19%


X63
0.1
0.4896 ± 0.0466
27.51%



0.2
0.4802 ± 0.0899
28.90%



0.05
0.4903 ± 0.0999
27.41%


X64
0.1
0.4840 ± 0.0397
28.34%



0.2
0.4626 ± 0.1067
31.51%



0.05
0.5761 ± 0.1145
14.70%


X65
0.1
0.5284 ± 0.1090
21.76%



0.2
0.5263 ± 0.0471
22.08%



0.05
0.5782 ± 0.0621
14.39%


X66
0.1
0.5153 ± 0.0677
23.70%



0.2
0.4344 ± 0.0692
35.68%



0.05
0.5022 ± 0.1074
25.64%


X67
0.1
0.4530 ± 0.0848
32.93%



0.2
0.4439 ± 0.0830
34.28%



0.05
0.6040 ± 0.0785
10.57%


X68
0.1
0.5933 ± 0.1197
12.16%



0.2
0.4581 ± 0.1171
32.17%



0.05
0.5825 ± 0.0498
13.75%


X69
0.1
0.5177 ± 0.1040
23.35%



0.2
0.4498 ± 0.0404
33.40%



0.05
0.5590 ± 0.0745
17.23%


X70
0.1
0.5293 ± 0.0927
21.63%



0.2
0.4868 ± 0.1146
27.92%



0.05
0.5929 ± 0.1211
12.21%


X71
0.1
0.4746 ± 0.0674
29.73%



0.2
0.4359 ± 0.1159
35.46%



0.05
0.6087 ± 0.0473
 9.88%


X72
0.1
0.5846 ± 0.0861
13.44%



0.2
0.5793 ± 0.0432
14.23%



0.05
0.5086 ± 0.0538
24.70%


X73
0.1
0.4995 ± 0.0594
26.04%



0.2
0.4403 ± 0.0526
34.81%



0.05
0.6150 ± 0.1195
 8.94%


X74
0.1
0.5118 ± 0.0370
24.22%



0.2
0.4796 ± 0.1055
28.99%



0.05
0.5665 ± 0.1103
16.12%


X75
0.1
0.5546 ± 0.0651
17.89%



0.2
0.5280 ± 0.0932
21.82%



0.05
0.5429 ± 0.0374
19.62%


X76
0.1
0.4940 ± 0.0946
26.86%



0.2
0.4538 ± 0.0644
32.81%



0.05
0.6037 ± 0.0672
10.62%


X77
0.1
0.5764 ± 0.0563
14.66%



0.2
0.5425 ± 0.0835
19.68%



0.05
0.5848 ± 0.0468
13.41%


X78
0.1
0.5644 ± 0.0524
16.43%



0.2
0.5128 ± 0.1213
24.07%



0.05
0.6191 ± 0.0595
 8.34%


X79
0.1
0.5640 ± 0.1173
16.49%



0.2
0.4454 ± 0.0759
34.05%



0.05
0.5708 ± 0.0931
15.49%


X80
0.1
0.5574 ± 0.0764
17.47%



0.2
0.4658 ± 0.0436
31.03%



0.05
0.5519 ± 0.0526
18.29%


X81
0.1
0.5357 ± 0.0666
20.68%



0.2
0.4510 ± 0.0848
33.22%



0.05
0.5582 ± 0.0773
17.35%


X82
0.1
0.5490 ± 0.0646
18.71%



0.2
0.4826 ± 0.0706
28.55%



0.05
0.5530 ± 0.0905
18.12%


X83
0.1
0.5396 ± 0.1234
20.11%



0.2
0.4676 ± 0.0973
30.77%



0.05
0.6088 ± 0.0952
 9.86%


X84
0.1
0.5420 ± 0.1007
19.75%



0.2
0.4782 ± 0.0856
29.20%



0.05
0.5653 ± 0.1097
16.30%


X85
0.1
0.5591 ± 0.0484
17.22%



0.2
0.5044 ± 0.0975
25.32%



0.05
0.5788 ± 0.0467
14.30%


X86
0.1
0.5520 ± 0.1060
18.27%



0.2
0.5355 ± 0.0589
20.71%



0.05
0.5785 ± 0.0641
14.35%


X87
0.1
0.5723 ± 0.0847
15.27%



0.2
0.4514 ± 0.0991
33.17%



0.05
0.5840 ± 0.0712
13.53%


X88
0.1
0.5793 ± 0.0628
14.23%



0.2
0.5360 ± 0.1234
20.64%



0.05
0.5860 ± 0.0529
13.24%


X89
0.1
0.5677 ± 0.0877
15.95%



0.2
0.5529 ± 0.0446
18.14%



0.05
0.6211 ± 0.0533
8.04%


X90
0.1
0.5274 ± 0.0429
21.91%



0.2
0.4483 ± 0.1024
33.62%


ConA

0.6754 ± 0.0312



Dex
20
0.3918 ± 0.1127
52.65%


Negative

0.6172 ± 0.0486










Results: Different polypeptides X1-X90 could inhibit the proliferation of splenic lymphocytes in mice to some extent. When the dose of X51 was 0.2 μM, the inhibition rate reached 36.20%. And the inhibition effect of each administration group showed a certain dose-dependent relationship.


Example 11

Effect of Polypeptides X1-X90 on IL-1β Production by Mouse Peritoneal Macrophages


(1) IL-1β production: Mice were injected intraperitoneally with 1 mL of broth culture medium (containing 6% of starch). Three days later, mice peritoneal macrophages were taken aseptically and washed twice with 1640 culture medium, and the cell concentration was adjusted to 2×106 cells/mL. The solutions were injected into 24-well culture plates at 1 mL per well. The cells were incubated in a cell incubator for 3 h and vibrated once every 30 min to make the cells fully adhere to the wall. Then, the cells were washed twice with a culture solution to remove non-adhered cells. PBS was added to the blank group, positive drug Dex was added to the positive group, no drug was added to the model group, and polypeptides X1-X90 with low, medium and high concentrations were added to the test groups; and the cells were continuously cultured for 48 h after administration, and then centrifuged at 1000 r/min for 15 min. The supernatant was collected as a sample to be tested for IL-1β activity.


(2) Determination of IL-1β content: A mouse IL-1β enzyme-linked immunosorbent assay kit from R&D Company was used for detection, and operations were according to the instructions as follows: tested samples and standards with different concentrations were added respectively, the reaction wells were sealed with sealing tap, and the cells were cultured at 37° C. for 90 min; well plates were washed four times; a biotinylated antibody working solution (100 μL/well) was added, the reaction wells were sealed with sealing tap, and the cells were cultured at 37° C. for 60 min; the plates were washed four times; an enzyme conjugate working solution (100 μL/well) was added, the reaction wells were sealed with sealing tap, and the cells were cultured at 37° C. for 30 min; the plates were washed four times; a chromogenic agent (100 μL/well) was added, and the cells were cultured for 10-20 min at 37° C. in the absence of light; a stopping solution (100 pt/well) was added, and OD450 values were measured after uniform mixing.









TABLE 16







Effect of polypeptides X1-X90 on IL-1β production


by mouse peritoneal macrophages











Dose
IL-1β
Inhibition


Group
(μM)
(pg/mL)
rate (%)














0.05
713.98 ± 14.81**
24.14%


X1
0.1
566.07 ± 12.62**
39.85%



0.2
504.81 ± 19.06**
46.36%



0.05
760.65 ± 17.43**
19.18%


X2
0.1
638.49 ± 11.83**
32.16%



0.2
571.18 ± 17.86**
39.31%



0.05
661.28 ± 18.24**
29.74%


X3
0.1
583.99 ± 12.75**
37.95%



0.2
538.48 ± 18.51**
42.78%



0.05
738.37 ± 16.5**
21.55%


X4
0.1
730.52 ± 19.01**
22.38%



0.2
520.72 ± 12.58**
44.67%



0.05
687.97 ± 14.45**
26.90%


X5
0.1
555.41 ± 15.34**
40.99%



0.2
515.77 ± 13.86**
45.20%



0.05
721.27 ± 12.54**
23.36%


X6
0.1
655.58 ± 17.35**
30.34%



0.2
511.66 ± 17.94**
45.63%



0.05
784.12 ± 10.28**
16.68%


X7
0.1
720.89 ± 10.55**
23.40%



0.2
616.03 ± 11.32**
34.54%



0.05
548.85 ± 13.67**
41.68%


X8
0.1
565.46 ± 15.31**
39.92%



0.2
712.66 ± 10.28**
24.28%



0.05
761.97 ± 10.58**
19.04%


X9
0.1
720.99 ± 15.53**
23.39%



0.2
671.04 ± 18.22**
28.70%



0.05
657.54 ± 13.71**
30.13%


X10
0.1
543.52 ± 12.38**
42.25%



0.2
519.81 ± 10.98**
44.77%



0.05
740.02 ± 18.07**
21.37%


X11
0.1
737.89 ± 10.66**
21.60%



0.2
696.04 ± 13.55**
26.04%



0.05
712.00 ± 19.81**
24.35%


X12
0.1
559.65 ± 14.15**
40.53%



0.2
531.24 ± 15.15**
43.55%



0.05
615.38 ± 19.33**
34.61%


X13
0.1
594.57 ± 14.52**
36.82%



0.2
508.42 ± 14.86**
45.98%



0.05
748.32 ± 12.75**
20.49%


X14
0.1
665.77 ± 10.48**
29.26%



0.2
613.65 ± 15.32**
34.80%



0.05
756.78 ± 16.91**
19.59%


X15
0.1
638.51 ± 15.98**
32.16%



0.2
588.83 ± 13.37**
37.43%



0.05
796.16 ± 15.1**
15.40%


X16
0.1
773.34 ± 14.38**
17.83%



0.2
592.05 ± 18.61**
37.09%



0.05
790.35 ± 11.07**
16.02%


X17
0.1
531.11 ± 17.61**
43.57%



0.2
528.00 ± 10.53**
43.90%



0.05
721.31 ± 12.75**
23.36%


X18
0.1
716.58 ± 16.56**
23.86%



0.2
683.26 ± 19.63**
27.40%



0.05
591.13 ± 10.54**
37.19%


X19
0.1
590.42 ± 10.34**
37.27%



0.2
589.21 ± 12.08**
37.39%



0.05
772.72 ± 18.78**
17.90%


X20
0.1
724.50 ± 12.58**
23.02%



0.2
631.59 ± 19.52**
32.89%



0.05
773.58 ± 10.52**
17.80%


X21
0.1
637.22 ± 12.95**
32.29%



0.2
526.94 ± 17.75**
44.01%



0.05
663.21 ± 13.73**
29.53%


X22
0.1
637.07 ± 19.81**
32.31%



0.2
578.51 ± 14.03**
38.53%



0.05
793.48 ± 19.42**
15.69%


X23
0.1
650.17 ± 14.98**
30.92%



0.2
623.64 ± 12.33**
33.74%



0.05
659.97 ± 17.07**
29.88%


X24
0.1
645.67 ± 11.87**
31.39%



0.2
548.82 ± 19.58**
41.69%



0.05
747.54 ± 18.25**
20.57%


X25
0.1
713.21 ± 19.17**
24.22%



0.2
659.86 ± 10.24**
29.89%



0.05
769.33 ± 19.82**
18.26%


X26
0.1
734.20 ± 13.89**
21.99%



0.2
663.38 ± 11.96**
29.51%



0.05
697.32 ± 17.18**
25.91%


X27
0.1
649.68 ± 18.74**
30.97%



0.2
624.72 ± 14.38**
33.62%



0.05
792.64 ± 11.74**
15.78%


X28
0.1
640.89 ± 14.7**
31.90%



0.2
637.34 ± 10.85**
32.28%



0.05
788.74 ± 15.39**
16.20%


X29
0.1
736.46 ± 14.72**
21.75%



0.2
557.81 ± 12.11**
40.73%



0.05
674.82 ± 10.45**
28.30%


X30
0.1
621.53 ± 19.69**
33.96%



0.2
589.79 ± 19.66**
37.33%



0.05
797.34 ± 10.46**
15.28%


X31
0.1
764.81 ± 19.08**
18.74%



0.2
723.57 ± 18.58**
23.12%



0.05
771.56 ± 13.41**
18.02%


X32
0.1
676.06 ± 19.82**
28.17%



0.2
533.56 ± 18.54**
43.31%



0.05
699.41 ± 11.17**
25.68%


X33
0.1
613.62 ± 19.23**
34.80%



0.2
593.32 ± 11.64**
36.96%



0.05
767.28 ± 18.52**
18.47%


X34
0.1
753.21 ± 13.97**
19.97%



0.2
676.31 ± 16.02**
28.14%



0.05
718.81 ± 11.53**
23.62%


X35
0.1
651.42 ± 15.51**
30.79%



0.2
615.43 ± 17.18**
34.61%



0.05
779.49 ± 11.56**
17.18%


X36
0.1
620.34 ± 15.26**
34.09%



0.2
619.62 ± 11.89**
34.16%



0.05
794.72 ± 11.93**
15.56%


X37
0.1
687.76 ± 15.11**
26.92%



0.2
642.75 ± 16.32**
31.71%



0.05
568.25 ± 16.41**
39.62%


X38
0.1
541.61 ± 11.54**
42.45%



0.2
506.70 ± 13.93**
46.16%



0.05
792.13 ± 13.67**
15.83%


X39
0.1
658.74 ± 19.08**
30.01%



0.2
573.90 ± 10.07**
39.02%



0.05
673.29 ± 16.27**
28.46%


X40
0.1
607.19 ± 14.25**
35.48%



0.2
574.54 ± 18.39**
38.95%



0.05
742.13 ± 13.85**
21.15%


X41
0.1
738.75 ± 15.58**
21.50%



0.2
693.24 ± 11.25**
26.34%



0.05
798.18 ± 18.97**
15.19%


X42
0.1
639.07 ± 15.55**
32.10%



0.2
597.39 ± 13.26**
36.52%



0.05
708.94 ± 18.65**
24.67%


X43
0.1
619.99 ± 18.36**
34.12%



0.2
532.86 ± 11.36**
43.38%



0.05
747.98 ± 18.08**
20.52%


X44
0.1
629.53 ± 18.12**
33.11%



0.2
521.12 ± 14.94**
44.63%



0.05
766.39 ± 19.61**
18.57%


X45
0.1
 556.6 ± 18.09**
40.86%



0.2
526.65 ± 12.66**
44.04%



0.05
768.77 ± 17.46**
18.32%


X46
0.1
714.74 ± 19.14**
24.06%



0.2
527.65 ± 17.23**
43.94%



0.05
694.15 ± 18.69**
26.24%


X47
0.1
658.30 ± 14.95**
30.05%



0.2
518.71 ± 14.69**
44.88%



0.05
747.87 ± 12.65**
20.54%


X48
0.1
618.52 ± 12.98**
34.28%



0.2
598.41 ± 17.15**
36.42%



0.05
667.29 ± 11.38**
29.10%


X49
0.1
637.37 ± 13.29**
32.28%



0.2
586.29 ± 16.72**
37.70%



0.05
566.55 ± 13.38**
39.80%


X50
0.1
566.54 ± 16.16**
39.81%



0.2
552.42 ± 15.46**
41.30%



0.05
778.04 ± 16.84**
17.33%


X51
0.1
741.14 ± 10.12**
21.25%



0.2
608.72 ± 11.49**
35.32%



0.05
737.61 ± 15.15**
21.63%


X52
0.1
589.49 ± 11.15**
37.36%



0.2
572.85 ± 13.85**
39.13%



0.05
633.83 ± 18.23**
32.65%


X53
0.1
620.13 ± 13.11**
34.11%



0.2
600.32 ± 15.37**
36.21%



0.05
749.61 ± 17.43**
20.35%


X54
0.1
616.42 ± 12.72**
34.50%



0.2
543.73 ± 18.82**
42.23%



0.05
739.52 ± 10.19**
21.43%


X55
0.1
724.78 ± 19.62**
22.99%



0.2
544.39 ± 15.61**
42.16%



0.05
781.78 ± 19.36**
16.93%


X56
0.1
706.46 ± 19.22**
24.94%



0.2
561.08 ± 19.21**
40.38%



0.05
672.72 ± 12.56**
28.52%


X57
0.1
666.13 ± 14.96**
29.22%



0.2
520.78 ± 16.49**
44.66%



0.05
717.32 ± 15.84**
23.78%


X58
0.1
620.62 ± 19.42**
34.06%



0.2
586.29 ± 10.36**
37.70%



0.05
695.91 ± 13.75**
26.06%


X59
0.1
647.53 ± 16.44**
31.20%



0.2
643.12 ± 11.69**
31.67%



0.05
630.91 ± 15.16**
32.96%


X60
0.1
554.56 ± 11.62**
41.08%



0.2
500.84 ± 17.46**
46.78%



0.05
797.35 ± 10.72**
15.28%


X61
0.1
697.13 ± 13.28**
25.93%



0.2
647.78 ± 12.47**
31.17%



0.05
628.45 ± 12.52**
33.22%


X62
0.1
601.72 ± 15.63**
36.06%



0.2
520.74 ± 18.21**
44.67%



0.05
765.84 ± 10.96**
18.63%


X63
0.1
686.65 ± 19.26**
27.04%



0.2
556.64 ± 13.23**
40.85%



0.05
778.79 ± 12.41**
17.25%


X64
0.1
759.88 ± 19.83**
19.26%



0.2
626.56 ± 18.32**
33.43%



0.05
765.38 ± 16.93**
18.68%


X65
0.1
660.18 ± 10.44**
29.85%



0.2
624.23 ± 19.35**
33.67%



0.05
796.38 ± 12.49**
15.38%


X66
0.1
770.99 ± 16.16**
18.08%



0.2
537.76 ± 15.01**
42.86%



0.05
790.87 ± 19.67**
15.97%


X67
0.1
677.49 ± 17.07**
28.01%



0.2
502.45 ± 16.43**
46.61%



0.05
748.68 ± 11.87**
20.45%


X68
0.1
742.75 ± 11.59**
21.08%



0.2
621.92 ± 18.74**
33.92%



0.05
727.04 ± 17.05**
22.75%


X69
0.1
617.67 ± 13.71**
34.37%



0.2
582.44 ± 18.89**
38.11%



0.05
786.31 ± 14.02**
16.45%


X70
0.1
604.32 ± 14.13**
35.79%



0.2
574.15 ± 11.84**
38.99%



0.05
679.18 ± 19.75**
27.83%


X71
0.1
634.58 ± 19.39**
32.57%



0.2
592.41 ± 15.53**
37.05%



0.05
655.35 ± 18.42**
30.37%


X72
0.1
604.85 ± 15.84**
35.73%



0.2
588.45 ± 13.52**
37.47%



0.05
771.73 ± 13.81**
18.00%


X73
0.1
753.73 ± 15.23**
19.91%



0.2
747.51 ± 19.92**
20.58%



0.05
624.73 ± 11.01**
33.62%


X74
0.1
568.59 ± 14.61**
39.58%



0.2
503.89 ± 18.51**
46.46%



0.05
773.81 ± 19.58**
17.78%


X75
0.1
739.94 ± 18.37**
21.38%



0.2
506.17 ± 15.62**
46.22%



0.05
727.25 ± 14.37**
22.73%


X76
0.1
598.53 ± 10.69**
36.40%



0.2
509.91 ± 14.79**
45.82%



0.05
718.21 ± 15.57**
23.69%


X77
0.1
596.49 ± 14.02**
36.62%



0.2
542.70 ± 12.94**
42.34%



0.05
785.31 ± 13.76**
16.56%


X78
0.1
614.30 ± 15.49**
34.73%



0.2
550.10 ± 10.22**
41.55%



0.05
730.61 ± 11.67**
22.37%


X79
0.1
655.09 ± 13.17**
30.39%



0.2
538.64 ± 15.15**
42.77%



0.05
740.71 ± 14.93**
21.30%


X80
0.1
731.38 ± 18.08**
22.29%



0.2
 686.4 ± 14.15**
27.07%



0.05
738.64 ± 12.83**
21.52%


X81
0.1
691.37 ± 19.49**
26.54%



0.2
683.57 ± 17.68**
27.37%



0.05
767.71 ± 15.67**
18.43%


X82
0.1
635.72 ± 18.53**
32.45%



0.2
610.38 ± 18.13**
35.14%



0.05
668.36 ± 12.95**
28.98%


X83
0.1
657.88 ± 15.28**
30.10%



0.2
581.18 ± 10.24**
38.25%



0.05
737.66 ± 15.78**
21.62%


X84
0.1
 646.9 ± 19.52**
31.26%



0.2
547.63 ± 15.44**
41.81%



0.05
756.78 ± 14.73**
19.59%


X85
0.1
618.25 ± 17.66**
34.31%



0.2
582.91 ± 16.51**
38.06%



0.05
721.79 ± 12.02**
23.31%


X86
0.1
562.02 ± 14.18**
40.28%



0.2
530.47 ± 16.01**
43.64%



0.05
709.45 ± 19.53**
24.62%


X87
0.1
577.97 ± 18.15**
38.59%



0.2
576.76 ± 16.2** 
38.72%



0.05
799.77 ± 14.02**
15.02%


X88
0.1
798.94 ± 10.54**
15.11%



0.2
541.63 ± 18.24**
42.45%



0.05
725.42 ± 10.43**
22.92%


X89
0.1
641.72 ± 17.95**
31.82%



0.2
554.33 ± 11.47**
41.10%



0.05
765.21 ± 19.43**
18.69%


X90
0.1
685.28 ± 18.66**
27.19%



0.2
582.61 ± 11.83**
38.10%


Dex
20
352.06 ± 17.29**
62.95%


Model group

941.14 ± 3.28   



Negative

 9.75 ± 0.75   










Results: Polypeptides X1-X90 all had obvious inhibitory effect on the proliferation of splenic lymphocytes in mice, which was significantly different from that of the negative group. When the dose of X60 was 0.2 μM, the inhibition rate reached 46.78%. And there is a certain dose-dependent relationship.


Example 12

Effect of Polypeptides X1-X90 on Xylene-Induced Mouse Ear Swelling


Kunming mice were taken, a normal saline group was taken as a blank control group, an aspirin group (200 mg/kg) was taken as a positive control group, and X1-X90 administration groups were taken as test groups. The mice were injected once a day for 5 consecutive days. The blank control group was given an equal volume of normal saline. One hour after the last administration, 0.05 mL of xylene was applied to both sides of the right ear of each mouse to cause inflammation, while no drug was applied to the left ear as a normal ear. Two hours later, the mice were put to death by dislocation. Two ears were cut along the auricle. Ear pieces were taken with a puncher and weighed, and the swelling degree and the swelling rate were calculated. Swelling degree=right ear piece weight-left ear piece weight, swelling rate=(swelling degree/left ear piece weight)*100%. Statistical t-test was conducted on the experimental results. *P<0.05 indicates significant difference, and **P<0.01 indicates extremely significant difference. The results are shown in Table 17.









TABLE 17







Effect of polypeptides X1-X90 on xylene-induced


mouse ear swelling













Dose
Swelling
Inhibition



Group
(mg/kg)
degree (mg)
rate (%)

















2
5.75 ± 0.39
 7.70%



X1
4
4.61 ± 0.63*
26.00%




8
4.09 ± 0.02**
34.35%



X2
2
4.52 ± 0.85*
27.45%




4
4.21 ± 0.82**
32.42%




8
3.81 ± 0.11**
38.84%




2
4.28 ± 0.46**
31.30%



X3
4
3.51 ± 0.46**
43.66%




8
3.32 ± 0.64**
46.71%




2
4.62 ± 0.77*
25.84%



X4
4
4.47 ± 0.87*
28.25%




8
3.57 ± 0.26**
42.70%




2
4.23 ± 0.62**
32.10%



X5
4
3.78 ± 0.37**
39.33%




8
3.43 ± 0.76**
44.94%




2
5.83 ± 0.49
 6.42%



X6
4
5.26 ± 0.18
15.57%




8
4.46 ± 0.19*
28.41%




2
5.17 ± 0.49
17.01%



X7
4
4.61 ± 0.21*
26.00%




8
3.47 ± 0.35**
44.30%




2
5.87 ± 0.95
 5.78%



X8
4
5.63 ± 0.56
 9.63%




8
5.26 ± 0.38*
15.57%




2
4.11 ± 0.32**
34.03%



X9
4
3.54 ± 0.73**
43.18%




8
3.01 ± 0.13**
51.69%




2
5.69 ± 0.57
 8.67%



X10
4
3.68 ± 0.47**
40.93%




8
3.46 ± 0.05**
44.46%




2
5.52 ± 0.97
11.40%



X11
4
3.81 ± 0.42**
38.84%




8
3.18 ± 0.17**
48.96%




2
5.87 ± 0.32
 5.78%



X12
4
5.53 ± 0.09
11.24%




8
5.32 ± 0.31
14.61%




2
5.78 ± 0.91
 7.22%



X13
4
4.91 ± 0.71*
21.19%




8
 3.8 ± 0.15**
39.00%




2
5.55 ± 0.31
10.91%



X14
4
4.78 ± 0.04*
23.27%




8
4.43 ± 0.09*
28.89%




2
5.76 ± 0.41
 7.54%



X15
4
5.58 ± 0.08
10.43%




8
 3.8 ± 0.94**
39.00%




2
5.00 ± 0.08
19.74%



X16
4
3.11 ± 0.71**
50.08%




8
3.10 ± 0.3**
50.24%




2
4.65 ± 0.79*
25.36%



X17
4
4.43 ± 0.75*
28.89%




8
3.53 ± 0.1**
43.34%




2
5.42 ± 0.18
13.00%



X18
4
5.28 ± 0.46
15.25%




8
4.18 ± 0.9**
32.91%




2
4.98 ± 0.72*
20.06%



X19
4
3.97 ± 0.61**
36.28%




8
 3.8 ± 0.03**
39.00%




2
5.72 ± 0.01
 8.19%



X20
4
3.78 ± 0.88**
39.33%




8
3.47 ± 0.07**
44.30%




2
5.39 ± 0.39
13.48%



X21
4
4.97 ± 0.14*
20.22%




8
3.15 ± 0.42**
49.44%




2
4.72 ± 0.29*
24.24%



X22
4
3.67 ± 0.77**
41.09%




8
3.42 ± 0.21**
45.10%




2
5.64 ± 0.84
 9.47%



X23
4
3.63 ± 0.51**
41.73%




8
3.47 ± 0.06**
44.30%




2
5.25 ± 0.06
15.73%



X24
4
4.98 ± 0.19*
20.06%




8
4.34 ± 0.68**
30.34%




2
5.62 ± 0.64
 9.79%



X25
4
4.45 ± 0.20*
28.57%




8
 3.3 ± 0.06**
47.03%




2
5.88 ± 0.72
 5.62%



X26
4
5.78 ± 0.62
 7.22%




8
4.54 ± 0.61**
49.76%




2
5.36 ± 0.32
13.96%



X27
4
4.76 ± 0.89*
23.60%




8
3.13 ± 0.38*
27.13%




2
5.25 ± 0.56**
33.87%



X28
4
4.86 ± 0.63
15.73%




8
4.12 ± 0.93*
21.99%




2
5.43 ± 0.91
12.84%



X29
4
4.96 ± 0.1*
20.39%




8
3.86 ± 0.45**
38.04%




2
5.19 ± 0.57
16.69%



X30
4
5.07 ± 0.49
18.62%




8
3.77 ± 0.38**
39.49%




2
3.16 ± 0.55
16.85%



X31
4
4.22 ± 0.51**
32.26%




8
5.18 ± 0.71**
49.28%




2
5.17 ± 0.06
17.01%



X32
4
4.83 ± 0.02*
22.47%




8
3.69 ± 0.56**
40.77%




2
3.22 ± 0.59
17.34%



X33
4
5.15 ± 0.19*
29.21%




8
4.41 ± 0.9**
48.31%




2
3.86 ± 0.43**
38.04%



X34
4
3.36 ± 0.53**
46.07%




8
 3.2 ± 0.39**
48.64%




2
5.59 ± 0.91
10.27%



X35
4
4.78 ± 0.64*
23.27%




8
3.48 ± 0.28**
44.14%




2
5.37 ± 0.84
13.80%



X36
4
5.37 ± 0.21
13.80%




8
 4.7 ± 0.97*
24.56%




2
5.41 ± 0.31
13.16%



X37
4
4.79 ± 0.47*
23.11%




8
3.41 ± 0.03**
45.26%




2
5.51 ± 0.41
11.56%



X38
4
5.30 ± 0.23
14.93%




8
3.61 ± 0.69**
42.05%




2
5.38 ± 0.22
13.64%



X39
4
5.09 ± 0.65
18.30%




8
4.85 ± 0.74*
22.15%




2
5.24 ± 0.55
15.89%



X40
4
4.63 ± 0.53*
25.68%




8
4.55 ± 0.37*
26.97%




2
5.67 ± 0.88
8.99%



X41
4
4.94 ± 0.99*
20.71%




8
4.72 ± 0.57*
24.24%




2
5.79 ± 0.06
 7.06%



X42
4
5.65 ± 0.17
 9.31%




8
3.15 ± 0.17**
49.44%




2
4.48 ± 0.02*
28.09%



X43
4
4.41 ± 0.42*
29.21%




8
3.51 ± 0.27**
43.66%




2
3.88 ± 0.39**
37.72%



X44
4
3.79 ± 0.37**
39.17%




8
3.45 ± 0.24**
44.62%




2
5.59 ± 0.47
10.27%



X45
4
4.73 ± 0.63*
24.08%




8
3.98 ± 0.69**
36.12%




2
4.27 ± 0.18**
31.46%



X46
4
3.90 ± 0.58**
37.40%




8
3.70 ± 0.54**
40.61%




2
4.26 ± 0.64**
31.62%



X47
4
3.51 ± 0.96**
43.66%




8
3.28 ± 0.62**
47.35%




2
5.99 ± 0.13
 3.85%



X48
4
4.53 ± 0.11*
27.29%




8
4.32 ± 0.21**
30.66%




2
5.63 ± 0.92
 9.63%



X49
4
4.74 ± 0.74*
23.92%




8
3.06 ± 0.86**
50.88%




2
5.45 ± 0.49
12.52%



X50
4
4.29 ± 0.14**
31.14%




8
3.55 ± 0.74**
43.02%




2
4.95 ± 0.22*
20.55%



X51
4
3.20 ± 0.28**
48.64%




8
3.02 ± 0.33**
51.52%




2
4.42 ± 0.91*
29.05%



X52
4
3.49 ± 0.92**
43.98%




8
3.24 ± 0.43**
47.99%




2
4.08 ± 0.11**
34.51%



X53
4
3.99 ± 0.84**
35.96%




8
3.67 ± 0.64**
41.09%




2
5.30 ± 0.11
14.93%



X54
4
4.71 ± 0.73*
24.40%




8
3.05 ± 0.28**
51.04%




2
5.46 ± 0.02
12.36%



X55
4
4.98 ± 0.55*
20.06%




8
3.16 ± 0.77**
49.28%




2
4.50 ± 0.07*
27.77%



X56
4
3.54 ± 0.9**
43.18%




8
3.50 ± 0.93**
43.82%




2
5.25 ± 0.24
15.73%



X57
4
4.99 ± 0.71
19.90%




8
4.09 ± 0.69**
34.35%




2
5.51 ± 0.96
11.56%



X58
4
5.33 ± 0.94
14.45%




8
4.87 ± 0.72*
21.83%




2
4.65 ± 0.12*
25.36%



X59
4
4.12 ± 0.29**
34.19%




8
3.12 ± 0.68**
50.24%




2
5.43 ± 0.30
12.84%



X60
4
3.83 ± 0.94**
38.52%




8
3.05 ± 0.71**
51.04%




2
5.99 ± 0.27
 3.85%



X61
4
5.29 ± 0.22
15.09%




8
4.44 ± 0.33*
28.73%




2
 4.9 ± 0.16*
21.35%



X62
4
4.62 ± 0.37*
25.84%




8
3.23 ± 0.25**
48.15%




2
5.87 ± 0.54
 5.78%



X63
4
3.90 ± 0.14**
37.40%




8
3.31 ± 0.21**
46.87%




2
5.01 ± 0.59
19.58%



X64
4
5.00 ± 0.74
19.74%




8
4.93 ± 0.36*
20.87%




2
5.46 ± 0.61
12.36%



X65
4
5.16 ± 0.99
17.17%




8
4.23 ± 0.45**
32.10%




2
4.78 ± 0.86*
23.27%



X66
4
3.74 ± 0.95*
39.97%




8
3.24 ± 0.37**
47.99%




2
3.42 ± 0.11**
45.10%



X67
4
3.09 ± 0.87**
50.40%




8
3.02 ± 0.05**
51.52%




2
5.96 ± 0.55
 4.33%



X68
4
5.69 ± 0.97
 8.67%




8
4.93 ± 0.13*
20.87%




2
5.67 ± 0.75
 8.99%



X69
4
4.45 ± 0.99*
28.57%




8
3.03 ± 0.91**
51.36%




2
4.60 ± 0.25*
26.16%



X70
4
4.02 ± 0.72**
35.47%




8
3.58 ± 0.41**
42.54%




2
5.96 ± 0.55
 8.03%



X71
4
5.15 ± 0.32
17.34%




8
4.43 ± 0.13*
28.89%




2
5.11 ± 0.99
17.98%



X72
4
4.77 ± 0.81*
23.43%




8
3.58 ± 0.48**
42.54%




2
4.72 ± 0.72*
24.24%



X73
4
4.42 ± 0.57*
29.05%




8
3.58 ± 0.63**
42.54%




2
5.56 ± 0.67
10.75%



X74
4
4.79 ± 0.29*
23.11%




8
3.69 ± 0.85**
40.77%




2
5.94 ± 0.47
 4.65%



X75
4
4.28 ± 0.41**
31.30%




8
3.32 ± 0.69**
46.71%




2
5.65 ± 0.24
 9.31%



X76
4
5.20 ± 0.91
16.53%




8
3.08 ± 0.39**
50.56%




2
5.03 ± 0.78
19.26%



X77
4
4.39 ± 0.95*
29.53%




8
3.99 ± 0.39**
35.96%




2
4.38 ± 0.19*
29.70%



X78
4
3.59 ± 0.66**
42.38%




8
3.41 ± 0.67**
45.26%




2
4.72 ± 0.72*
24.24%



X79
4
4.42 ± 0.57*
29.05%




8
3.58 ± 0.63**
42.54%




2
5.56 ± 0.67
10.75%



X80
4
4.79 ± 0.29*
23.11%




8
3.69 ± 0.85**
40.77%




2
5.94 ± 0.47
 4.65%



X81
4
4.28 ± 0.41**
31.30%




8
3.32 ± 0.69**
46.71%




2
5.65 ± 0.24
 9.31%



X82
4
5.20 ± 0.91
16.53%




8
3.08 ± 0.39**
50.56%




2
5.03 ± 0.78
19.26%



X83
4
4.39 ± 0.95*
29.53%




8
3.99 ± 0.39**
35.96%




2
5.15 ± 0.62
17.34%



X84
4
5.11 ± 0.84
17.98%




8
4.52 ± 0.43*
27.45%




2
4.83 ± 0.77*
22.47%



X85
4
4.81 ± 0.03*
22.79%




8
3.66 ± 0.62**
41.25%




2
5.72 ± 0.64
 8.19%



X86
4
4.69 ± 0.72*
24.72%




8
4.06 ± 0.46**
34.83%




2
5.52 ± 0.64
11.40%



X87
4
5.21 ± 0.39
16.37%




8
3.58 ± 0.38**
42.54%




2
4.04 ± 0.34
35.15%



X88
4
3.68 ± 0.52**
40.93%




8
3.50 ± 0.65**
43.82%




2
5.08 ± 0.69
18.46%



X89
4
4.42 ± 0.67*
29.05%




8
4.08 ± 0.06**
34.51%




2
4.99 ± 0.57
19.90%



X90
4
4.20 ± 0.9**
32.58%




8
3.22 ± 0.96**
48.31%



Aspirin
200
3.08 ± 0.31**
51.04%



control

6.23 ± 0.29











Results: Polypeptides X1-X90 could have obvious inhibitory effects on xylene-induced mouse ear swelling. The inhibition rate of the polypeptide X51 reached 51.52%, which was better than that of the positive group and showed a dose-dependent relationship.


Example 13

In Vivo Immunoprotective Effect of Polypeptides X1-X90 on a Mouse Collagen-Induced Arthritis (CIA) Animal Model


A mouse CIA animal model was established to study the therapeutic effects of X1-X90 on mouse CIA. Mice were used as test animals. SPF DBA/1 mice, male, 7-8 weeks old, were used. They each weighed 18-22 g and were randomly divided into a normal control group, a model control group, X1-X90 groups and a positive drug control group (methotrexate at 1 mg/kg). Except the normal group, mouse CIA models were established in each test group on day 0 by dissolving chicken cartilage type III collagen (cIII) into 4 mg/mL solution with 0.1 mol/L acetic acid and standing overnight in a refrigerator at 4° C. On the day of the test, type III collagen and complete Freund's adjuvant (CFA) containing 4 mg/mL Myeobaeterium tuberculosis strain H37Rv were fully emulsified in the same volume. After DBA/1 mice were anesthetized, 50 μL of emulsifier was injected into the tail skin of each mouse for sensitization. After 21 days, 4 mg/mL type III collagen (cIII) and incomplete Freund's adjuvant (IFA) were fully emulsified in the same volume and then re-immunization was performed with the same dose of emulsifier in the tail. Subcutaneous injection was started from day 30 of modeling: the X1-X90 groups: once every three days; the positive drug control group (methotrexate at 1 mg/kg): once every 5 d, 3 times consecutively; and the normal control group and the model control group (normal saline): continuous for 10 d. Every 3 days from day 21 to day 70 after modeling, the body weights were weighed, joint scores were made, and the diameters of left and right hind foot ankles were measured respectively to observe the effect of drugs on mouse CIA. On day 70, the mice were killed by dislocation.


Arthritis evaluation indexes are as follows: (1) Joint score: limbs: score on a scale of 0-4: 0=no erythema or swelling; 1=slight erythema or swelling, one of the foretoe/hind toe joints has erythema or swelling; 2=erythema or swelling of more than one toe; 3=paw swelling under ankle or wrist joints; and 4=swelling of all paws including ankle joints. The four paws of the mice were scored respectively, with the highest score being 16 points. Every 3 days from day 21 to day 70 after modeling, joint scores were made, and results were recorded. (2) Measurement of ankle diameter: The diameters from medial to lateral of left and right ankles and ankle thicknesses of mice were measured with vernier calipers every 3 days before modeling and from day 21 to day 70 after modeling, and the results were recorded.


The experiment was repeated independently three times. The results were expressed as mean±SD, and statistical T test was conducted. In the table, *P<0.05 indicates significant difference, and **P<0.01 indicates extremely significant difference.









TABLE 18







In vivo immunoprotective effect of polypeptides X1-X90


on a mouse CIA animal model















Left and







right paw
Joint






swelling
swelling




Num-
Dose
degree
degree
Clinical


Group
ber
(mg/kg)
(mm)
(mm)
score





Normal
10

0.18 ± 0.07  
0.16 ± 0.05  
 0.00 ± 0.00


control







group







Model
10

2.29 ± 0.39  
2.00 ± 0.47  
15.65 ± 1.90


control







group







Positive
10
1
0.70 ± 0.12**
0.73 ± 0.12**
 8.32 ± 1.35**


control







group







X1
10
4.0
0.81 ± 0.11**
0.79 ± 0.15**
 9.17 ± 1.44**


X2
10
4.0
0.71 ± 0.15**
0.77 ± 0.18**
 9.18 ± 1.41**


X3
10
4.0
0.72 ± 0.11**
0.81 ± 0.17**
 8.88 ± 1.25**


X4
10
4.0
0.76 ± 0.14**
0.82 ± 0.11**
 8.91 ± 1.43**


X5
10
4.0
0.85 ± 0.12**
0.81 ± 0.17**
 8.89 ± 1.28**


X6
10
4.0
0.71 ± 0.14**
0.81 ± 0.11**
 8.77 ± 1.26**


X7
10
4.0
0.79 ± 0.11**
0.73 ± 0.14**
 8.79 ± 1.23**


X8
10
4.0
0.74 ± 0.13**
0.82 ± 0.17**
 8.99 ± 1.31**


X9
10
4.0
0.71 ± 0.15**
0.81 ± 0.12**
 8.91 ± 1.25**


X10
10
4.0
0.82 ± 0.11**
0.72 ± 0.18**
 8.83 ± 1.36**


X11
10
4.0
0.78 ± 0.18**
0.76 ± 0.17**
 8.99 ± 1.43**


X12
10
4.0
0.74 ± 0.18**
0.74 ± 0.19**
 8.84 ± 1.41**


X13
10
4.0
0.79 ± 0.12**
0.75 ± 0.15**
 8.94 ± 1.26**


X14
10
4.0
0.84 ± 0.13**
0.83 ± 0.11**
 8.97 ± 1.36**


X15
10
4.0
0.83 ± 0.13**
0.71 ± 0.11**
 8.84 ± 1.42**


X16
10
4.0
0.70 ± 0.13**
0.68 ± 0.18**
 8.32 ± 1.27**


X17
10
4.0
0.78 ± 0.17**
0.79 ± 0.12**
 9.13 ± 1.31**


X18
10
4.0
0.79 ± 0.12**
0.72 ± 0.11**
 8.91 ± 1.29**


X19
10
4.0
0.82 ± 0.14**
0.84 ± 0.18**
 8.72 ± 1.41**


X20
10
4.0
0.74 ± 0.14**
0.82 ± 0.17**
 9.07 ± 1.33**


X21
10
4.0
0.83 ± 0.16**
0.81 ± 0.14**
 8.79 ± 1.43**


X22
10
4.0
0.83 ± 0.13**
0.75 ± 0.14**
 8.67 ± 1.32**


X23
10
4.0
0.77 ± 0.15**
0.77 ± 0.17**
 9.15 ± 1.47**


X24
10
4.0
0.71 ± 0.12**
0.82 ± 0.11**
 8.94 ± 1.41**


X25
10
4.0
0.74 ± 0.14**
0.71 ± 0.18**
 9.21 ± 1.33**


X26
10
4.0
0.84 ± 0.12**
0.71 ± 0.14**
 9.07 ± 1.32**


X27
10
4.0
0.75 ± 0.13**
0.78 ± 0.19**
 8.75 ± 1.43**


X28
10
4.0
0.73 ± 0.18**
0.72 ± 0.18**
 8.83 ± 1.26**


X29
10
4.0
0.71 ± 0.13**
0.81 ± 0.15**
 8.98 ± 1.44**


X30
10
4.0
0.79 ± 0.16**
0.83 ± 0.16**
 8.73 ± 1.29**


X31
10
4.0
0.77 ± 0.15**
0.78 ± 0.15**
 8.75 ± 1.38**


X32
10
4.0
0.81 ± 0.13**
0.81 ± 0.16**
 9.06 ± 1.26**


X33
10
4.0
0.74 ± 0.17**
0.82 ± 0.11**
 9.08 ± 1.25**


X34
10
4.0
0.72 ± 0.15**
0.84 ± 0.13**
  8.8 ± 1.34**


X35
10
4.0
0.85 ± 0.14**
0.76 ± 0.13**
 8.78 ± 1.23**


X36
10
4.0
0.77 ± 0.13**
0.74 ± 0.14**
 8.86 ± 1.23**


X37
10
4.0
0.83 ± 0.16**
 0.8 ± 0.12**
 9.16 ± 1.31**


X38
10
4.0
0.76 ± 0.13**
0.71 ± 0.11**
 9.18 ± 1.33**


X39
10
4.0
0.74 ± 0.19**
0.81 ± 0.13**
 8.93 ± 1.34**


X40
10
4.0
0.84 ± 0.12**
0.83 ± 0.13**
 8.92 ± 1.45**


X41
10
4.0
0.72 ± 0.12**
0.79 ± 0.12**
 9.11 ± 1.41**


X42
10
4.0
0.79 ± 0.17**
0.76 ± 0.18**
 8.79 ± 1.32**


X43
10
4.0
0.73 ± 0.18**
0.71 ± 0.16**
 8.83 ± 1.33**


X44
10
4.0
0.81 ± 0.16**
0.73 ± 0.11**
 8.78 ± 1.24**


X45
10
4.0
0.77 ± 0.17**
0.75 ± 0.11**
 9.14 ± 1.43**


X46
10
4.0
0.83 ± 0.11**
0.77 ± 0.13**
 9.11 ± 1.47**


X47
10
4.0
0.75 ± 0.18**
0.77 ± 0.13**
 8.94 ± 1.45**


X48
10
4.0
0.82 ± 0.13**
0.74 ± 0.19**
 8.97 ± 1.23**


X49
10
4.0
0.81 ± 0.19**
0.84 ± 0.14**
 9.08 ± 1.34**


X50
10
4.0
0.83 ± 0.12**
0.74 ± 0.18**
 9.19 ± 1.42**


X51
10
4.0
0.83 ± 0.16**
0.81 ± 0.19**
 9.15 ± 1.31**


X52
10
4.0
0.71 ± 0.16**
0.79 ± 0.18**
 9.07 ± 1.13**


X53
10
4.0
0.79 ± 0.13**
0.78 ± 0.15**
 8.73 ± 1.14**


X54
10
4.0
0.77 ± 0.18**
0.73 ± 0.18**
 9.09 ± 1.32**


X55
10
4.0
0.72 ± 0.18**
0.84 ± 0.11**
 8.93 ± 1.33**


X56
10
4.0
0.81 ± 0.18**
0.73 ± 0.17**
 8.70 ± 1.33**


X57
10
4.0
0.72 ± 0.13**
0.81 ± 0.12**
 8.87 ± 1.41**


X58
10
4.0
0.71 ± 0.15**
0.83 ± 0.12**
 8.77 ± 1.44**


X59
10
4.0
0.72 ± 0.15**
0.85 ± 0.13**
 8.99 ± 1.43**


X60
10
4.0
0.72 ± 0.16**
0.85 ± 0.17**
 9.01 ± 1.26**


X61
10
4.0
0.85 ± 0.13**
0.72 ± 0.12**
 8.82 ± 1.39**


X62
10
4.0
0.82 ± 0.12**
0.78 ± 0.15**
 8.76 ± 1.25**


X63
10
4.0
0.72 ± 0.14**
0.72 ± 0.15**
 8.85 ± 1.28**


X64
10
4.0
0.81 ± 0.12**
0.84 ± 0.17**
 8.72 ± 1.39**


X65
10
4.0
0.72 ± 0.17**
0.8 2 ± 0.12**
 8.66 ± 1.32**


X66
10
4.0
0.71 ± 0.13**
0.84 ± 0.13**
 8.96 ± 1.26**


X67
10
4.0
0.79 ± 0.10**
0.71 ± 0.13**
 9.05 ± 1.26**


X68
10
4.0
0.84 ± 0.11**
0.81 ± 0.14**
 8.75 ± 1.29**


X69
10
4.0
0.73 ± 0.15**
0.78 ± 0.14**
 8.78 ± 1.24**


X70
10
4.0
0.78 ± 0.18**
0.73 ± 0.12**
 8.96 ± 1.43**


X71
10
4.0
0.82 ± 0.14**
0.77 ± 0.15**
 8.78 ± 1.46**


X72
10
4.0
0.82 ± 0.13**
0.74 ± 0.16**
 9.03 ± 1.33**


X73
10
4.0
0.74 ± 0.12**
0.72 ± 0.17**
 8.66 ± 1.38**


X74
10
4.0
0.79 ± 0.17**
 0.7 ± 0.17**
 8.92 ± 1.46**


X75
10
4.0
0.85 ± 0.13**
0.77 ± 0.14**
 8.99 ± 1.38**


X76
10
4.0
0.75 ± 0.14**
0.85 ± 0.14**
 9.07 ± 1.31**


X77
10
4.0
 0.8 ± 0.18**
0.74 ± 0.12**
 8.98 ± 1.44**


X78
10
4.0
0.77 ± 0.12**
0.73 ± 0.19**
 8.71 ± 1.35**


X79
10
4.0
0.84 ± 0.18**
0.78 ± 0.14**
 9.03 ± 1.31**


X80
10
4.0
0.75 ± 0.12**
0.79 ± 0.18**
 8.88 ± 1.35**


X81
10
4.0
0.75 ± 0.11**
0.78 ± 0.14**
 8.82 ± 1.39**


X82
10
4.0
0.74 ± 0.14**
0.75 ± 0.14**
 8.89 ± 1.22**


X83
10
4.0
0.81 ± 0.15**
0.83 ± 0.13**
 8.65 ± 1.43**


X84
10
4.0
0.78 ± 0.17**
0.79 ± 0.14**
 8.65 ± 1.38**


X85
10
4.0
0.79 ± 0.12**
0.73 ± 0.11**
 9.13 ± 1.36**


X86
10
4.0
0.78 ± 0.17**
0.72 ± 0.12**
 8.71 ± 1.26**


X87
10
4.0
0.81 ± 0.16**
0.77 ± 0.15**
 9.12 ± 1.33**


X88
10
4.0
0.79 ± 0.14**
0.72 ± 0.11**
 8.81 ± 1.42**


X89
10
4.0
0.85 ± 0.13**
0.76 ± 0.17**
 8.68 ± 1.41**


X90
10
4.0
0.81 ± 0.11**
0.73 ± 0.19**
 8.72 ± 1.26**









Results: Compared with normal mice, mice after modeling were intracutaneously injected in the tail with an emulsifier containing inactivated mycobacterium tuberculosis CFA and collagen in the same volume. After 21 days, mice were intracutaneously injected in the tail with an emulsifier containing IFA and collagen in the same volume. On day 27 after immunization, CIA mice's paw became red and swollen, and the arthritis index score increased. The swelling peak occurred on day 45 to 60 in the model group. The body weight of the model group hardly increased from day 35 and slightly decreased in the later period. Polypeptide X1-X90 could play an in vivo immunoprotective role in mouse CIA animal models. Compared with the model group, the positive control group and X1-X90 groups had extremely significant differences (p**<0.01). The limb score of the polypeptide X16 group was significantly lower than that of the model control group, and had the most significant protective effect.


Example 14

In Vivo Immunoprotective Effect of X1-X90 on a Rat Adjuvant Arthritis (AA) Animal Model


A rat AA animal model was established to study the therapeutic effects of X1-X90 on rats infected with AA. Rats were used as test animals. SPF SD mice, male, were used. They each weighed 140-160 g and were randomly divided into a normal control group, a model control group, X1-X90 groups and a positive drug control group (methotrexate at 1 mg/kg). Except the normal group, the rat AA model was established for each test group on day 0. The method was to inject 0.08 mL of CFA containing inactivated Mycobacterium tuberculosis (H37RA, 10 mg/mL) into the hind feet of the left sides of the rats to create the rat AA model. The drug was injected intravenously in the tail from day 10 of modeling: X1-X90: once every five days; the positive drug control group (methotrexate at 1 mg/kg): once every five days, 3 times consecutively; and the normal control group and the model control group (normal saline): continuous for ten days. On days 8, 11, 14, 17, 20, 23 and 26 after modeling, joint scores were made and the ankle diameters of left and right hind feet were measured respectively to observe the effect of drugs on rat AA.


Arthritis evaluation indexes are as follows: (1) Joint score: limbs: score on a scale of 0-4: 0=no erythema or swelling; 1=slight erythema or swelling, one of the foretoe/hind toe joints has erythema or swelling; 2=erythema or swelling of more than one toe; 3=paw swelling under ankle or wrist joints; and 4=swelling of all paws including ankle joints. The four paws of the rats were scored respectively, with the highest score being 16 points. Joint scores were made on days 8, 11, 14th, 17, 20, 23 and 26 after modeling, and results were recorded. (2) Measurement of ankle diameter: The diameters from medial to lateral of left and right ankles and ankle thicknesses of rats were measured with vernier calipers before modeling and on days 8, 11, 14, 17, 20, 23 and 26 after modeling, and the results were recorded. The experiment was repeated independently three times. The results were expressed as mean±SD, and statistical T test was conducted. In the table, *P<0.05 indicates significant difference, and **P<0.01 indicates extremely significant difference.









TABLE 19







In vivo immunoprotective effect of X1-X90 on a rat AA animal model















Left and







right paw
Joint






swelling
swelling





Dose
degree
degree



Group
Number
(mg/kg)
(mm)
(mm)
Clinical score





Normal control group
10

0.93 ± 0.14
0.30 ± 0.15
 0.00 ± 0.00


Model control group
10

6.98 ± 1.27
3.74 ± 0.72
13.86 ± 1.65


Positive control group
10
1
3.29 ± 0.39**
0.64 ± 0.21**
 5.06 ± 1.07**


X1
10
4.0
3.94 ± 0.95**
0.71 ± 0.14**
 5.87 ± 1.04**


X2
10
4.0
3.78 ± 0.55**
0.72 ± 0.12**
 5.57 ± 1.08**


X3
10
4.0
3.86 ± 0.21**
0.83 ± 0.15**
 5.69 ± 1.07**


X4
10
4.0
3.91 ± 0.35**
0.78 ± 0.19**
 5.76 ± 1.1**


X5
10
4.0
3.90 ± 0.26**
0.74 ± 0.12**
 5.73 ± 1.1**


X6
10
4.0
3.79 ± 0.94**
0.77 ± 0.13**
 5.76 ± 1.13**


X7
10
4.0
3.82 ± 0.22**
0.82 ± 0.18**
 5.55 ± 1.11**


X8
10
4.0
3.92 ± 0.79**
0.75 ± 0.18**
 5.55 ± 1.06**


X9
10
4.0
3.95 ± 0.55**
0.82 ± 0.15**
 5.57 ± 1.16**


X10
10
4.0
3.74 ± 0.76**
0.82 ± 0.11**
 5.61 ± 1.07**


X11
10
4.0
3.88 ± 0.34**
0.81 ± 0.14**
 5.54 ± 1.06**


X12
10
4.0
3.87 ± 0.89**
0.72 ± 0.17**
 5.85 ± 1.04**


X13
10
4.0
3.91 ± 0.44**
0.78 ± 0.16**
 5.78 ± 1.15**


X14
10
4.0
3.94 ± 0.22**
0.84 ± 0.15**
 5.60 ± 1.15**


X15
10
4.0
3.76 ± 0.92**
0.84 ± 0.14**
 5.61 ± 1.16**


X16
10
4.0
3.75 ± 0.77**
0.77 ± 0.11**
 5.8 ± 1.09**


X17
10
4.0
3.84 ± 0.88**
0.78 ± 0.15**
 5.82 ± 1.05**


X18
10
4.0
3.81 ± 0.85**
0.83 ± 0.15**
 5.67 ± 1.04**


X19
10
4.0
3.74 ± 0.4**
0.81 ± 0.16**
 5.63 ± 1.04**


X20
10
4.0
3.87 ± 0.95**
 0.8 ± 0.17**
 5.74 ± 1.11**


X21
10
4.0
3.98 ± 0.17**
0.82 ± 0.18**
 5.61 ± 1.14**


X22
10
4.0
3.92 ± 0.18**
0.83 ± 0.14**
 5.67 ± 1.12**


X23
10
4.0
3.85 ± 0.29**
0.73 ± 0.15**
 5.79 ± 1.06**


X24
10
4.0
3.94 ± 0.70**
0.76 ± 0.15**
 5.73 ± 1.15**


X25
10
4.0
3.76 ± 0.09**
0.71 ± 0.16**
 5.72 ± 1.11**


X26
10
4.0
3.81 ± 0.59**
0.74 ± 0.18**
 5.65 ± 1.07**


X27
10
4.0
3.86 ± 0.85**
0.74 ± 0.17**
 5.63 ± 1.12**


X28
10
4.0
3.98 ± 0.12**
0.75 ± 0.16**
 5.79 ± 1.15**


X29
10
4.0
3.72 ± 0.80**
0.84 ± 0.16**
 5.72 ± 1.06**


X30
10
4.0
3.76 ± 0.64**
0.82 ± 0.12**
 5.73 ± 1.05**


X31
10
4.0
3.72 ± 0.98**
0.84 ± 0.12**
 5.74 ± 1.12**


X32
10
4.0
3.91 ± 0.64**
0.81 ± 0.18**
 5.81 ± 1.14**


X33
10
4.0
3.93 ± 0.08**
0.76 ± 0.15**
 5.62 ± 1.08**


X34
10
4.0
3.84 ± 0.88**
0.83 ± 0.17**
 5.66 ± 1.09**


X35
10
4.0
3.78 ± 0.56**
0.85 ± 0.13**
 5.83 ± 1.07**


X36
10
4.0
4.00 ± 0.44**
0.81 ± 0.12**
 5.71 ± 1.09**


X37
10
4.0
3.92 ± 0.36**
0.73 ± 0.16**
 5.75 ± 1.14**


X38
10
4.0
3.95 ± 0.09**
0.82 ± 0.14**
 5.87 ± 1.13**


X39
10
4.0
3.78 ± 0.22**
0.83 ± 0.17**
 5.82 ± 1.05**


X40
10
4.0
3.71 ± 0.15**
0.75 ± 0.17**
 5.54 ± 1.16**


X41
10
4.0
3.87 ± 0.86**
0.85 ± 0.15**
 5.57 ± 1.12**


X42
10
4.0
3.86 ± 0.56**
0.85 ± 0.17**
 5.84 ± 1.16**


X43
10
4.0
3.87 ± 0.26**
0.81 ± 0.19**
 5.61 ± 1.03**


X44
10
4.0
3.82 ± 0.37**
0.72 ± 0.15**
 5.78 ± 1.09**


X45
10
4.0
3.90 ± 0.75**
0.83 ± 0.12**
 5.85 ± 1.06**


X46
10
4.0
3.78 ± 0.46**
0.83 ± 0.17**
 5.81 ± 1.05**


X47
10
4.0
3.86 ± 0.07**
0.85 ± 0.17**
 5.82 ± 1.05**


X48
10
4.0
3.85 ± 0.98**
0.72 ± 0.18**
 5.72 ± 1.03**


X49
10
4.0
3.82 ± 0.45**
0.83 ± 0.16**
 5.58 ± 1.12**


X50
10
4.0
3.75 ± 0.47**
0.73 ± 0.11**
 5.72 ± 1.15**


X51
10
4.0
3.96 ± 0.31**
0.71 ± 0.17**
 5.73 ± 1.06**


X52
10
4.0
3.98 ± 0.10**
0.75 ± 0.16**
 5.64 ± 1.12**


X53
10
4.0
3.92 ± 0.62**
0.78 ± 0.13**
 5.58 ± 1.09**


X54
10
4.0
3.85 ± 0.28**
0.83 ± 0.15**
 5.66 ± 1.04**


X55
10
4.0
3.89 ± 0.38**
0.82 ± 0.14**
 5.73 ± 1.15**


X56
10
4.0
3.72 ± 0.63**
0.76 ± 0.18**
 5.54 ± 1.05**


X57
10
4.0
3.79 ± 0.39**
0.77 ± 0.11**
 5.85 ± 1.09**


X58
10
4.0
3.79 ± 0.48**
0.77 ± 0.17**
 5.62 ± 1.15**


X59
10
4.0
3.93 ± 0.6**
0.74 ± 0.16**
 5.86 ± 1.06**


X60
10
4.0
3.75 ± 0.33**
0.79 ± 0.15**
 5.58 ± 1.09**


X61
10
4.0
3.87 ± 0.49**
0.78 ± 0.12**
 5.76 ± 1.13**


X62
10
4.0
3.70 ± 0.23**
0.82 ± 0.12**
 5.61 ± 1.12**


X63
10
4.0
3.74 ± 0.58**
0.75 ± 0.13**
 5.82 ± 1.07**


X64
10
4.0
3.76 ± 0.45**
0.84 ± 0.15**
 5.89 ± 1.12**


X65
10
4.0
3.99 ± 0.06**
0.82 ± 0.18**
 5.68 ± 1.09**


X66
10
4.0
3.86 ± 0.49**
0.81 ± 0.11**
 5.73 ± 1.04**


X67
10
4.0
3.84 ± 0.34**
0.72 ± 0.12**
 5.75 ± 1.08**


X68
10
4.0
3.88 ± 0.32**
0.79 ± 0.16**
 5.82 ± 1.11**


X69
10
4.0
3.70 ± 0.12**
0.75 ± 0.13**
 5.83 ± 1.05**


X70
10
4.0
3.81 ± 0.14**
0.73 ± 0.15**
 5.74 ± 1.06**


X71
10
4.0
3.95 ± 0.57**
0.85 ± 0.11**
 5.55 ± 1.04**


X72
10
4.0
3.83 ± 0.92**
0.84 ± 0.18**
 5.63 ± 1.08**


X73
10
4.0
3.72 ± 0.79**
0.84 ± 0.17**
 5.78 ± 1.05**


X74
10
4.0
 3.9 ± 0.09**
0.82 ± 0.17**
 5.86 ± 1.04**


X75
10
4.0
3.94 ± 0.91**
0.79 ± 0.11**
 5.73 ± 1.11**


X76
10
4.0
3.67 ± 0.36**
0.70 ± 0.16**
 5.51 ± 1.13**


X77
10
4.0
3.71 ± 0.7**
0.78 ± 0.12**
 5.57 ± 1.1**


X78
10
4.0
3.73 ± 0.42**
0.83 ± 0.16**
 5.77 ± 1.05**


X79
10
4.0
3.71 ± 0.83**
0.85 ± 0.16**
 5.74 ± 1.03**


X80
10
4.0
3.95 ± 0.19**
0.72 ± 0.18**
 5.56 ± 1.12**


X81
10
4.0
3.82 ± 0.66**
0.71 ± 0.14**
 5.55 ± 1.09**


X82
10
4.0
3.93 ± 0.16**
0.81 ± 0.19**
 5.75 ± 1.11**


X83
10
4.0
3.81 ± 0.79**
0.74 ± 0.18**
 5.67 ± 1.06**


X84
10
4.0
3.84 ± 0.27**
0.72 ± 0.15**
 5.83 ± 1.15**


X85
10
4.0
3.76 ± 0.43**
0.73 ± 0.13**
 5.85 ± 1.03**


X86
10
4.0
3.91 ± 0.69**
0.77 ± 0.13**
 5.79 ± 1.12**


X87
10
4.0
3.99 ± 0.21**
0.77 ± 0.11**
 5.82 ± 1.06**


X88
10
4.0
3.88 ± 0.55**
0.77 ± 0.11**
 5.81 ± 1.09**


X89
10
4.0
3.76 ± 0.15**
0.82 ± 0.18**
 5.84 ± 1.14**


X90
10
4.0
3.95 ± 0.78**
0.73 ± 0.18**
 5.61 ± 1.07**









Results: Compared with normal rats, the rats after modeling were injected in the left hind feet with inactivated mycobacterium tuberculosis CFA, and then the left hind feet were rapidly subjected to primary arthritis with obvious swelling and ulceration. Secondary arthritis began to appear in the right hind feet about 10 days later, and the scores gradually increased. At the same time, the ear vascular proliferation was obvious, and swelling was obvious; and swelling appeared in the tail joint. Compared with the model group, X1-X90 groups with different molecular weights could exert in vivo immunoprotective effect on rat AA animal models, and X76 had the most significant effect.


Example 15

Effect of X1-X90 on Acute Inflammation of Carrageenan-Induced Toe Swelling in Rats


SD rats were taken and divided into a blank model group, a Dex positive group (5 mg/kg) and X1-X90 test groups. The rats were injected once a day, and the model group was given the same volume of normal saline for 3 d and fed normally. One hour after the last administration, 0.1 mL of 1% carrageenan was injected subcutaneously into the right hind soles of rats to induce inflammation, and the foot volume was measured at 1 h, 3 h, 5 h and 7 h after inflammation. The foot swelling degree was calculated according to the following formula: foot swelling degree (mL)=foot volume after inflammation-foot volume before inflammation. The number of milliliters of overflow liquid was recorded (method: a ballpoint pen is used to circle the protruding point of the right joint as a measurement mark, and the right hind feet of each rat are sequentially placed into the volume measurer, so that the hind limbs are exposed outside the barrel, and the immersion depth is at the coincidence of the circle and the liquid level. After the foot enters the liquid, the liquid level rises, and the volume of overflow liquid is the volume of the right hind foot of the rat, and the normal volume of the right hind foot of each rat is measured in sequence).









TABLE 20







Effect of X1-X90 on acute inflammation of carrageenan-induced toe swelling in rats










Dose
Swelling degree (mg)












Group
(mg/kg)
1 h
3 h
5 h
7 h





X1
 2.0
0.31 ± 0.16*
0.39 ± 0.15
0.42 ± 0.13*
0.35 ± 0.18*



 4.0
0.25 ± 0.14*
0.33 ± 0.17
0.41 ± 0.13*
0.33 ± 0.18*


X2
 2.0
0.28 ± 0.12*
0.38 ± 0.17
0.43 ± 0.13*
0.36 ± 0.11*



 4.0
0.27 ± 0.13*
0.36 ± 0.15
0.39 ± 0.12*
0.35 ± 0.11*


X3
 2.0
0.30 ± 0.19*
0.38 ± 0.16
0.45 ± 0.17*
0.38 ± 0.13*



 4.0
0.31 ± 0.11*
0.35 ± 0.12
0.43 ± 0.18*
0.36 ± 0.17*


X4
 2.0
0.28 ± 0.11*
0.38 ± 0.16
0.41 ± 0.17*
0.33 ± 0.12*



 4.0
0.27 ± 0.17*
0.37 ± 0.13
0.40 ± 0.14*
0.31 ± 0.11*


X5
 2.0
0.29 ± 0.16*
0.34 ± 0.11
0.41 ± 0.14*
0.32 ± 0.12*



 4.0
0.23 ± 0.18*
0.30 ± 0.19
0.34 ± 0.17*
0.30 ± 0.16*


X6
 2.0
0.29 ± 0.13*
0.33 ± 0.15
0.35 ± 0.19*
0.34 ± 0.11*



 4.0
0.28 ± 0.12*
0.31 ± 0.16
0.34 ± 0.11*
0.32 ± 0.13*


X7
 2.0
0.28 ± 0.16*
0.37 ± 0.14
0.37 ± 0.18*
0.37 ± 0.13*



 4.0
0.27 ± 0.13*
0.33 ± 0.16
0.35 ± 0.18*
0.36 ± 0.11*


X8
 2.0
0.29 ± 0.14*
0.38 ± 0.12
0.43 ± 0.17*
0.35 ± 0.16*



 4.0
0.26 ± 0.11*
0.36 ± 0.14
0.41 ± 0.17*
0.34 ± 0.16*


X9
 2.0
0.30 ± 0.14*
0.33 ± 0.16
0.42 ± 0.15*
0.39 ± 0.13*



 4.0
0.29 ± 0.14*
0.32 ± 0.16
0.38 ± 0.13*
0.34 ± 0.19*


X10
 2.0
0.28 ± 0.11*
0.37 ± 0.17
0.39 ± 0.18*
0.36 ± 0.14*



 4.0
0.25 ± 0.18*
0.36 ± 0.12
0.37 ± 0.13*
0.33 ± 0.16*


X11
 2.0
0.23 ± 0.13*
0.33 ± 0.15
0.39 ± 0.12*
0.35 ± 0.11*



 4.0
0.22 ± 0.16*
0.32 ± 0.14
0.38 ± 0.18*
0.34 ± 0.11*


X12
 2.0
0.25 ± 0.13*
0.32 ± 0.12
0.38 ± 0.16*
0.34 ± 0.19*



 4.0
0.22 ± 0.12*
0.30 ± 0.12
0.37 ± 0.17*
0.33 ± 0.19*


X13
 2.0
0.27 ± 0.15*
0.36 ± 0.12
0.42 ± 0.18*
0.33 ± 0.14*



 4.0
0.25 ± 0.12*
0.35 ± 0.14
0.41 ± 0.18*
0.32 ± 0.15*


X14
 2.0
0.26 ± 0.14*
0.35 ± 0.15
0.41 ± 0.19*
0.35 ± 0.11*



 4.0
0.25 ± 0.12*
0.33 ± 0.1
0.37 ± 0.14*
0.34 ± 0.11*


X15
 2.0
0.32 ± 0.15*
0.37 ± 0.18
0.41 ± 0.12*
0.33 ± 0.14*



 4.0
0.26 ± 0.12*
0.31 ± 0.18
0.36 ± 0.19*
0.32 ± 0.15*


X16
 2.0
0.29 ± 0.17*
0.34 ± 0.16
0.42 ± 0.12*
0.33 ± 0.15*



 4.0
0.28 ± 0.11*
0.32 ± 0.16
0.41 ± 0.13*
0.32 ± 0.17*


X17
 2.0
0.27 ± 0.15*
0.32 ± 0.14
0.38 ± 0.17*
0.35 ± 0.19*



 4.0
0.24 ± 0.12*
0.31 ± 0.19
0.37 ± 0.17*
0.34 ± 0.15*


X18
 2.0
0.23 ± 0.18*
0.33 ± 0.16
0.36 ± 0.15*
0.32 ± 0.13*



 4.0
0.24 ± 0.17*
0.39 ± 0.18
0.45 ± 0.15*
0.33 ± 0.12*


X19
 2.0
0.21 ± 0.13*
0.33 ± 0.15
0.36 ± 0.17*
0.32 ± 0.12*



 4.0
0.26 ± 0.11*
0.38 ± 0.17
0.42 ± 0.15*
0.32 ± 0.18*


X20
 2.0
0.25 ± 0.18*
0.34 ± 0.13
0.36 ± 0.13*
0.37 ± 0.12*



 4.0
0.24 ± 0.15*
0.34 ± 0.12
0.35 ± 0.16*
0.35 ± 0.12*


X21
 2.0
0.23 ± 0.19*
0.32 ± 0.17
0.39 ± 0.16*
0.33 ± 0.12*



 4.0
0.25 ± 0.17*
0.33 ± 0.13
0.39 ± 0.14*
0.35 ± 0.18*


X22
 2.0
0.24 ± 0.13*
0.31 ± 0.15
0.42 ± 0.14*
0.38 ± 0.18*



 4.0
0.23 ± 0.11*
0.31 ± 0.16
0.36 ± 0.13*
0.37 ± 0.13*


X23
 2.0
0.28 ± 0.17*
0.34 ± 0.19
0.37 ± 0.11*
0.35 ± 0.18*



 4.0
0.26 ± 0.16*
0.34 ± 0.19
0.38 ± 0.13*
0.34 ± 0.17*


X24
 2.0
0.24 ± 0.16*
0.34 ± 0.18
0.43 ± 0.12*
0.38 ± 0.13*



 4.0
0.23 ± 0.17*
0.35 ± 0.13
0.38 ± 0.16*
0.32 ± 0.12*


X25
 2.0
0.29 ± 0.17*
0.38 ± 0.12
0.46 ± 0.18*
0.34 ± 0.13*



 4.0
0.27 ± 0.15*
0.36 ± 0.19
0.44 ± 0.18*
0.33 ± 0.12*


X26
 2.0
0.28 ± 0.17*
0.31 ± 0.18
0.42 ± 0.11*
0.39 ± 0.12*



 4.0
0.25 ± 0.18*
0.31 ± 0.13
0.40 ± 0.15*
0.30 ± 0.16*


X27
 2.0
0.27 ± 0.13*
0.33 ± 0.14
0.39 ± 0.17*
0.36 ± 0.16*



 4.0
0.24 ± 0.12*
0.33 ± 0.16
0.32 ± 0.17*
0.34 ± 0.14*


X28
 2.0
0.29 ± 0.13*
0.35 ± 0.15
0.45 ± 0.17*
0.36 ± 0.14*



 4.0
0.28 ± 0.15*
0.34 ± 0.11
0.37 ± 0.17*
0.35 ± 0.18*


X29
 2.0
0.27 ± 0.16*
0.35 ± 0.18
0.36 ± 0.19*
0.33 ± 0.17*



 4.0
0.22 ± 0.12*
0.34 ± 0.15
0.35 ± 0.13*
0.32 ± 0.17*


X30
 2.0
0.26 ± 0.15*
0.36 ± 0.18
0.40 ± 0.16*
0.35 ± 0.11*



 4.0
0.25 ± 0.19*
0.33 ± 0.13
0.39 ± 0.18*
0.34 ± 0.15*


X31
 2.0
0.23 ± 0.18*
0.37 ± 0.12
0.38 ± 0.16*
0.33 ± 0.11*



 4.0
0.22 ± 0.12*
0.36 ± 0.16
0.38 ± 0.15*
0.35 ± 0.14*


X32
 2.0
0.25 ± 0.18*
0.35 ± 0.13
0.36 ± 0.12*
0.31 ± 0.17*



 4.0
0.24 ± 0.14*
0.33 ± 0.17
0.41 ± 0.15*
0.35 ± 0.12*


X33
 2.0
0.22 ± 0.13*
0.37 ± 0.11
0.42 ± 0.17*
0.35 ± 0.13*



 4.0
0.25 ± 0.14*
0.31 ± 0.13
0.44 ± 0.19*
0.33 ± 0.18*


X34
 2.0
0.26 ± 0.18*
0.38 ± 0.13
0.39 ± 0.11*
0.35 ± 0.14*



 4.0
0.22 ± 0.18*
0.38 ± 0.15
0.36 ± 0.16*
0.34 ± 0.13*


X35
 2.0
0.25 ± 0.11*
0.38 ± 0.16
0.38 ± 0.19*
0.33 ± 0.15*



 4.0
0.23 ± 0.11*
0.36 ± 0.16
0.44 ± 0.14*
0.32 ± 0.12*


X36
 2.0
0.29 ± 0.17*
0.34 ± 0.18
0.43 ± 0.13*
0.32 ± 0.15*



 4.0
0.23 ± 0.15*
0.33 ± 0.13
0.35 ± 0.12*
0.32 ± 0.17*


X37
 2.0
0.24 ± 0.17*
0.38 ± 0.12
0.41 ± 0.11*
0.33 ± 0.16*



 4.0
0.21 ± 0.13*
0.33 ± 0.16
0.37 ± 0.18*
0.32 ± 0.19*


X38
 2.0
0.27 ± 0.17*
0.32 ± 0.14
0.42 ± 0.16*
0.38 ± 0.14*



 4.0
0.26 ± 0.18*
0.31 ± 0.13
0.41 ± 0.16*
0.31 ± 0.17*


X39
 2.0
0.27 ± 0.15*
0.37 ± 0.11
0.46 ± 0.16*
0.34 ± 0.18*



 4.0
0.22 ± 0.18*
0.36 ± 0.11
0.42 ± 0.19*
0.31 ± 0.13*


X40
 2.0
0.27 ± 0.14*
0.37 ± 0.14
0.38 ± 0.12*
0.35 ± 0.13*



 4.0
0.24 ± 0.15*
0.36 ± 0.14
0.37 ± 0.13*
0.34 ± 0.18*


X41
 2.0
0.28 ± 0.17*
0.33 ± 0.12
0.37 ± 0.11*
0.35 ± 0.18*



 4.0
0.26 ± 0.11*
0.31 ± 0.15
0.43 ± 0.14*
0.34 ± 0.15*


X42
 2.0
0.24 ± 0.17*
0.39 ± 0.12
0.41 ± 0.18*
0.36 ± 0.18*



 4.0
0.21 ± 0.19*
0.38 ± 0.14
0.40 ± 0.15*
0.35 ± 0.13*


X43
 2.0
0.29 ± 0.15*
0.38 ± 0.13
0.44 ± 0.17*
0.36 ± 0.12*



 4.0
0.25 ± 0.18*
0.35 ± 0.11
0.42 ± 0.13*
0.33 ± 0.16*


X44
 2.0
0.21 ± 0.12*
0.32 ± 0.14
0.41 ± 0.15*
0.37 ± 0.13*



 4.0
 0.3 ± 0.15*
0.31 ± 0.14
0.40 ± 0.18*
0.36 ± 0.16*


X45
 2.0
0.24 ± 0.13*
0.35 ± 0.17
0.42 ± 0.12*
0.37 ± 0.12*



 4.0
0.21 ± 0.16*
0.34 ± 0.17
0.41 ± 0.11*
0.31 ± 0.14*


X46
 2.0
0.27 ± 0.12*
0.38 ± 0.15
0.45 ± 0.17*
0.35 ± 0.19*



 4.0
0.24 ± 0.18*
0.36 ± 0.13
0.44 ± 0.15*
0.31 ± 0.12*


X47
 2.0
0.27 ± 0.18*
0.34 ± 0.15
0.41 ± 0.12*
0.32 ± 0.14*



 4.0
0.26 ± 0.16*
0.33 ± 0.12
0.39 ± 0.18*
0.31 ± 0.15*


X48
 2.0
0.29 ± 0.12*
0.37 ± 0.16
0.36 ± 0.15*
0.32 ± 0.17*



 4.0
0.29 ± 0.12*
0.32 ± 0.19
0.35 ± 0.16*
0.31 ± 0.16*


X49
 2.0
0.24 ± 0.16*
0.37 ± 0.12
0.43 ± 0.15*
0.36 ± 0.11*



 4.0
0.24 ± 0.13*
0.31 ± 0.12
0.42 ± 0.14*
0.33 ± 0.15*


X50
 2.0
0.28 ± 0.15*
0.34 ± 0.15
0.42 ± 0.16*
0.36 ± 0.14*



 4.0
0.27 ± 0.17*
0.31 ± 0.11
0.36 ± 0.15*
0.34 ± 0.18*


X51
 2.0
0.29 ± 0.17*
0.33 ± 0.11
0.36 ± 0.17*
0.34 ± 0.15*



 4.0
0.23 ± 0.15*
0.31 ± 0.18
0.34 ± 0.18*
0.33 ± 0.18*


X52
 2.0
0.27 ± 0.12*
0.39 ± 0.13
0.43 ± 0.17*
0.37 ± 0.17*



 4.0
0.23 ± 0.17*
0.35 ± 0.11
0.41 ± 0.18*
0.36 ± 0.11*


X53
 2.0
0.32 ± 0.11*
0.36 ± 0.12
0.41 ± 0.19*
0.36 ± 0.13*



 4.0
0.25 ± 0.18*
0.33 ± 0.12
0.38 ± 0.15*
0.34 ± 0.14*


X54
 2.0
0.25 ± 0.11*
0.35 ± 0.15
0.39 ± 0.17*
0.35 ± 0.17*



 4.0
0.24 ± 0.16*
0.34 ± 0.18
0.38 ± 0.13*
0.32 ± 0.17*


X55
 2.0
0.28 ± 0.12*
0.41 ± 0.12
0.44 ± 0.17*
0.36 ± 0.17*



 4.0
0.27 ± 0.19*
0.32 ± 0.14
0.42 ± 0.14*
0.35 ± 0.18*


X56
 2.0
0.24 ± 0.12*
0.34 ± 0.14
0.39 ± 0.11*
0.32 ± 0.14*



 4.0
0.24 ± 0.11*
0.32 ± 0.12
0.35 ± 0.13*
0.24 ± 0.11*


X57
 2.0
0.24 ± 0.16*
0.31 ± 0.16
0.37 ± 0.15*
0.35 ± 0.12*



 4.0
0.27 ± 0.12*
0.33 ± 0.12
0.35 ± 0.12*
0.32 ± 0.12*


X58
 2.0
0.26 ± 0.15*
0.36 ± 0.18
0.42 ± 0.11*
0.35 ± 0.16*



 4.0
0.23 ± 0.12*
0.35 ± 0.12
0.41 ± 0.18*
0.34 ± 0.15*


X59
 2.0
0.26 ± 0.13*
0.35 ± 0.16
0.37 ± 0.14*
0.36 ± 0.19*



 4.0
0.25 ± 0.12*
0.34 ± 0.17
0.36 ± 0.13*
0.32 ± 0.13*


X60
 2.0
0.26 ± 0.11*
0.36 ± 0.12
0.39 ± 0.12*
0.33 ± 0.12*



 4.0
0.25 ± 0.15*
0.35 ± 0.17
0.39 ± 0.11*
0.32 ± 0.17*


X61
 2.0
0.27 ± 0.13*
0.38 ± 0.11
0.39 ± 0.16*
0.37 ± 0.15*



 4.0
0.26 ± 0.16*
0.35 ± 0.11
0.36 ± 0.13*
0.36 ± 0.17*


X62
 2.0
0.21 ± 0.13*
0.32 ± 0.16
0.41 ± 0.11*
0.34 ± 0.12*



 4.0
0.27 ± 0.11*
0.37 ± 0.18
0.37 ± 0.15*
0.31 ± 0.11*


X63
 2.0
0.27 ± 0.16*
0.38 ± 0.13
0.41 ± 0.18*
0.33 ± 0.16*



 4.0
0.26 ± 0.17*
0.32 ± 0.17
0.40 ± 0.19*
0.31 ± 0.16*


X64
 2.0
0.25 ± 0.17*
0.35 ± 0.11
0.43 ± 0.13*
0.36 ± 0.14*



 4.0
0.25 ± 0.13*
0.34 ± 0.12
0.38 ± 0.16*
0.31 ± 0.11*


X65
 2.0
0.27 ± 0.15*
0.38 ± 0.16
0.43 ± 0.13*
0.36 ± 0.11*



 4.0
0.25 ± 0.11*
0.35 ± 0.11
0.42 ± 0.14*
0.33 ± 0.15*


X66
 2.0
0.29 ± 0.13*
0.37 ± 0.18
0.38 ± 0.13*
0.32 ± 0.18*



 4.0
0.22 ± 0.11*
0.34 ± 0.14
0.38 ± 0.19*
0.32 ± 0.14*


X67
 2.0
0.23 ± 0.13*
0.34 ± 0.19
0.42 ± 0.17*
0.38 ± 0.16*



 4.0
0.23 ± 0.18*
0.31 ± 0.18
0.38 ± 0.15*
0.33 ± 0.15*


X68
 2.0
0.24 ± 0.15*
0.37 ± 0.13
0.44 ± 0.12*
0.31 ± 0.12*



 4.0
0.23 ± 0.18*
0.33 ± 0.14
0.38 ± 0.18*
0.35 ± 0.18*


X69
 2.0
0.28 ± 0.11*
0.35 ± 0.15
0.41 ± 0.18*
0.37 ± 0.14*



 4.0
0.25 ± 0.12*
0.34 ± 0.13
0.40 ± 0.14*
0.36 ± 0.12*


X70
 2.0
0.21 ± 0.18*
0.31 ± 0.15
0.41 ± 0.12*
0.34 ± 0.15*



 4.0
0.23 ± 0.13*
0.32 ± 0.16
0.42 ± 0.12*
0.34 ± 0.17*


X71
 2.0
0.25 ± 0.11*
0.31 ± 0.12
0.38 ± 0.14*
0.33 ± 0.11*



 4.0
0.24 ± 0.12*
0.30 ± 0.18
0.34 ± 0.12*
0.32 ± 0.12*


X72
 2.0
0.26 ± 0.15*
0.37 ± 0.18
0.43 ± 0.13*
0.35 ± 0.12*



 4.0
0.25 ± 0.17*
0.35 ± 0.17
0.42 ± 0.16*
0.31 ± 0.12*


X73
 2.0
0.26 ± 0.12*
0.36 ± 0.12
0.43 ± 0.11*
0.34 ± 0.13*



 4.0
0.21 ± 0.14*
0.35 ± 0.12
0.39 ± 0.17*
0.32 ± 0.19*


X74
 2.0
0.28 ± 0.16*
0.32 ± 0.13
0.39 ± 0.18*
0.38 ± 0.14*



 4.0
0.26 ± 0.14*
0.33 ± 0.15
0.38 ± 0.16*
0.34 ± 0.17*


X75
 2.0
0.27 ± 0.12*
0.39 ± 0.12
0.41 ± 0.11*
0.35 ± 0.18*



 4.0
0.26 ± 0.16*
0.35 ± 0.15
0.39 ± 0.19*
0.34 ± 0.18*


X76
 2.0
0.27 ± 0.18*
0.38 ± 0.19
0.42 ± 0.12*
0.32 ± 0.14*



 4.0
0.24 ± 0.18*
0.33 ± 0.18
0.38 ± 0.16*
0.34 ± 0.14*


X77
 2.0
0.25 ± 0.13*
0.37 ± 0.13
0.43 ± 0.12*
0.32 ± 0.17*



 4.0
0.23 ± 0.12*
0.36 ± 0.18
0.39 ± 0.16*
0.35 ± 0.13*


X78
 2.0
0.26 ± 0.11*
0.31 ± 0.11
0.44 ± 0.17*
0.36 ± 0.16*



 4.0
0.27 ± 0.16*
0.38 ± 0.11
0.43 ± 0.19*
0.35 ± 0.13*


X79
 2.0
0.29 ± 0.14*
0.35 ± 0.11
0.38 ± 0.13*
0.39 ± 0.12*



 4.0
0.22 ± 0.16*
0.33 ± 0.19
0.36 ± 0.19*
0.37 ± 0.11*


X80
 2.0
0.22 ± 0.11*
0.31 ± 0.15
0.44 ± 0.17*
0.33 ± 0.19*



 4.0
0.23 ± 0.11*
0.32 ± 0.12
0.41 ± 0.13*
0.35 ± 0.19*


X81
 2.0
0.24 ± 0.18*
0.35 ± 0.13
0.42 ± 0.11*
0.36 ± 0.19*



 4.0
0.22 ± 0.13*
0.34 ± 0.15
0.36 ± 0.16*
0.33 ± 0.13*


X82
 2.0
0.25 ± 0.16*
0.33 ± 0.12
0.38 ± 0.17*
0.34 ± 0.19*



 4.0
0.24 ± 0.14*
0.39 ± 0.13
0.43 ± 0.18*
0.33 ± 0.18*


X83
 2.0
0.26 ± 0.11*
0.34 ± 0.14
0.44 ± 0.18*
0.35 ± 0.15*



 4.0
0.24 ± 0.11*
0.36 ± 0.11
0.44 ± 0.13*
0.35 ± 0.14*


X84
 2.0
0.26 ± 0.12*
0.34 ± 0.16
0.38 ± 0.11*
0.34 ± 0.11*



 4.0
0.23 ± 0.13*
0.33 ± 0.15
0.37 ± 0.11*
0.32 ± 0.14*


X85
 2.0
0.24 ± 0.11*
0.34 ± 0.13
0.41 ± 0.14*
0.39 ± 0.13*



 4.0
0.23 ± 0.11*
0.32 ± 0.13
0.40 ± 0.16*
0.32 ± 0.16*


X86
 2.0
0.29 ± 0.13*
0.31 ± 0.11
0.45 ± 0.17*
0.34 ± 0.13*



 4.0
0.25 ± 0.14*
0.30 ± 0.13
0.41 ± 0.17*
0.31 ± 0.12*


X87
 2.0
0.26 ± 0.16*
0.39 ± 0.16
0.43 ± 0.19*
0.36 ± 0.14*



 4.0
0.25 ± 0.16*
0.31 ± 0.12
0.41 ± 0.13*
0.34 ± 0.19*


X88
 2.0
0.35 ± 0.14*
0.32 ± 0.19
0.42 ± 0.14*
0.35 ± 0.15*



 4.0
0.26 ± 0.18*
0.31 ± 0.11
0.41 ± 0.18*
0.34 ± 0.16*


X89
 2.0
0.23 ± 0.12*
0.36 ± 0.16
0.42 ± 0.18*
0.33 ± 0.17*



 4.0
0.22 ± 0.17*
0.35 ± 0.17
0.38 ± 0.17*
0.32 ± 0.15*


X90
 2.0
0.27 ± 0.11*
0.34 ± 0.17
0.42 ± 0.16*
0.33 ± 0.12*



 4.0
0.26 ± 0.12*
0.33 ± 0.14
0.39 ± 0.16*
0.32 ± 0.16*


Dex
10
0.22 ± 0.10**
0.24 ± 0.11**
0.29 ± 0.11**
0.23 ± 0.08*


control

0.26 ± 0.18
0.45 ± 0.19
0.56 ± 0.05
0.39 ± 0.20









Results: the hind toes of rats in each group swelled rapidly after modeling, reaching the peak of swelling at about 3-5 h, and the swelling began to fade at 7 h. Polypeptide X1-X90 groups could have obvious inhibitory effects on carrageenan-induced toe swelling in rats, and the effect of a high-dose group had a better effect than a low-dose group, among which X5 had the most significant effect when the dose was 2.0 mg/kg.


Example 16

Proliferation Inhibition Effect of Polypeptides X1-X90 on Human Retinal Capillary Endothelial Cells (HRCECs)


An MTT method was used to detect the inhibitory activity of the angiogenesis inhibitor polypeptide on proliferation of HRCECs. HRCECs were digested and collected with trypsin after being cultured in an incubator at 37° C. with 5% CO2 to a density of 90% or more. The cells were resuspended with a culture solution and counted under a microscope, the cell concentration was adjusted to 3.0×104 cells/mL, and the cell suspension was inoculated into a 96-well plate at 100 μL/well, and cultured overnight in an incubator at 37° C. with 5% CO2. After the cells were completely adhered to the wall, cells with the addition of the angiogenesis inhibitor polypeptide were used as administration groups, cells with the addition of Avastin were used as a positive control group, and cells with the addition of culture solution without any drugs were used as a blank control group. The cells were diluted to respective predetermined concentrations with the culture solution. The diluent were added into 96-well plates respectively at 100 μL per well, and the cells were cultured at 37° C. for 48 h in an incubator with 5% CO2. 20 μL of 5 mg/mL MTT was added into each well of the 96-well plate, and the cultivation was continued for 4 h. The culture medium was removed, and 100 μL of DMSO was added to each well for dissolution. The absorbance was measured at a detection wavelength of 570 nm and a reference wavelength of 630 nm using a microplate reader, and the PIR was calculated by the formula as follows:





PIR (%)=1−administration group/negative group


The experiment was repeated independently three times. The results were expressed as mean±SD, and statistical T test was conducted. *P<0.05 indicates significant difference, and **P<0.01 indicates extremely significant difference. The experimental results are shown in Table 21.









TABLE 21







Proliferation inhibition effect of polypeptides


X1-X90 on HRCECs











Dose

Inhibition rate


Group
(μM)
A570 nm-A630 nm
(%)





X1
0.05
0.6900 ± 0.09402
47.79%*



0.1
0.5959 ± 0.0814
54.91%**



0.2
0.5154 ± 0.00343
61.00%*


X2
0.05
0.6952 ± 0.04815
47.40%*



0.1
0.6597 ± 0.05816
50.09%**



0.2
0.4139 ± 0.01863
68.68%**


X3
0.05
0.6832 ± 0.00473
48.31%*



0.1
0.5950 ± 0.00446
54.98%**



0.2
0.5784 ± 0.07639
56.24%*


X4
0.05
0.6807 ± 0.06246
48.50%*



0.1
0.6427 ± 0.08818
51.37%**



0.2
0.5107 ± 0.09081
61.36%*


X5
0.05
 0.772 ± 0.00377
41.59%*



0.1
0.7666 ± 0.05195
42.00%**



0.2
0.7106 ± 0.00437
46.24%*


X6
0.05
0.7612 ± 0.08455
42.41%*



0.1
0.7031 ± 0.02017
46.80%**



0.2
0.4613 ± 0.07983
65.10%*


X7
0.05
0.6845 ± 0.03192
48.21%*



0.1
0.6126 ± 0.02039
53.65%**



0.2
0.4791 ± 0.06283
63.75%*


X8
0.05
0.7692 ± 0.08937
41.80%*



0.1
0.4646 ± 0.03545
64.85%**



0.2
0.4092 ± 0.06909
69.06%*


X9
0.05
0.7595 ± 0.03958
42.54%*



0.1
0.4953 ± 0.01919
62.53%**



0.2
0.4704 ± 0.03443
64.41%*


X10
0.05
0.5234 ± 0.00498
60.40%*



0.1
0.4511 ± 0.06292
65.87%**



0.2
0.4501 ± 0.06223
65.95%*


X11
0.05
0.7098 ± 0.07736
46.30%*



0.1
0.6334 ± 0.09489
52.08%**



0.2
0.4571 ± 0.01564
65.42%*


X12
0.05
0.7739 ± 0.09091
41.45%*



0.1
0.7007 ± 0.03361
46.98%**



0.2
0.5484 ± 0.09013
58.51%*


X13
0.05
0.6041 ± 0.03298
54.29%*



0.1
0.5231 ± 0.0749
60.42%**



0.2
0.4230 ± 0.02522
68.00%*


X14
0.05
0.7206 ± 0.01593
45.48%*



0.1
0.6032 ± 0.02038
54.36%**



0.2
0.4592 ± 0.05767
65.26%*


X15
0.05
0.6971 ± 0.00527
47.26%*



0.1
0.6356 ± 0.05105
51.91%**



0.2
0.6335 ± 0.04622
52.07%*


X16
0.05
0.6661 ± 0.07224
49.60%*



0.1
0.5209 ± 0.00575
60.59%**



0.2
0.4429 ± 0.09044
66.49%*


X17
0.05
0.5934 ± 0.03887
55.10%*



0.1
0.5001 ± 0.02347
62.16%**



0.2
0.4616 ± 0.02184
65.08%*


X18
0.05
0.7586 ± 0.05265
42.60%*



0.1
0.6304 ± 0.03508
52.30%**



0.2
0.5051 ± 0.08266
61.78%*


X19
0.05
0.6472 ± 0.01829
51.03%*



0.1
0.4852 ± 0.07133
63.29%**



0.2
0.4664 ± 0.01886
64.71%*


X20
0.05
0.7365 ± 0.05032
44.28%*



0.1
0.7121 ± 0.0349
46.12%**



0.2
0.5268 ± 0.01299
60.14%*


X21
0.05
0.6761 ± 0.01737
48.85%*



0.1
0.4342 ± 0.04189
67.15%**



0.2
0.4076 ± 0.06848
69.16%*


X22
0.05
0.6701 ± 0.07545
49.30%*



0.1
0.4738 ± 0.00344
64.15%**



0.2
0.4425 ± 0.04816
66.52%*


X23
0.05
0.7191 ± 0.07483
45.59%*



0.1
0.7043 ± 0.07872
46.74%**



0.2
0.6753 ± 0.00095
48.91%*


X24
0.05
0.7929 ± 0.02399
40.01%*



0.1
0.7286 ± 0.00571
44.87%**



0.2
0.6661 ± 0.02372
49.60%*


X25
0.05
0.6578 ± 0.08044
50.23%*



0.1
0.6052 ± 0.09358
54.21%**



0.2
0.4847 ± 0.06551
63.33%*


X26
0.05
0.7736 ± 0.06908
41.47%*



0.1
0.6810 ± 0.02943
48.48%**



0.2
0.4162 ± 0.00082
68.51%*


X27
0.05
0.6629 ± 0.02448
49.84%*



0.1
0.5753 ± 0.02814
56.47%**



0.2
0.5731 ± 0.04774
56.64%*


X28
0.05
0.6796 ± 0.03488
48.58%*



0.1
0.6249 ± 0.09489
52.72%**



0.2
0.4004 ± 0.02963
69.71%*


X29
0.05
0.6256 ± 0.09549
52.67%*



0.1
0.5549 ± 0.02011
58.02%**



0.2
0.5151 ± 0.01135
61.03%*


X30
0.05
0.7605 ± 0.00513
42.46%*



0.1
0.5268 ± 0.06831
60.14%**



0.2
0.4517 ± 0.03378
65.82%*


X31
0.05
0.7676 ± 0.04187
41.92%*



0.1
0.7183 ± 0.03361
45.65%**



0.2
0.4824 ± 0.04754
63.50%*


X32
0.05
0.6224 ± 0.08338
52.91%*



0.1
0.6030 ± 0.05575
54.38%**



0.2
0.4030 ± 0.00097
69.51%*


X33
0.05
0.7579 ± 0.03744
42.66%*



0.1
0.7024 ± 0.04477
46.86%**



0.2
0.4991 ± 0.04854
62.24%*


X34
0.05
0.6536 ± 0.08102
50.55%*



0.1
0.6420 ± 0.08726
51.43%**



0.2
0.5298 ± 0.07541
59.92%*


X35
0.05
0.7413 ± 0.08995
43.91%*



0.1
0.5720 ± 0.01284
56.72%**



0.2
0.5624 ± 0.01279
57.45%*


X36
0.05
0.5915 ± 0.05135
55.25%*



0.1
0.5237 ± 0.03194
60.38%**



0.2
0.4664 ± 0.03733
64.71%*


X37
0.05
0.6812 ± 0.09473
48.46%*



0.1
0.4537 ± 0.03356
65.67%**



0.2
0.4053 ± 0.09286
69.33%*


X38
0.05
0.5470 ± 0.08782
58.61%*



0.1
0.4341 ± 0.02751
67.16%**



0.2
0.4319 ± 0.01987
67.32%*


X39
0.05
0.6346 ± 0.04812
51.99%*



0.1
0.5761 ± 0.04869
56.41%**



0.2
0.5379 ± 0.07322
59.30%*


X40
0.05
0.7728 ± 0.04511
41.53%*



0.1
0.5990 ± 0.01488
54.68%**



0.2
0.5890 ± 0.08771
55.44%*


X41
0.05
0.7140 ± 0.00296
45.98%*



0.1
0.6940 ± 0.04213
47.49%**



0.2
0.6212 ± 0.03696
53.00%*


X42
0.05
0.7927 ± 0.00393
40.02%*



0.1
0.7502 ± 0.04961
43.24%**



0.2
0.5605 ± 0.08514
57.59%*


X43
0.05
0.7585 ± 0.06573
42.61%*



0.1
0.6311 ± 0.06472
52.25%**



0.2
0.5077 ± 0.02457
61.59%*


X44
0.05
0.7080 ± 0.02655
46.43%*



0.1
0.5709 ± 0.01156
56.81%**



0.2
0.5140 ± 0.06297
61.11%*


X45
0.05
0.7645 ± 0.08831
42.16%*



0.1
0.5517 ± 0.06286
58.26%**



0.2
0.5097 ± 0.05998
61.44%*


X46
0.05
0.7214 ± 0.05055
45.42%*



0.1
0.6007 ± 0.02905
54.55%**



0.2
0.4615 ± 0.02667
65.08%*


X47
0.05
0.7323 ± 0.05099
44.59%*



0.1
0.5705 ± 0.01511
56.84%**



0.2
0.4145 ± 0.09859
68.64%*


X48
0.05
0.7421 ± 0.02423
43.85%*



0.1
0.6677 ± 0.01791
49.48%**



0.2
0.4615 ± 0.02514
65.08%*


X49
0.05
0.4682 ± 0.01676
64.58%*



0.1
0.4492 ± 0.06833
66.01%**



0.2
0.4010 ± 0.05362
69.66%*


X50
0.05
0.6098 ± 0.01925
53.86%*



0.1
0.6071 ± 0.03868
54.07%**



0.2
0.5590 ± 0.07807
57.71%*


X51
0.05
0.7370 ± 0.04085
44.24%*



0.1
0.4626 ± 0.01562
65.00%**



0.2
0.4308 ± 0.05013
67.41%*


X52
0.05
0.7292 ± 0.00462
44.83%*



0.1
0.6922 ± 0.07646
47.63%**



0.2
0.5217 ± 0.01318
60.53%*


X53
0.05
0.6058 ± 0.06277
54.17%*



0.1
0.5519 ± 0.03497
58.24%**



0.2
0.5346 ± 0.01624
59.55%*


X54
0.05
0.6960 ± 0.03088
47.34%*



0.1
0.4847 ± 0.09197
63.32%**



0.2
0.4203 ± 0.07008
68.20%*


X55
0.05
0.7288 ± 0.03166
44.85%*



0.1
0.6577 ± 0.00076
50.23%**



0.2
0.4451 ± 0.00508
66.32%*


X56
0.05
0.6110 ± 0.01015
53.77%*



0.1
0.4387 ± 0.02343
66.81%**



0.2
0.4218 ± 0.01031
68.08%*


X57
0.05
0.6057 ± 0.06594
54.17%*



0.1
0.4783 ± 0.03174
63.81%**



0.2
0.4125 ± 0.0892
68.79%*


X58
0.05
0.7350 ± 0.04037
44.39%*



0.1
0.5535 ± 0.04093
58.12%**



0.2
0.5020 ± 0.06759
62.02%*


X59
0.05
0.6513 ± 0.08257
50.72%*



0.1
0.5967 ± 0.07994
54.85%**



0.2
0.4118 ± 0.09488
68.84%*


X60
0.05
0.7965 ± 0.09236
39.73%*



0.1
0.6741 ± 0.01064
48.99%**



0.2
0.4310 ± 0.06113
67.39%*


X61
0.05
0.6654 ± 0.03872
49.65%*



0.1
0.5495 ± 0.00776
58.42%**



0.2
0.5150 ± 0.05485
61.03%*


X62
0.05
0.7115 ± 0.01869
46.16%*



0.1
0.6619 ± 0.02252
49.92%**



0.2
0.4690 ± 0.01251
64.51%*


X63
0.05
0.7325 ± 0.04718
44.57%*



0.1
0.4304 ± 0.04148
67.43%**



0.2
0.4184 ± 0.09622
68.34%*


X64
0.05
0.7396 ± 0.00238
44.04%*



0.1
0.7051 ± 0.05311
46.65%**



0.2
0.4070 ± 0.07432
69.20%*


X65
0.05
0.7765 ± 0.01256
41.25%*



0.1
0.7264 ± 0.07863
45.04%**



0.2
0.6533 ± 0.04283
50.57%*


X66
0.05
0.7863 ± 0.03541
40.50%*



0.1
0.7815 ± 0.05931
40.87%**



0.2
0.6563 ± 0.03135
50.34%*


X67
0.05
0.7007 ± 0.00869
46.98%*



0.1
0.6861 ± 0.02168
48.09%**



0.2
0.5419 ± 0.03429
59.00%*


X68
0.05
0.7466 ± 0.08994
43.51%*



0.1
0.6496 ± 0.06733
50.85%**



0.2
0.6456 ± 0.01534
51.15%*


X69
0.05
0.7592 ± 0.03113
42.55%*



0.1
0.7117 ± 0.03907
46.15%**



0.2
0.4354 ± 0.02235
67.06%*


X70
0.05
0.7793 ± 0.05924
41.03%*



0.1
0.6176 ± 0.01467
53.27%**



0.2
0.5270 ± 0.06539
60.12%*


X71
0.05
0.7504 ± 0.03175
43.22%*



0.1
0.5795 ± 0.05806
56.15%**



0.2
0.4639 ± 0.01851
64.90%*


X72
0.05
0.7920 ± 0.03144
40.07%*



0.1
0.5688 ± 0.07895
56.96%**



0.2
0.4627 ± 0.01624
64.99%*


X73
0.05
0.6761 ± 0.03535
48.84%*



0.1
0.6738 ± 0.01619
49.02%**



0.2
0.6044 ± 0.03818
54.27%*


X74
0.05
0.7835 ± 0.04916
40.72%*



0.1
0.6877 ± 0.03265
47.96%**



0.2
0.5071 ± 0.07328
61.63%*


X75
0.05
0.6155 ± 0.01446
53.43%*



0.1
0.5841 ± 0.04054
55.80%**



0.2
0.5267 ± 0.05865
60.15%*


X76
0.05
0.6315 ± 0.04026
52.22%*



0.1
0.5306 ± 0.00069
59.85%**



0.2
0.4825 ± 0.08079
63.49%*


X77
0.05
0.6396 ± 0.02907
51.60%*



0.1
0.5502 ± 0.05927
58.37%**



0.2
0.4973 ± 0.00893
62.37%*


X78
0.05
0.7676 ± 0.06622
41.92%*



0.1
0.5403 ± 0.04745
59.12%**



0.2
0.4331 ± 0.04096
67.23%*


X79
0.05
0.6465 ± 0.04753
51.08%*



0.1
0.5171 ± 0.00162
60.87%**



0.2
0.5039 ± 0.06602
61.87%*


X80
0.05
0.7637 ± 0.04841
42.21%*



0.1
0.5098 ± 0.08356
61.43%**



0.2
0.4724 ± 0.08499
64.26%*


X81
0.05
0.7363 ± 0.01771
44.29%*



0.1
0.6572 ± 0.00217
50.27%**



0.2
0.4376 ± 0.07394
66.89%*


X82
0.05
0.7715 ± 0.03515
41.62%*



0.1
0.6098 ± 0.07588
53.86%**



0.2
0.5004 ± 0.02218
62.14%*


X83
0.05
0.7383 ± 0.05988
44.14%*



0.1
0.7125 ± 0.02437
46.13%**



0.2
0.5649 ± 0.07386
57.26%*


X84
0.05
0.7587 ± 0.03942
42.59%*



0.1
0.5954 ± 0.04671
54.95%**



0.2
0.4487 ± 0.02541
66.05%*


X85
0.05
0.6537 ± 0.02097
50.54%*



0.1
0.6066 ± 0.07551
54.10%**



0.2
0.5765 ± 0.05608
56.38%*


X86
0.05
0.6984 ± 0.06728
47.15%*



0.1
0.5645 ± 0.01108
57.29%**



0.2
0.5643 ± 0.02159
57.30%*


X87
0.05
0.6381 ± 0.08827
51.72%*



0.1
0.5551 ± 0.05137
58.00%**



0.2
0.4162 ± 0.06198
68.51%*


X88
0.05
0.6294 ± 0.07175
52.38%*



0.1
0.5393 ± 0.07136
59.19%**



0.2
0.5189 ± 0.02832
60.74%*


X89
0.05
0.7991 ± 0.08908
39.54%*



0.1
0.6056 ± 0.08945
54.18%**



0.2
0.4076 ± 0.05343
69.16%*


X90
0.05
0.7823 ± 0.07108
40.81%*



0.1
0.5321 ± 0.03975
59.74%**



0.2
0.4695 ± 0.06418
64.47%*


Avastin
0.5
0.4325 ± 0.01108
67.30%**


control

1.3217 ± 0.08914
 0.00%









Results: X1-X90 with different molecular weights could have obvious inhibitory effects on the proliferation of HRCECs, and showed a dose-dependent relationship. The inhibition rate in the high-dose group was close to that of the positive drug. The inhibition rate reached 69.71% when X28 was administered at a dose of 0.2 μM, slightly higher than that of the positive drug.


Example 17

Effect of Polypeptides X1-X90 on Corneal Neovascularization in BALB/c Mice


(1) Preparation of a model of corneal neovascularization induced by alkali burn in BALB/c mice: The mice were randomly grouped, and marked as X1-X90 test groups and control group, with 5 mice in each group. After alkali burn, X1-X90 and normal saline were injected in the vitreous chamber once a day for 1 week. Inflammatory reaction and neovascularization of corneas in each group were observed under a slit lamp microscope on days 1, 7 and 14 after alkali burn. On day 14 after alkali burn, corneal neovascularization of each group was photographed and recorded under a slit lamp microscope with anterior segment photography. Then all mice were killed by a cervical dislocation method and eyeballs were extracted. Blood was washed with normal saline, the eyeballs were fixed with 4% paraformaldehyde for 1.5 h, dehydrated overnight in PBS containing 30% sucrose, embedded with OCT frozen section embedding agent and stored in a refrigerator at −80° C. Frozen section was performed to a thickness of 8 μm, and expression of CD31 was detected by immunohistochemistry.


(2) Quantitative measurement of corneal microvascular density: Microvessel density (MVD) is an indicator for evaluating angiogenesis. An anti-CD31 antibody immunohistochemical method was used to label vascular endothelial cells and count the number of microvessels in unit area to measure the degree of neoangiogenesis. The standard for statistics of microvessels: endothelial cells or cell clusters in a corneal tissue that are clearly demarcated from adjacent tissues and dyed brownish yellow or brown are counted as neovascularization under a microscope. The number of neovascularization in the whole section was counted under a 10×20 microscope. After the corneal tissue section was photographed, the area of the whole corneal tissue section was calculated by image processing software Image J, and the neovascularization density of the whole section was calculated.


The experiment was repeated independently three times. The results were expressed as mean±SD, and statistical T test was conducted. *P<0.05 indicates significant difference, and ** P<0.01 indicates extremely significant difference. The experimental results are shown in Table 22.









TABLE 22







Effect of polypeptides X1-X90 on corneal


neovascularization in mice













Inhibition rate



Group
MVD
(%)







X1
39.28 ± 4.061*
41.58%



X2
33.84 ± 3.805**
49.67%



X3
34.20 ± 6.078**
49.14%



X4
37.39 ± 3.344*
44.39%



X5
36.23 ± 4.86**
46.12%



X6
31.53 ± 6.34**
53.11%



X7
32.19 ± 6.641**
52.13%



X8
32.16 ± 5.44**
52.17%



X9
39.39 ± 3.884*
41.42%



X10
39.00 ± 4.194*
42.00%



X11
32.51 ± 4.294**
51.65%



X12
37.84 ± 6.113*
43.72%



X13
34.19 ± 5.411**
49.15%



X14
30.54 ± 5.794**
54.58%



X15
39.85 ± 3.153*
40.73%



X16
38.83 ± 4.871*
42.25%



X17
34.93 ± 4.725**
48.05%



X18
33.50 ± 5.649**
50.18%



X19
39.38 ± 4.833*
41.43%



X20
37.24 ± 6.113*
44.62%



X21
36.36 ± 3.663**
45.93%



X22
35.84 ± 6.594**
46.70%



X23
35.67 ± 6.861**
46.95%



X24
36.15 ± 4.199**
46.24%



X25
31.67 ± 6.856**
52.90%



X26
37.44 ± 4.646*
44.32%



X27
37.70 ± 3.805*
43.93%



X28
35.91 ± 4.891**
46.59%



X29
30.27 ± 4.918**
54.98%



X30
35.55 ± 5.717**
47.13%



X31
36.70 ± 5.505**
45.42%



X32
33.45 ± 6.453**
50.25%



X33
35.50 ± 3.223**
47.20%



X34
34.72 ± 6.051**
48.36%



X35
37.25 ± 4.806**
44.60%



X36
36.63 ± 5.284**
45.52%



X37
30.12 ± 6.961**
55.21%



X38
33.63 ± 6.163**
49.99%



X39
34.06 ± 6.441**
49.35%



X40
31.19 ± 5.089**
53.61%



X41
34.49 ± 6.982**
48.71%



X42
34.66 ± 5.340**
48.45%



X43
30.78 ± 4.182**
54.22%



X44
39.89 ± 6.464*
40.68%



X45
33.58 ± 4.495**
50.06%



X46
32.30 ± 4.971**
51.96%



X47
37.45 ± 3.897*
44.30%



X48
38.39 ± 4.908*
42.91%



X49
39.48 ± 3.684*
41.28%



X50
31.41 ± 4.385**
53.29%



X51
33.79 ± 3.902**
49.75%



X52
31.75 ± 4.837**
52.78%



X53
35.73 ± 6.955**
46.86%



X54
32.09 ± 3.526**
52.28%



X55
32.62 ± 5.356**
51.49%



X56
30.87 ± 4.765**
54.09%



X57
30.94 ± 3.893**
53.99%



X58
35.87 ± 5.015**
46.65%



X59
34.04 ± 6.473**
49.38%



X60
33.59 ± 4.055**
50.04%



X61
36.31 ± 4.693**
46.00%



X62
37.50 ± 5.197*
44.23%



X63
32.96 ± 4.213**
50.98%



X64
38.20 ± 6.446*
43.19%



X65
34.72 ± 4.489**
48.36%



X66
31.96 ± 4.478**
52.47%



X67
35.94 ± 4.335**
46.55%



X68
34.80 ± 3.496**
48.25%



X69
39.34 ± 3.192*
41.49%



X70
32.83 ± 4.159**
51.17%



X71
33.33 ± 3.004**
50.43%



X72
38.75 ± 5.524*
42.37%



X73
38.89 ± 4.593*
42.16%



X74
35.04 ± 5.106**
47.89%



X75
39.54 ± 4.543*
41.20%



X76
30.37 ± 6.648**
54.83%



X77
33.48 ± 6.956**
50.21%



X78
33.47 ± 6.931**
50.22%



X79
36.78 ± 4.743**
45.30%



X80
39.64 ± 4.856*
41.05%



X81
38.49 ± 6.821*
42.76%



X82
30.94 ± 5.093**
53.99%



X83
39.67 ± 4.978*
41.00%



X84
39.66 ± 4.989*
41.02%



X85
37.36 ± 4.485*
44.44%



X86
30.43 ± 5.512**
54.74%



X87
38.66 ± 4.202*
42.50%



X88
36.50 ± 6.089**
45.72%



X89
33.05 ± 5.016**
50.85%



X90
34.91 ± 3.786**
48.08%



control
67.24 ± 7.341
 0.00%










The experimental results showed that different polypeptides X1-X90 could significantly inhibit the growth of corneal neovascularization, and the inhibition rate of X37 reached 55.21%.


Example 18

Effect of X1-X90 on Iris Neovascularization in Rabbits


577 nm argon ion laser was used to coagulate main and branch veins of rabbit retina, and fundus fluorescein angiography (FFA) confirmed the success of vein occlusion. 5-12 days later, the iris fluorescein angiography (IFA) showed that the leakage of fluorescein was obvious compared with that of the normal control group, confirming the formation of an animal model of iris neovascularization (NVI).


273 eyes with successful modeling were taken and randomly grouped with 3 eyes in each group. The groups were respectively marked as a negative control group and X1-X90 treatment groups, and every 3 eyes fell into one group. The doses of normal saline and X1-X90 were each 0.05 μM, and were injected in the vitreous chamber once a day for 2 weeks. In the third week, observation was made with optical and electron microscopes.


Results: Under the optical microscope, the anterior surface of iris had fibrovascular membrane remnants mainly composed of fibrous tissues, with only a few open vascular cavities. Vascular remnants could be seen in iris stroma, which were necrotic cells and cell fragments. The iris surface of the control eye under the light microscope had the fibrovascular membrane with branching and potential lumen. The ultrastructure of iris in the treatment group had a series of degenerative changes: endothelial cells of large blood vessels in the middle of the iris stroma had normal nucleus, cytoplasm and cell junctions, capillary remnants were found in the iris stroma and the anterior surface of the iris, cell fragments and macrophage infiltration were found around the iris stroma, and there were no capillaries with potential lumen and no degenerated parietal cells, indicating the fading of neovascularization.


The experimental results showed that X1-X90 could inhibit the formation of iris neovascularization in rabbits and degrade the formed blood vessels.


Example 19

Effect of X1-X90 on Choroidal Neovascularization in Rats


6-8 weeks male BN rats were fully anesthetized by intraperitoneal injection of 846 compound anesthetic with a concentration of 0.5 mL/kg. Compound tropicamide eye drops were used once 5 min before laser photocoagulation to fully dilate the pupils of both eyes. The animals were fixed and subjected to krypton laser photocoagulation equidistantly around an optic disc with the aid of a −53.00D corneal contact lens at a distance of 2PD from the optic disc. A total of 8 photocoagulation spots were obtained. The laser wavelength was 647.1 nm, the power was 350 mW, and the diameter and time of the photocoagulation spots were 50 μm and 0.05 s respectively. Fundus photography was performed immediately after photocoagulation. FFA, histopathology and transmission electron microscopy were performed on the days 3, 7, 14, 21 and 28 after photocoagulation respectively.


Through fundus photography and FFA examination, it was confirmed that the fluorescein leakage of the photocoagulation spot reached its peak on day 21 after photocoagulation. At the same time, histopathological examination was carried out. On day 21 after photocoagulation, CNV showed significant fibrovascular proliferation under a light microscope, in which a large number of neovascularization could be seen, and red blood cells were seen in lumen. Under the microscope, capillaries between choroidal melanocytes showed coagulative changes and endothelial cells coagulated. The results showed that the choroidal neovascularization model of rats was formed 21 days later.


Rats with successful modeling were randomly grouped, with 5 rats in each group. The groups were marked as a negative control group and X1-X90 treatment groups respectively. The rats were injected with normal saline and X1-X90 (the doses of X1-X90 were each 0.05 μM) in the vitreous chamber once a day for 1 week. FFA examination was carried out 3 days, 7 days, 14 days and 28 days after administration. The experimental results are shown in Table 23.









TABLE 23







Effect of polypeptides X1-X90 on choroidal neovascularization in rats









Detection time












day 3
day 7
day 14
day 28



The total light spot
The total light spot
The total light spot
The total light spot



number was 297
number was 186
number was 137
number was 69
















Leakage

Leakage

Leakage

Leakage




Light
CNV
Light
CNV
Light
CNV
Light
CNV



spot
Incidence
spot
Incidence
spot
Incidence
spot
Incidence


Group
number
(%)
number
(%)
number
(%)
number
(%)


















control
248
83.50%
139
74.73%
88
64.23%
43
62.31%


X1
161
54.21%
87
46.77%
62
45.26%
25
36.23%


X2
157
52.86%
85
45.70%
54
39.42%
25
36.23%


X3
150
50.51%
89
47.85%
62
45.26%
30
43.48%


X4
157
52.86%
85
45.70%
57
41.61%
27
39.13%


X5
153
51.52%
85
45.70%
60
43.80%
25
36.23%


X6
148
49.83%
87
46.77%
55
40.15%
27
39.13%


X7
149
50.17%
84
45.16%
59
43.07%
27
39.13%


X8
157
52.86%
92
49.46%
64
46.72%
29
42.03%


X9
160
53.87%
84
45.16%
64
46.72%
25
36.23%


X10
148
49.83%
87
46.77%
62
45.26%
29
42.03%


X11
158
53.20%
85
45.70%
58
42.34%
24
34.78%


X12
147
49.49%
92
49.46%
64
46.72%
27
39.13%


X13
158
53.20%
90
48.39%
64
46.72%
26
37.68%


X14
160
53.87%
84
45.16%
60
43.80%
30
43.48%


X15
151
50.84%
88
47.31%
63
45.99%
25
36.23%


X16
157
52.86%
88
47.31%
55
40.15%
29
42.03%


X17
163
54.88%
90
48.39%
58
42.34%
28
40.58%


X18
160
53.87%
86
46.24%
63
45.99%
31
44.93%


X19
155
52.19%
85
45.70%
57
41.61%
31
44.93%


X20
156
52.53%
91
48.92%
58
42.34%
27
39.13%


X21
151
50.84%
89
47.85%
64
46.72%
28
40.58%


X22
160
53.87%
89
47.85%
60
43.80%
26
37.68%


X23
157
52.86%
85
45.70%
61
44.53%
26
37.68%


X24
161
54.21%
92
49.46%
63
45.99%
31
44.93%


X25
154
51.85%
88
47.31%
59
43.07%
31
44.93%


X26
164
55.22%
92
49.46%
62
45.26%
30
43.48%


X27
163
54.88%
86
46.24%
58
42.34%
25
36.23%


X28
149
50.17%
87
46.77%
62
45.26%
28
40.58%


X29
161
54.21%
85
45.70%
56
40.88%
27
39.13%


X30
154
51.85%
91
48.92%
63
45.99%
28
40.58%


X31
159
53.54%
87
46.77%
57
41.61%
31
44.93%


X32
161
54.21%
86
46.24%
59
43.07%
29
42.03%


X33
161
54.21%
86
46.24%
62
45.26%
26
37.68%


X34
155
52.19%
88
47.31%
63
45.99%
29
42.03%


X35
155
52.19%
89
47.85%
64
46.72%
31
44.93%


X36
150
50.51%
92
49.46%
55
40.15%
30
43.48%


X37
154
51.85%
85
45.70%
59
43.07%
26
37.68%


X38
163
54.88%
88
47.31%
57
41.61%
26
37.68%


X39
154
51.85%
88
47.31%
59
43.07%
31
44.93%


X40
157
52.86%
91
48.92%
55
40.15%
26
37.68%


X41
157
52.86%
91
48.92%
60
43.80%
28
40.58%


X42
151
50.84%
88
47.31%
63
45.99%
29
42.03%


X43
148
49.83%
89
47.85%
59
43.07%
25
36.23%


X44
152
51.18%
91
48.92%
59
43.07%
29
42.03%


X45
155
52.19%
92
49.46%
58
42.34%
27
39.13%


X46
153
51.52%
86
46.24%
60
43.80%
31
44.93%


X47
161
54.21%
89
47.85%
62
45.26%
30
43.48%


X48
161
54.21%
85
45.70%
59
43.07%
25
36.23%


X49
157
52.86%
91
48.92%
57
41.61%
27
39.13%


X50
157
52.86%
84
45.16%
60
43.80%
25
36.23%


X51
158
53.20%
91
48.92%
60
43.80%
26
37.68%


X52
150
50.51%
84
45.16%
58
42.34%
31
44.93%


X53
161
54.21%
92
49.46%
63
45.99%
27
39.13%


X54
164
55.22%
92
49.46%
56
40.88%
26
37.68%


X55
156
52.53%
92
49.46%
62
45.26%
29
42.03%


X56
162
54.55%
92
49.46%
55
40.15%
31
44.93%


X57
149
50.17%
90
48.39%
56
40.88%
26
37.68%


X58
157
52.86%
84
45.16%
59
43.07%
28
40.58%


X59
153
51.52%
84
45.16%
63
45.99%
29
42.03%


X60
159
53.54%
86
46.24%
58
42.34%
26
37.68%


X61
161
54.21%
91
48.92%
62
45.26%
27
39.13%


X62
164
55.22%
88
47.31%
62
45.26%
31
44.93%


X63
150
50.51%
87
46.77%
61
44.53%
31
44.93%


X64
153
51.52%
86
46.24%
58
42.34%
30
43.48%


X65
157
52.86%
85
45.70%
61
44.53%
26
37.68%


X66
162
54.55%
92
49.46%
56
40.88%
29
42.03%


X67
153
51.52%
89
47.85%
60
43.80%
27
39.13%


X68
158
53.20%
87
46.77%
60
43.80%
29
42.03%


X69
164
55.22%
87
46.77%
62
45.26%
31
44.93%


X70
160
53.87%
90
48.39%
61
44.53%
31
44.93%


X71
154
51.85%
88
47.31%
58
42.34%
26
37.68%


X72
150
50.51%
89
47.85%
64
46.72%
27
39.13%


X73
160
53.87%
91
48.92%
63
45.99%
26
37.68%


X74
151
50.84%
88
47.31%
60
43.80%
28
40.58%


X75
162
54.55%
88
47.31%
59
43.07%
30
43.48%


X76
148
49.83%
91
48.92%
55
40.15%
28
40.58%


X77
148
49.83%
92
49.46%
63
45.99%
29
42.03%


X78
147
49.49%
89
47.85%
60
43.80%
31
44.93%


X79
153
51.52%
92
49.46%
57
41.61%
30
43.48%


X80
156
52.53%
84
45.16%
61
44.53%
30
43.48%


X81
163
54.88%
91
48.92%
57
41.61%
30
43.48%


X82
159
53.54%
87
46.77%
61
44.53%
27
39.13%


X83
163
54.88%
88
47.31%
60
43.80%
30
43.48%


X84
161
54.21%
92
49.46%
58
42.34%
25
36.23%


X85
157
52.86%
91
48.92%
63
45.99%
25
36.23%


X86
155
52.19%
90
48.39%
64
46.72%
30
43.48%


X87
163
54.88%
88
47.31%
58
42.34%
25
36.23%


X88
147
49.49%
84
45.16%
63
45.99%
28
40.58%


X89
161
54.21%
84
45.16%
63
45.99%
29
42.03%


X90
156
52.53%
84
45.16%
59
43.07%
28
40.58%









Results: The FFA examination showed that, at 3 days after administration, the leakage of fluorescein in X1-X90 treatment groups was significantly changed compared with that before administration. At 7 and 14 days after administration, the leakage of fluorescein in the treatment groups decreased gradually. On day 28 after administration, the leakage of fluorescein was less than that on day 14 after administration. It showed that X1-X90 could treat choroidal neovascularization in rats, among which X11 had the most obvious effect, and the CNV incidence was the lowest (34.78%) on day 28 after administration.


Example 20

Effects of X1-X90 on Retinal Vessels in OIR Mice


Establishment of an OIR model: Young mice and their mothers were exposed in a 75% hyperoxic environment from day 7 to day 12 after the birth of C57/B16 mice, which caused capillaries in their central retina to disappear rapidly. The mice were returned to the indoor air on day 12, retinal vessels exposed to hyperoxia quickly disappeared, causing extensive abnormal neoangiogenesis, and the central part of the retina remained largely avascular for a long time. After the blood vessels disappeared completely, the mice were injected with normal saline (a negative group), X1-X12, X13-X44, X45-X90 in the vitreous chamber on day 13 respectively, and retinal vessels were evaluated on day 17 (50 mL of Texas red labeled tomato agglutinin was injected into the left ventricle to mark unclosed vessels and circulated for 5 min). The experimental results are shown in Table 24.









TABLE 24







Effect of polypeptides X1-X90 on retinal vessels in OIR mice












Area of




Dose
neovascular plexus
Inhibition rate


Group
(μM)
(mm2)
(%)





control

0.212 ± 0.008
 0.00%


X1
0.05
0.115 ± 0.009
45.75%*


X2
0.05
0.081 ± 0.005
61.79%**


X3
0.05
0.084 ± 0.012
60.38%**


X4
0.05
0.116 ± 0.014
45.28%*


X5
0.05
0.101 ± 0.021
52.36%**


X6
0.05
0.108 ± 0.005
49.06%**


X7
0.05
0.108 ± 0.004
49.06%**


X8
0.05
0.091 ± 0.003
57.08%**


X9
0.05
0.110 ± 0.016
48.11%*


X10
0.05
0.097 ± 0.004
54.25%**


X11
0.05
0.103 ± 0.003
51.42%**


X12
0.05
0.090 ± 0.002
57.55%**


X13
0.05
0.080 ± 0.015
62.26%**


X14
0.05
0.101 ± 0.005
52.36%**


X15
0.05
0.091 ± 0.003
57.08%**


X16
0.05
0.110 ± 0.016
48.11%*


X17
0.05
0.084 ± 0.009
60.38%**


X18
0.05
0.119 ± 0.011
43.87%*


X19
0.05
0.083 ± 0.019
60.85%**


X20
0.05
0.118 ± 0.014
44.34%*


X21
0.05
0.118 ± 0.012
44.34%*


X22
0.05
0.082 ± 0.005
61.32%**


X23
0.05
0.101 ± 0.002
52.36%**


X24
0.05
0.107 ± 0.012
49.53%*


X25
0.05
0.096 ± 0.012
54.72%**


X26
0.05
0.104 ± 0.001
50.94%**


X27
0.05
0.106 ± 0.002
50.00%**


X28
0.05
0.088 ± 0.004
58.49%**


X29
0.05
0.109 ± 0.012
48.58%*


X30
0.05
0.118 ± 0.012
44.34%*


X31
0.05
0.101 ± 0.013
52.83%**


X32
0.05
0.096 ± 0.001
54.72%**


X33
0.05
0.089 ± 0.029
58.02%**


X34
0.05
0.120 ± 0.014
43.40%*


X35
0.05
0.101 ± 0.005
52.36%**


X36
0.05
0.084 ± 0.009
60.38%**


X37
0.05
0.084 ± 0.011
60.38%**


X38
0.05
0.110 ± 0.016
48.11%*


X39
0.05
0.111 ± 0.012
47.64%*


X40
0.05
0.089 ± 0.002
58.02%**


X41
0.05
0.092 ± 0.006
56.60%**


X42
0.05
0.092 ± 0.019
56.60%**


X43
0.05
0.112 ± 0.004
47.17%*


X44
0.05
0.084 ± 0.017
60.38%**


X45
0.05
0.100 ± 0.013
52.83%**


X46
0.05
0.110 ± 0.019
48.11%**


X47
0.05
0.114 ± 0.014
46.23%*


X48
0.05
0.102 ± 0.012
51.89%**


X49
0.05
0.089 ± 0.006
58.02%**


X50
0.05
0.118 ± 0.012
44.34%*


X51
0.05
0.095 ± 0.019
55.19%**


X52
0.05
0.117 ± 0.011
44.81%*


X53
0.05
0.083 ± 0.009
60.85%**


X54
0.05
0.116 ± 0.018
45.28%*


X55
0.05
0.116 ± 0.015
45.28%*


X56
0.05
0.107 ± 0.007
49.53%**


X57
0.05
0.103 ± 0.008
51.42%


X58
0.05
0.112 ± 0.013
47.17%*


X59
0.05
0.081 ± 0.013
61.79%**


X60
0.05
0.116 ± 0.005
45.28%*


X61
0.05
0.085 ± 0.002
59.91%**


X62
0.05
0.112 ± 0.019
47.17%*


X63
0.05
0.100 ± 0.006
52.83%**


X64
0.05
0.118 ± 0.017
44.34%*


X65
0.05
0.083 ± 0.012
60.85%**


X66
0.05
0.081 ± 0.008
61.79%**


X67
0.05
0.102 ± 0.003
51.89%**


X68
0.05
0.098 ± 0.019
53.77%**


X69
0.05
0.104 ± 0.012
50.94%**


X70
0.05
0.090 ± 0.022
57.55%**


X71
0.05
0.087 ± 0.018
58.96%**


X72
0.05
0.084 ± 0.010
60.38%**


X73
0.05
0.110 ± 0.015
48.11%*


X74
0.05
0.094 ± 0.009
55.66%**


X75
0.05
0.111 ± 0.009
47.64%*


X76
0.05
0.100 ± 0.016
52.83%**


X77
0.05
0.087 ± 0.001
58.96%**


X78
0.05
0.091 ± 0.017
57.08%**


X79
0.05
0.113 ± 0.005
46.70%*


X80
0.05
0.095 ± 0.011
55.19%*


X81
0.05
0.083 ± 0.011
60.85%**


X82
0.05
0.108 ± 0.017
49.06%**


X83
0.05
0.106 ± 0.007
50.00%**


X84
0.05
0.094 ± 0.018
55.66%**


X85
0.05
0.119 ± 0.002
43.87%*


X86
0.05
0.103 ± 0.015
51.42%**


X87
0.05
0.081 ± 0.003
61.79%**


X88
0.05
0.112 ± 0.017
47.17%*


X89
0.05
0.094 ± 0.006
55.66%**


X90
0.05
0.106 ± 0.014
50.00%**









Compared with negative control, the neovascular plexus in retinas of OIR mice treated with polypeptide X1-X90 was significantly reduced. X13 in the polypeptides X1-X90 administration groups had the best effect, and the inhibition rate reached 62.26% when the dose was 0.05 μm.


Example 21

Effect of X1-X90 on Neovascularization in a Rat Model of Premature Retinopathy


Using a fluctuating oxygen-induced animal model, newborn rats born naturally on the same day (within 12 h) were randomly divide into three groups: an oxygen model group, an oxygen treatment group and a normal control group. The oxygen model was further divided into three sub-group model groups, and the sub-group model groups and the treatment group were all placed in a semi-closed oxygen chamber made of organic glass; medical oxygen was introduced into the chamber, and the concentration was adjusted to 80%±2% by an oxygen meter; nitrogen was introduced into the oxygen chamber after 24 h, and the oxygen concentration was adjusted to 10%±2% rapidly and maintained for 24 h. This was repeated to keep the oxygen concentration in the oxygen chamber alternating between 80% and 10% every 24 h, the oxygen concentration was maintained for 7 d, and then the rats were fed in the air. The oxygen concentration was monitored 8 times a day, and the ambient temperature in the chamber was controlled at 23° C.±2° C. Bedding was replaced, feed was added, and water and mother rats were replaced once. The normal control group was placed in the animal room feeding environment. Compared with the control group, if the ADP enzyme staining of retinal serial sections in the model group showed obvious vascular changes, and the number of vascular endothelial cell nuclei that broke through the inner limiting membrane of the retina and grew into the vitreous body increased with a statistically significant difference, the modeling was successful.


The oxygen treatment group was divided into three subgroups. On day 7 of modeling, X1-X30, X31-X60 and X61-X90 were injected in the vitreous chamber respectively, and the oxygen model group and the control group were only given normal saline for one week. On day 14, after the rats were anesthetized by diethyl ether and killed, eyeballs were extracted and fixed in 40 g/L paraformaldehyde solution for 24 h. Gradient dehydration by alcohol was performed, and the eyeballs were processed by xylene to be transparent. After waxing, the eyeballs were sectioned continuously to a thickness of 4μm, and the periphery of the optic disc should be avoided as much as possible. The sections were parallel to the sagittal plane from cornea to the optic disc. Ten sections of each eyeball were randomly taken and stained with hematoxylin eosin, the number of vascular endothelial nuclei that broke through the inner limiting membrane of the retina (only the number of vascular endothelial nuclei closely related to the inner limiting membrane were counted) was counted, and statistics of the average number of cells per section per eyeball was performed.


Results: In the control group, there were no vascular endothelial nuclei that broke through the inner limiting membrane of the retina and grew into vitreous body, or the vascular endothelial nuclei were occasionally found in only a few sections. In the model group, there were many vascular endothelial nuclei that broke through the inner limiting membrane of the retina, some appeared alone, and some appeared in clusters. At the same time, on some sections, these vascular endothelial nuclei were also found adjacent to deep retinal vessels, confirming that they originated from the retina rather than the vitreous body or other ocular tissues. In the treatment group, only a few vascular endothelial nuclei that broke through the inner limiting membrane of retina could be seen in the sections. The experimental results are shown in Table 25.









TABLE 25







Retinal vascular endothelial nuclei count in each group












Dose




Group
(μM)
Nuclei count







X1
0.05
 8.755 ± 2.888



X2
0.05
 8.561 ± 2.673



X3
0.05
 7.169 ± 1.551



X4
0.05
 7.604 ± 3.526



X5
0.05
 9.043 ± 2.651



X6
0.05
 9.085 ± 2.938



X7
0.05
 9.425 ± 3.563



X8
0.05
 9.066 ± 1.229



X9
0.05
 7.249 ± 3.321



X10
0.05
 7.741 ± 3.738



X11
0.05
 9.059 ± 1.301



X12
0.05
 8.232 ± 1.126



X13
0.05
 8.331 ± 3.318



X14
0.05
 8.539 ± 3.671



X15
0.05
 8.814 ± 1.616



X16
0.05
 8.221 ± 1.355



X17
0.05
 7.012 ± 1.321



X18
0.05
 8.002 ± 3.606



X19
0.05
 7.236 ± 1.218



X20
0.05
 9.374 ± 3.742



X21
0.05
 7.222 ± 3.567



X22
0.05
 7.368 ± 1.842



X23
0.05
 8.275 ± 1.713



X24
0.05
 7.699 ± 3.108



X25
0.05
 8.923 ± 1.954



X26
0.05
 8.343 ± 2.131



X27
0.05
 8.358 ± 1.328



X28
0.05
 9.261 ± 3.879



X29
0.05
 9.533 ± 2.225



X30
0.05
 8.256 ± 3.403



X31
0.05
 7.228 ± 3.184



X32
0.05
 8.394 ± 2.665



X33
0.05
 7.654 ± 1.142



X34
0.05
 7.292 ± 3.827



X35
0.05
 8.544 ± 3.087



X36
0.05
 8.726 ± 3.273



X37
0.05
 8.921 ± 2.863



X38
0.05
 8.325 ± 3.699



X39
0.05
 8.695 ± 2.322



X40
0.05
 8.963 ± 1.695



X41
0.05
 8.953 ± 1.042



X42
0.05
 7.149 ± 2.242



X43
0.05
 8.781 ± 1.541



X44
0.05
 8.554 ± 1.518



X45
0.05
 7.841 ± 3.399



X46
0.05
 7.316 ± 1.838



X47
0.05
 9.352 ± 2.961



X48
0.05
 8.817 ± 1.029



X49
0.05
 8.059 ± 2.391



X50
0.05
 7.461 ± 1.469



X51
0.05
 9.049 ± 1.682



X52
0.05
 7.727 ± 1.706



X53
0.05
 8.649 ± 1.067



X54
0.05
 7.539 ± 1.845



X55
0.05
 9.378 ± 3.044



X56
0.05
 9.403 ± 3.439



X57
0.05
 7.437 ± 1.847



X58
0.05
 7.215 ± 1.261



X59
0.05
 8.466 ± 2.301



X60
0.05
 9.131 ± 3.321



X61
0.05
 9.151 ± 3.533



X62
0.05
 9.312 ± 1.889



X63
0.05
 8.748 ± 3.796



X64
0.05
 7.686 ± 1.242



X65
0.05
 7.333 ± 3.716



X66
0.05
 7.576 ± 1.162



X67
0.05
 8.823 ± 1.792



X68
0.05
 9.115 ± 1.754



X69
0.05
 8.616 ± 3.698



X70
0.05
 8.274 ± 3.515



X71
0.05
 7.678 ± 2.426



X72
0.05
 8.886 ± 1.692



X73
0.05
 7.601 ± 2.727



X74
0.05
 9.149 ± 1.759



X75
0.05
 8.371 ± 1.232



X76
0.05
 7.354 ± 2.263



X77
0.05
 7.752 ± 3.349



X78
0.05
 8.482 ± 2.669



X79
0.05
 7.974 ± 3.165



X80
0.05
 7.124 ± 2.409



X81
0.05
 8.034 ± 3.187



X82
0.05
 7.399 ± 2.401



X83
0.05
 8.728 ± 1.165



X84
0.05
 7.795 ± 3.921



X85
0.05
 8.157 ± 2.676



X86
0.05
 8.499 ± 2.052



X87
0.05
 7.629 ± 2.335



X88
0.05
 7.353 ± 2.599



X89
0.05
 7.327 ± 2.279



X90
0.05
 8.755 ± 2.888



Model group

27.463 ± 2.213



control

 1.329 ± 0.259










The results showed that compared with 27.463±2.213 in the oxygen model group, retinal vascular endothelial nuclei count in the X1-X90 treatment groups was significantly reduced, which proved that the X1-X90 treatment groups could inhibit the neoangiogenesis in oxygen-induced retinopathy model of neonatal rats to some extent. Among them, X17 had the best effect, and nuclei count was 7.012±1.321 when the dose was 0.05 μm.












SEQUENCE LISTING

















SEQ ID NO: 1



RGADRAGGGGRGD







SEQ ID NO: 2



GGGGRGD







SEQ ID NO: 3



RGADRA







SEQ ID NO: 4



GGGG







SEQ ID NO: 5



EAAAK







SEQ ID NO: 6



GSSSS







SEQ ID NO: 7



GGGGK









Claims
  • 1. A modified angiogenesis inhibitor polypeptide, wherein a maleimide group is used to modify the angiogenesis inhibitor polypeptide, and the carboxyl group of the maleimide group forms an amide bond with the amino group of N-terminal Arg of the polypeptide.
  • 2. The modified angiogenesis inhibitor polypeptide according to claim 1, wherein the modified angiogenesis inhibitor polypeptide sequence comprises two functional groups A and B, wherein the functional group A is Arg-Gly-Ala-Asp-Arg-Ala (SEQ ID NO: 3) or a derived polypeptide obtained by substituting, deleting or adding one or two amino acid residues in Arg-Gly-Ala-Asp-Arg-Ala (SEQ ID NO: 3) and the derived polypeptide has the same angiogenesis inhibition, anti-tumor and anti-inflammatory activities as Arg-Gly-Ala-Asp-Arg-Ala (SEQ ID NO: 3); the functional group B is Arg-Gly-Asp, wherein the functional groups A and B are ligated with each other through a linker, that is, the modified polypeptide sequence structure is A-linker-B.
  • 3. The modified angiogenesis inhibitor polypeptide according to claim 2, wherein the linker is Gly-Gly-Gly-Gly (SEQ ID NO: 4), Glu-Ala-Ala-Ala-Lys (SEQ ID NO: 5) or Gly-Ser-Ser-Ser-Ser (SEQ ID NO: 6).
  • 4. The modified angiogenesis inhibitor polypeptide according to claim 3, wherein the modified polypeptide sequence is preferably:
  • 5. The modified angiogenesis inhibitor polypeptide according to claim 4, wherein a polypeptide chain is ligated with the maleimide group by different linkers, wherein n, m, x and y are the numbers of repeating structural unit methylene, methylene, oxyethylene and methylene respectively; the n, m, x and y are all integers, and specific numerical ranges are: n=1-12, m=1-12, x=1-5, y=0-6.
  • 6. Use of the modified angiogenesis inhibitor polypeptide according to claim 4 in the preparation of a medicament for treating tumors, inflammations and ocular neovascular diseases.
  • 7. The use of the modified angiogenesis inhibitor polypeptide according to claim 6 in the preparation of a medicament for treating tumors, inflammations and ocular neovascular diseases, wherein the tumors are primary or secondary cancers, melanoma, hemangioma and sarcoma originating from human head and neck, brain, thyroid, esophagus, pancreas, lung, liver, stomach, breast, kidney, gallbladder, colon or rectum, ovary, blood vessel, cervix, prostate, bladder or testis.
  • 8. The use of the modified angiogenesis inhibitor polypeptide according to claim 6 in the preparation of a medicament for treating tumors, inflammations and ocular neovascular diseases, wherein the inflammations comprise rheumatoid arthritis, gouty arthritis, reactive arthritis, osteoarthritis, psoriasis, infectious arthritis, traumatic arthritis and ankylosing spondylitis.
  • 9. The use of the modified angiogenesis inhibitor polypeptide according to claim 6 in the preparation of a medicament for treating tumors, inflammations and ocular neovascular diseases, wherein the ocular neovascular diseases comprise age-related macular degeneration (AMD), iris neovascular eye diseases, choroidal neovascular eye diseases, retinal neovascular eye diseases or corneal neovascular eye diseases.
  • 10. A medicament for treating tumors, inflammations and/or ocular neovascular diseases, comprising the modified angiogenesis inhibitor polypeptide according to claim 3 and pharmaceutically acceptable excipients.
  • 11. The medicament for treating tumors, inflammations and/or ocular neovascular diseases according to claim 10, wherein the medicament is administered by injection, comprising subcutaneous injection, intramuscular injection, intravenous injection, vitreous injection and intravenous drip.
Priority Claims (1)
Number Date Country Kind
201710826497.6 Sep 2017 CN national
PCT Information
Filing Document Filing Date Country Kind
PCT/CN2018/104578 9/7/2018 WO 00